Characterization, Epigenetic Drug Effect, and Gene Delivery to Breast Cancer Cells by Lu, Shan
  
 
CHARACTERIZATION, EPIGENETIC DRUG EFFECT, AND GENE DELIVERY TO 
BREAST CANCER CELLS 
 
 
A Dissertation 
Presented to 
The Graduate Faculty of The University of Akron 
 
In Partial Fulfillment 
of Requirements for the Degree 
Doctor of Philosophy 
 
 
 
 
 
 
 
Shan Lu 
December, 2015 
ii 
CHARACTERIZATION, EPIGENETIC DRUG EFFECT, AND GENE DELIVERY TO 
BREAST CANCER CELLS 
Shan Lu 
Dissertation 
Approved:  Accepted: 
Advisor       Department Chair 
Dr. Vinod Labhasetwar  Dr. Stephen Weeks      
Committee Chair  Dean of the College     
Dr. Coleen Pugh   Dr. John Green
Committee Member Dean of Graduate School
Dr. Abraham Joy Dr. Chand Midha       
Committee Member 
Dr. Ali Dhinojwala         
Committee Member 
Dr. Anand Ramamurthi 
Committee Member 
Dr. Peter Niewiarowski 
iii 
ABSTRACT 
Cancer relapse is strongly associated with the presence of cancer stem cells (CSCs), 
which drive the development of metastasis and drug resistance. 
In human breast cancer, CSCs are identified by the CD44
+
/CD24
-
 phenotype and
characterized by drug resistance, high tumorigenicity and metastatic potential. In this 
study, I found that MCF-7/Adr cells that are breast cancer cells resistant to doxorubicin 
(Dox) uniformly displayed CSC surface markers, possessed CSC proteins, formed in 
vitro mammospheres, yet retained low migratory rate. They were also able to self-renew 
and differentiate under floating culture condition and are responsive to epigenetic drug 
treatment. 
High degree of DNA methylation (modifications of the cytosine residues of DNA) 
and histone deacetylation are major epigenetic landmarks of CSCs. In this work, I 
showed that MCF-7/Adr cells are sensitive to histone deacetylation inhibitor 
suberoylanilide hydroxamic acid (SAHA). Through RNA-sequencing technology, I also 
found that decitabine (DAC) and SAHA similarly affected a large number of the 
examined pathways, including drug and nanoparticle cellular uptake and transport, lipid 
metabolism, carcinogenesis and nuclear transport pathways. However, DAC significantly 
down-regulated several drug metabolism and drug resistant genes whereas SAHA 
showed no effect on them. 
iv 
siRNA therapy is the only approved genomic drug up to date; and is under clinical 
trials for cancer treatment. Cationic polymers are effective in complexing nucleotide 
through electrostatic interactions, forming polyplexes. Therefore, I further investigated 
the ability of a polyethyleneimine (PEI)-based cationic polymer, polyethylene glycol 
(Peg) modified L-arginine oligo (alkylaminosiloxane)-graft PEI ((P(SiDAAr)5Peg3), in 
delivering siRNA. The delivery system enabled effective siRNA delivery in vitro. In vivo 
in xenograft tumor model, polyplex showed insignificant reduction in bioluminanance 
signal following single-dose intravenous administration than other control groups but the 
data were not statistically significant, suggesting that further dose optimization of 
polyplex required to achieve a greater effect. In a drug resistant cell line, the delivery 
system also enabled anti-ABCB1 siRNA to effectively knockdown its target ABCB1 
protein and enhance the Dox uptake as well as its therapeutic efficacy. Furthermore, I 
conducted DNA-siRNA co-delivery using P(SiDAAr)5Peg3, and obtained significantly 
enhanced transfection levels for both DNA and siRNA using the co-delivery approach. 
In summary, this study identified stem-like characteristics in drug resistant cell line 
MCF-7/Adr, showed that epigenetic drugs DAC and SAHA are effective in targeting dug 
resistant cells, investigated the transcriptomic effects of DAC and SAHA through RNA 
sequencing, and developed a siRNA and DNA-co-siRNA delivery system that effectively 
transfected both metastatic and drug resistant breast cancer cell lines in vitro. 
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CHAPTER I 
INTRODUCTION 
1.1 Breast Cancer 
Breast cancer is a leading cause of morbidity and mortality among women with 
approximately 14 million new cases and 8.2 million deaths in 2012 worldwide [1]. Breast 
cancer is caused by the mutation of breast tissues. Among all initial diagnosis, about 6%-
10% people have Stage IV breast cancer. 
Breast cancer can be classified in several ways. Histologically, breast cancer can be 
separated into ductal, lobular, nipple, or not otherwise specified (NOS). Based on the 
presence of estrogen receptors (ER), progesterone receptors (PR), and human epidermal 
growth factor receptor-2 (HER2), breast cancer can be categorized into luminal A (ER+ 
and/or PR+; HER2–), luminal B (ER+ and/or PR+; HER2+), triple negative (ER–, PR–, 
and HER2–), and HER2 (ER–, PR–, and HER2+) type. ER-positive tumors are benign 
and account for over 70% of breast cancer [2, 3]. ER-negative tumors are more 
malignant [4]. The over-expression of HER2 has a strong association with poor 
survival [5]. 
2 
1.1.1 Clinical Hurdles for Breast Cancer Treatment 
Difficulties in treating breast cancer largely lie in the heterogeneous nature of the 
various tumor types, including the diverse morphological and molecular characteristics as 
well as treatment responses [6]. Current treatment challenges include cancer relapse, the 
development of drug resistance and metastasis. 
1.1.2 Drug Resistance 
In spite of the advances in chemotherapy of breast cancer, drug resistance is a major 
clinical challenge for patient survival [7]. Resistance is the result of both genetic and 
epigenetic alterations. Mechanisms of resistance to chemotherapy are complex, including 
increased drug efflux and decreased drug uptake, compartmentalization of drug into 
intracellular vesicles, impaired anti-apoptotic machinery, inability of drugs to reach the 
target, and increased cellular mechanism of repair of DNA damage (Fig 1.1) [8]. 
Therefore, the identification and reversal of drug resistance genes as well as elucidation 
of mechanisms of resistance is crucial for more effective treatment strategies. Currently, 
new therapies are under development with the aim to overcome the resistance to chemo- 
and radio-therapy of tumors. What are these new therapies? Either delete the line or 
explain 
Acquired drug resistance often results from overexpression of energy-dependent 
membrane transporters, such as P-glycoprotein (P-gp), which pump out anticancer drugs. 
Resistance can also occur through reduced intracellular drug uptake.  Multidrug resistance 
protein 1 (MDR-1) and multidrug resistance associated protein 1 (MRP-1) are the two 
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most common pump-related drug resistant genes in humans [9, 10]. MCF-7/Adr, a widely 
studied multi-drug resistant breast cancer cell line is derived from its parental MCF-7 cell 
line through drug-induced transformation. Compared with MCF-7, which is estrogen 
receptor (ER) positive, MCF-7/Adr is ER negative, and not susceptible to hormone and 
drug therapy. Therefore, MCF-7/Adr serves as an ideal model for the understanding and 
conquest of drug resistance. 
 
1.1.3 Metastasis 
Metastatic breast cancer (also called stage IV or advanced breast cancer) remains a 
major cause of morbidity and mortality worldwide. At present, around 155,000 
Americans are diagnosed with metastatic breast cancer, which leads to 40,000 deaths 
annually. The majority (over 80%) of metastatic breast cancer cases are detected months 
or years after local (stage I, II or III) breast cancer treatment. The common sites of 
metastasis include lymph nodes, bones and bone marrow, muscle, fatty tissue and skin, 
liver, lungs and brain. 
 
One of the well-established metastatic adenocarcinoma cell lines extracted from the 
mammary gland is MDA-MB-231-D3H2LN, which is claudin-low, triple negative (ER–, 
PR–, HER2–), and produces metastasis to clinically relevant tissues such as lymph nodes 
[11].  
 
 
 
4 
1.2 Mechanisms of Cancer Progression 
Mechanisms of cancer progress are composed of genetic mutations as well as 
epigenetic alterations. 
1.2.1 Genetic Mutations 
Hereditary accounts for between 5% and 10% of all breast cancers. Most inherited 
breast cancers are associated with BRCA1 (breast cancer gene 1) and BRCA2 (breast 
cancer gene 2). 
Figure 1.1 Mechanisms of drug resistance in cancer cells. 
The increase of drug efflux, decrease of drug uptake, compartmentalization and 
mutation/loss of cellular targets, inactivation of drugs and anti-apoptotic machinery are 
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some major drug resistance mechanisms of cancer cells. Adapted from Gottesman, M.M., 
et al., Defeating drug resistance in cancer. Discov Med, 2006. 6(31): p. 18-23. [8]. 
 
Other genetic changes in breast cancer include ABC transporters, genes regulated by 
calcium signaling, genes associated with apoptosis, ion channels (ex. potassium and 
chloride), Ras family and glutathione S-transferase [12]. Mutations in all these genes 
contribute to the advancement of breast cancer. Furthermore, poor breast cancer 
prognosis has been shown to correlate with gene mutations, including PACSIN3, OGG1, 
KCNN4, and CALB2 [12]. 
 
1.2.2 Epigenetic Alterations  
Epigenetic reprogramming is involved in a number of diseases, including 
neurodegenerative disorders (ex. schizophrenia or Alzheimer’s disease) and cancer [13-
15]. Epigenetics was originally defined by C.H. Waddington as interactions between 
genes and their products which generate their phenotype [16]. A more modern definition 
of epigenetics is changes in gene expression independent of DNA changes, linking gene 
expressions with chromatin structure [15]. Recently, studies have shown an even greater 
role of epigenetic regulation in cellular malignant transfection and the development of 
breast cancer [17].  
 
Epigenetic modulations include histone modifications, DNA methylation, and 
miRNA expression, which may function independently or in concert (Fig 1.2). Chromatin 
structure determines the accessibility of genes in a cell, thus regulating the expression 
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level of a gene. An ‘epigenetic landscape’ can be created by altering the local structural 
dynamics of chromatin, its morphology and accessibility. Histone deacetylation is a 
crucial mechanism of cancer progression. Histone deacetylase (HDACs) can alter the 
chromatin conformation and bind to proteins that affect RNA transcription, thus affecting 
cell growth, differentiation and apoptosis. DNA methylation is another important 
mechanism for control of gene transcription and is tightly connected to cell 
differentiation [18]. Most methylation takes place on CpG islands, the regions of high 
CpG dinucleotide density located in the promoters of housekeeping genes. The 
methylation of those areas not normally methylated in normal cells may induce the 
silencing of tumor suppressor genes such as BRCA1 [19, 20]. Understanding the 
biomarkers and molecular changes caused by epigenetic regulation will be valuable for 
effective treatment of breast cancer [21]. 
 
1.2.3 Epithelial-Mesenchymal Transition (EMT) and Cancer Stem Cells (CSC) 
Two new concepts in the area of breast cancer are: 1) CSC and its influence on tumor 
initiation, 2) EMT and its effect on the acquisition of malignant characteristics. 
Epithelial-mesenchymal transition (EMT) is defined as the transitioning of a cell from an 
epithelial to a mesenchymal state, which is related to increasing cancer aggressiveness 
and malignancy [22]. EMT is triggered by hypoxia, growth factor signaling, and tumor–
stromal cell interactions, and is a driver for the formation of cancer stem cells (CSC) [23]. 
Breast CSCs are cancer cells with stem characteristics and distinct immunological 
markers and may be an important source of tumor recurrence and drug resistance. 
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In vitro, it has been shown that growth factors such as Notch, transforming growth 
factor beta (TGF-beta), Wnt, and Hedgehog were able to form CSC through EMT [24], 
inducing mesenchymal proteins such as vimentin (VIM), tumor growth factor-β (TGF-β), 
Wnt, Notch, receptor tyrosine kinases (RTKs), and tumor necrosis factor-β (TNF-β) (Fig 
1.3) [25-28]. Adriamycin has been shown to induce the expression of TWIST1, an EMT 
protein, in MCF-7 cells [29]. Thus, it is essential that new strategies be formulated that 
could reverse EMT pathways, thus aiming to eliminate CSCs. 
 
1.3 Treatment Options for Breast Cancer 
The treatment of breast cancer is multidisciplinary. Common treatment methods 
include surgery, systemic therapy (chemotherapy, hormonal therapy) and radiation 
therapy. Beside the traditional treatment methods, biological drugs, epigenetic drugs, and 
gene therapy are also being actively investigated in their effectiveness in treating cancer. 
 
1.3.1 Hormone Therapy 
Hormone therapy is an integral part for breast cancer treatment, but is effective only 
for hormone-dependent cancer types. For example, tamoxifen and fulvestrant, two 
hormonal therapies, directly block the estrogen receptor (ER), and anastrazole works to 
prevent the body from producing estrogen. In spite of the success of those drugs, 
resistance to those treatments is often developed by patients, especially in cases of tumor 
metastasis.  
 
 
 8 
 
1.3.2 Chemotherapy 
For treatment of late stage cancer, chemotherapy is most common and has the 
potential to effectively control and eradicate cancer tissue.  Chemotherapy is often used 
in conjunction with radiation or surgery and has the advantage of reaching cancer cells at 
remote locations that cannot be accessed through surgery. Chemotherapy can also be 
used for metastatic cancer, but cytotoxic drugs have a relatively narrow therapeutic index 
as a result of dose-limiting toxic effects [30]. Chemotherapy is often limited only to 
certain cell cycle stages, and the frequent emergence of multiple drug resistance is a 
major disadvantage.  
 
1.3.3 Epigenetic Drug Therapy 
Due to the limitations of radiation and traditional chemotherapy, there is increasing 
interest in epigenetic drugs to overcome drug resistance in cancer through differentiation 
therapy targeting CSCs. Epigenetic drugs are able to decrease chemoresistance, stem-like 
behavior, cell proliferation, metastasis, stem-like behavior, and increase immune 
responsiveness and apoptosis (Fig 1.4) [31]. In T-cell prolymphocytic leukemia, 
epigenetic therapy has shown to help in overcoming treatment induced drug resistance 
[32]. Suberanilohydroxamic acid (SAHA), under the name Zolinza, was used for the 
treatment of cutaneous T cell lymphoma (CTCL). Currently, epigenetic drugs have 
shown to overcome drug resistance in cancer. Work from our group also showed that 
epigenetic drug decitabine (DAC) was effective in enhancing the efficacy of a 
chemotherapeutic doxorubicin (Dox) in breast cancer drug resistant cell line MCF-7/Adr 
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[33]. An example of the FDA approved epigenetic therapy is vorinostat, a histone-
deacetylation inhibitor for cutaneous T-cell lymphoma.  
 
Despite the success of epigenetic drugs such as decitabine (DAC) in clinical trials 
against hematologic malignancies and its antiproliferative effect in vitro, its efficacy in 
solid tumors has been disappointing [34]. This is due to the difference in the 
pharmacokinetics and pharmacodynamics of DAC between solid and hematologic 
malignancies. DAC has a very high clearance rate in vivo (half-life = 10-35 min) due to 
its low plasma protein binding and hence rapid clearance and inactivation by cytidine 
deaminase (CDA), found principally in the liver, as well as in granulocytes, intestinal 
epithelium and plasma [35]. The discrepancy between the in vitro efficacy of epigenetic 
drugs, including DAC, and their in vivo efficacy in solid tumor has been attributed to the 
slowly dividing nature of cancer cells in vivo vs. in vitro [36, 37]. Since DAC is S-phase 
specific, its activity in the tumor, when injected intravenously, may not last long enough 
for all the tumor cells to pass through the S-phase and thus for DAC to be effective. It is 
estimated that it takes approximately 5-15 d, depending on the tumor type and growth 
rate, for all the cancer cells in solid tumors to pass through S-phase [37-39]. Since DAC 
targets rapidly dividing cells such as bone marrow stem cells [40], its repeated and high 
dosing to achieve therapeutic levels in solid tumors was found to have serious side effects, 
such as chronic myelosuppression and leukopenia [36]. The toxicity of DAC at higher 
doses is due to its DNA-damaging activity rather than DNA demethylation activity [41].  
Therefore, several modified epigenetic drugs which are more stable or drug delivery 
systems for delivery of existing epigenetic drugs are under investigations [42]. 
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Figure 1.2 Epigenetic illustration of gene regulation. 
In a cell, epigenetic modulations such as DNA methylation and chromatin structuring (e.g. 
chromatin condensation, histone deacetylation) are major regulators (activators and 
silencers) of gene transcription. Therefore, the reversal of above actions, which is the 
demethylation of the CpG islands and histone deacetylation inhibition could activate the 
otherwise silenced genes in cancer cells. Adapted by permission from Macmillan 
Publishers Ltd: [Nat. Rev. Clin. Oncol.] (Azad, N. et al., The future of epigenetic therapy 
in solid tumors—lessons from the past) [31], copyright (2013). 
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Figure 1.3 The overview of epithelial-mesenchymal transition (EMT) and metastasis 
signaling networks. 
Tumor factor-β (TGF-β), Wnt, Notch, receptor tyrosine kinases (RTKs), and tumor 
necrosis factor-β (TNF-β) are major pathways that induce tumorigenesis. Upon activation, 
they induce EMT transcription factors such as Snail, Slug, and Twist. During EMT, the 
cancer cell undergoes a transformation to acquire stem –like characteristics. This enables 
them to possess resistance to chemotherapy and radiation therapy, immunosuppression 
and senescence. Reproduced from Wang, Y. et al. (2013) [43]. 
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Figure 1.4 Concurrent widespread changes in gene expression with epigenetic therapy. 
The anticancer efficacy of epigenetic drugs is strongly connected with widespread 
changes in gene expression that affect numerous biological processes as listed in the 
figure. Abbreviation: EMT, epithelial–mesenchymal transition. Reproduced /adapted by 
permission from Macmillan Publishers Ltd: [Nat. Rev. Clin. Oncol.] (Azad, N. et al.) [31], 
copyright (2013). 
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Vorinostat is a HDAC inhibitor, promotes cell-cycle arrest. It is a strong anti-drug 
resistant and anti-metastatic agent [44, 45]. It acts as a zinc ion chelator to bind to the 
active site of histone deacetylases, and is in several phase I and II clinical trials for 
hematological and solid tumors [46, 47]. However, the precise mechanisms of drug 
action are unclear, such as the upstream transcription regulators and downstream targets 
by which these inhibitors exert their effect. By gaining a more detailed understanding on 
the mechanisms of action of the drug and therapeutic effect, better treatment strategies 
can be devised. 
At its infancy in drug discovery, we are just starting to grasp the complexities of 
histone modification and the consequent changes in gene modulation. Although the 
epigenetic drugs have promise in reversing drug resistance, knowledge of the 
mechanisms of drug action and the underlying biology of cellular responses remains 
fragmentary. 
1.3.4 Gene Therapy 
Gene therapy is defined as the use of genes to treat or prevent disease. Several ways 
to utilize gene therapy include: 1) replace a mutated gene; 2) down-regulate an over-
expressed gene; and 3) insert a new gene into the body. Gene therapy encompasses DNA, 
small interfering RNA (siRNA) or short hairpin RNA (shRNA), and microRNA. 
There have been over 400 clinical studies in gene therapy under evaluation in the past 
15 years, 70% of which are cancer-focused [48]. Breast cancer, which is caused by 
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multiple genetic mutations, is an ideal candidate for gene therapy. Tumor suppressors 
including BRCA1 have been studied widely. However, one major obstacle confronting 
the effective application of gene therapy is identifying suitable targets that are selective 
for cancer cells as opposed to non-cancerous tissue. [49]  
 
1.3.4.1 siRNA Therapy 
RNA interference (RNAi) therapeutics is revolutionary in that it represents a 
powerful new tool for biological research of gene silencing. Among various means of 
RNAi, siRNA is the most commonly used. siRNA is a double-stranded RNA with 21-24 
nucleotides derived from mRNAs or viral RNAs [50], having an average size of less than 
10 nm.  They target, bind and degrade complementary mRNAs through the RNA-induced 
silencing complexes (RISCs) in the cytoplasm [51, 52]. siRNA has enormous therapeutic 
potential in repressing cancer cell proliferation as well as the metastasis and drug 
resistance [53]. One other advantage of siRNA is there is no need to penetrate into the 
nucleus, which is difficult to achieve due to the tight regulation of the nuclear membrane. 
siRNA also exerts longer silencing activity compared to antisense oligonucleotides [54]. 
Upon repeated dosing, siRNA is able to exert gene silencing for a long time without 
influencing the endogenous miRNA functionality of the cell, due to its target specific 
property [55]. The effective delivery of siRNA in vivo can be used to study gene 
functions, validate gene targets, for gene therapy. However, disadvantages include the 
easy degradation of siRNA in the blood serum and the triggering of the innate immune 
system in vivo [56-58]. 
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1.3.4.2 Gene Delivery Nano-carriers  
A bottleneck in gene therapy lies in its delivery. Disseminated breast cancer is far 
from accessible. Also, there are intracellular as well as extracellular biological barriers, 
which are yet to be overcome. Nano-vehicles are effective in delivering gene therapy to 
its target tissue and assist in gene transfection. By definition, nano-carriers have 
dimensions in two axes of less than 1000 nm [59]. In order to be effective in delivery, 
they are typically smaller than 300 nm in diameter. They can be organic or inorganic, 
forming different classes of carriers. Much research has been dedicated to gene delivery 
in the past 2 decades, using vehicles such as viruses, biological carriers, polymeric 
carriers, and metals, etc. Viruses are effective in transfecting cells, but concerns about 
safety and immunogenicity made scientists shift focus to non-viral carriers [60]. Some of 
the materials used include chitin, gelatin (natural), and polylactides and poly alkyl 
cyanoacrylates (synthetic). Among these, cationic polymers, peptides and liposomes were 
all investigated [61].  
 
Cationic vehicles have the advantage of forming electrostatic complexation with 
anionic nucleotides. For example, polyethylenimine (PEI) complexes siRNA through 
cationic functional groups (amines), bind the siRNA phosphate group through 
electrostatic interactions, and also play an important role in the polyplexes uptake [62]. 
Although showing good siRNA condensation and uptake [63, 64], the stability of PEI as 
well as transfection efficiency in vivo are also major hurdles in its clinical applications 
[65, 66]. Also its toxicity level and rapid clearance adversely narrowed the dosing 
capacity and the therapeutic window. PEGylation-the covalent attachment of 
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polyethylene glycol (PEG), and a number of other chemical modifications have been 
done to PEI to exert a shielding effect on the positively charged polyplexes with the goal 
of reducing toxicity and improving complex stability and hydrophilicity [67].  
 
1.4 Deep-Sequencing 
The transcriptome is the complete set of cellular transcripts under a specific condition. 
“Whole Transcriptome Shotgun Sequencing", also called deep sequencing, is an 
emerging technology to globally assess the RNA content from the sequencing of cDNA 
[68]. Through RNA-seq, we can obtain an unbiased, global understanding of the 
transcriptome and gain a more precise measurement of transcript levels, which is 
essential for interpreting the functional elements of the genome and their molecular 
regulations. This technology is well adapted to cancer studies and is especially 
advantageous because it provides deep coverage at base-level resolution [69]. Also, 
RNA-seq it gives information on genes’ quantitative changes under different conditions, 
differential splicing, non-coding RNAs, post-transcriptional modifications, and has been 
seen as "a revolutionary tool for transcriptomics" [70].
 
 
 
Recent advances in high-throughput sequencing have enabled genome-wide mapping 
of chromatin changes occurring during tumorigenesis, including a global loss of 
acetylated H4-lysine 16 and H4-lysine 20 trimethylation [71]. Such loss of histone 
acetylation caused by HDACs is a reason behind repression of genes. The global 
transcriptomic profiling enables a very high resolution of the intricate inner workings of 
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the transcriptome, enabling us to explore the distinct nature of each cancer landscape, and 
provide a new tool for the analysis of therapeutic targets [72]. 
 
1.5 Hypothesis 
I hypothesize that CSC characteristics can be identified in breast cancer cell lines; 
epigenetic drugs are capable of reversing stem-like characteristics; through global 
transcriptomics analysis, I can elucidate new genes and pathways used by epigenetic 
drugs to reverse drug resistance; finally, effective siRNA and DNA-siRNA co- 
transfection can be achieved using arginine and polyethylene glycol (PEG) modified 
cationic polymer. 
 
1.6 Specific Aims 
Aim 1. To examine the CSC characteristics in breast cancer cell lines and the effect of 
epigenetic drug SAHA. 
Aim 2. To analyze the transcriptomic alterations in drug resistant breast cancer cells as a 
result of epigenetic drug treatments.  
Aim 3. To generate a cationic construct to facilitate siRNA and DNA-co-siRNA delivery. 
 
1.7 General Dissertation Overview 
 This project combined innovative and integrative approaches involving molecular 
and cellular biology, bioinformatics, and gene transfection using nano-vehicles. In this 
study, I observed significant changes in the metastatic potential, drug resistance level, 
tumorigenic potential, as well as morphological changes due to the epigenetic drugs DAC 
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and SAHA treatments. Using high-seq analysis, I unraveled genes and pathways that 
were differentially regulated by DAC and SAHA. The effectiveness of gene therapy lies 
in having delivery vehicles that are effective to transfect tissues of interest. By optimizing 
the construct formulation, I developed a novel delivery system with an effective 
nucleotide condensation and endocytotic rate. The formed polyplexes were able to 
transfect both metastatic and drug resistant breast cancer cell lines in vitro and 
insignificantly reduce luminescence level in vivo in the luc-MDA-MB-231 xenograft 
tumor model. 
 
In the next 4 chapters, this dissertation tests the overall hypothesis and its specific 
aims. Chapter 2 identifies CSC phenotype from drug resistant breast cancer cells with 
induced drug resistance, and illustrates the effects of SAHA in combating those cells. 
Chapter 3 focuses on the elucidation of pathways and mechanisms through deep-
sequencing technology. Chapter 4 and 5 describe a novel vehicle for siRNA delivery and 
DNA-siRNA co-delivery. 
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CHAPTER II 
 
DRUG RESISTANT BREAST CANCER CELL LINE DISPLAYS CANCER STEM 
CELL PHENOTYPE AND RESPONDS SENSITIVELY TO EPIGENETIC DRUGS 
SAHA AND DAC 
 
Keywords: surface markers; epithelial mesenchymal transition; epigenetic therapy; 
cancer therapy 
2.1 Introduction 
According to cancer stem cell (CSC) theory, CSCs are the only cell population in a 
tumor that causes tumorigenesis, cancer progression and metastasis, and resistant cancer 
chemotherapy. They are able to self-renew and differentiate, possessing stem cell 
characteristics [73]. They are also responsible for tumor re-growth in post-treatment [74]. 
First identified in acute myeloid leukemia, CSCs and the existence of multiple stem cell 
classes was evidenced by the fact that only ~1% of leukemic cells (signifying clonogenic 
progenitors) are able to proliferate, distinguishing them from the majority of cells [75, 
76]. Soon afterward, CSCs were reported in solid tumors. Many identification systems 
and treatments then followed, focusing on conquering CSCs, which are drug resistant 
[77-83]. However, gaps exist in the CSC theory, such as the lack of an established CSC 
hierarchy in a solid tumor and linking cellular lineage with their functions.  Also, it is 
difficult to establish connections between CSCs and normal stem cells in a tissue, and 
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trace back the cellular origin of the identified CSCs. It has been demonstrated that the 
selected populations possess sphere-forming ability, able to self-renew (making identical 
replicates), and express a high level of malignancy which allow them to resist treatment 
and initiate and re-initiate tumors after chemo and radiation therapy. 
The most widely recognized breast CSC (BCSC) markers are CD44
+
/CD24
-/low
 [84-
89]. Subsequent studies have distinguished CD44
-
/CD24
+
 as luminal cells while
CD44
+
/CD24
-
 possess basal-like phenotype [76]. Heterogeneous (CD44
+
/CD24
+
 or
CD44
-
/CD24
-
) expressions were also observed in the tumors [90]. The CD44
+
/CD24
-
sub-population of a tumor are shown to be able to initiate and propagate a tumor, and has 
been used to signify its ability to self-renew. The same cell population has also displayed 
considerable chemo-resistance and distant metastasis [81, 91]. 
Beside CD44
+
/CD24
-
, a number of other markers have also shown connection with
tumor-initiation and treatment survival, most of which have to do with cellular adhesion 
and mobility. Epithelial-specific antigen (ESA), CD49f and CD201 are a few that have 
been identified for BCSC. ESA has been shown to support migration and invasion in 
human metastatic cell line MDA-MB-231 [92], while CD49f is connected with cell 
adhesion and surface signaling. In this research, for the first time, I demonstrated the 
uniform and prolonged display of CD44
+
/CD24
-
 phenotype along with the above-
mentioned BCSC markers in a well-established multi-drug resistant breast cancer cell 
line MCF-7/Adr without special supplements or culture conditions, bringing new 
perspectives on the current knowledge of CD44
+
/CD24
-
 phenotype, and that of BCSC.
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Global epigenetic mutation is a significant landmark for cancer. Epigenetic drugs are 
promising in overcoming and reversing cancer malignancy through cellular 
differentiation targeting CSCs. Epigenetic drug suberoylanilide hydroxamic acid (SAHA), 
approved to treat cutaneous T-cell lymphoma, is a strong anti-drug resistant and anti-
metastatic agent [44]. Taking into account the transient therapeutic nature of SAHA, I 
further explored its effect to alter the cell surface markers through short-term drug 
exposure, the understanding of which could profoundly affect the targeting and selecting 
strategies toward malignant cancer types especially utilizing epigenetic drugs as the 
combination therapy. 
2.2 Materials and Methods 
The materials and the methods to characterize the breast cancer cell lines MCF-7, MCF-
7/Adr, MDA-MB-231, SkBr3 were listed below. 
2.2.1 Materials 
Human breast cancer cell lines MCF-7, MDA-MB-231, SkBr3 were obtained from 
ATCC (American Type Culture Collection). DCIS (ductal carcinoma in situ) was 
purchased from Celprogen (San Pedro, CA). MCF-7/Adr cell line was established 
through long-term doxorubicin incubation.  Human mesenchymal stem cell (hMSC), 
hMSC basal medium, MSCGM bullet kit (PT-3238 & PT-4105) and hMSC 
trypsin/EDTA were purchased from Lonza Inc. (Walkersville, MD). APC Mouse Anti-
Human CD44, PE Mouse Anti-Human CD24, FITC Mouse Anti-Human CD326 (ESA), 
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PE Mouse Anti-Human CD201, PE-Cy™5 Mouse Anti-Human CD49f was purchased 
from BD Biosciences and BD Pharmingen (San Jose, CA). Twenty four-well ultra-low 
binding plates were purchased from Corning (NY). Fetal bovine serum (FBS) was 
purchased from Gibco (Invitrogen, Milan, Italy). Crystal violet solution (HT90132-1L) 
and MTT reagents were purchased from Sigma-Aldrich (St. Louis, MO). B-27 Serum-
Free Supplement (50X) (17504-044) and all antibodies were obtained from Invitrogen 
Inc. Human recombinant fibroblast growth factor basic (GF003) was purchased from 
Millipore (Billerica, MA). Keratinocyte serum-free medium (K-SFM) and accompanying 
supplements (bovine pituitary extract, final concentration 50 μg/ml, recombinant human 
epidermal growth factor, final concentration 5 ng/ml) were obtained from 
GIBCO.  SAHA was purchased from Sigma-Aldrich.   
 
2.2.2 Cell Culture  
All cancer cell lines were cultured in DMEM supplemented with 15% heat-
inactivated fetal bovine serum and 1% penicillin-streptomycin. Cultures were incubated 
at 37 °C in a humidified atmosphere containing 5% CO2 using 75T cell culture flask. 
Cells were sub-cultured reaching 90% confluency. hMSCs were expanded using hMSC 
Basal Medium containing MSCGM Bullet Kits and experiments were conducted in 
DMEM containing 10% FBS and 1% penicillin-streptomycin. Medium was changed 
every 3 days and cells were sub-cultured at 85-90% confluency. hMSCs up to passage 6 
were used for experiments.  
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2.2.3 Flow Cytometric Analysis 
Breast cancer cell lines were analyzed for the expression of selected BCSC markers 
including CD44, CD24, CD201 CD49f and ESA. For all experiments, after trypsinization, 
cells were washed twice with PBS and re-suspended in staining buffer with 
fluorochrome-conjugated antibody and incubated on ice in the dark for 30 min with 
antibody solution in flow butter for 30 min on ice bath. The flow buffer consists of PBS 
with 10% FBS and 0.1% NaN3 sodium azide. Antibody concentrations were consistent 
throughout experiments. After staining, all samples were washed thrice with PBS, re-
suspended in flow buffer and tested using LSR II. Cells were shielded from light at all 
times. Cells from each cell line were treated with the same procedure but without 
antibody to serve as the control sample. The samples were analyzed with FlowJo 
software. A minimum of 2000 events were recorded for each sample and analyzed.  
 
2.2.4 Mammosphere Formation Assay 
Cells were single-suspended at a density of 5000 cells in culture media in six-well 
ultra-low attachment plates (2.5 mL per plate). 2 culture systems were used: 1) Phenol 
red free serum free DMEM supplemented with 20 ng/ml human basic fibroblast growth 
factor, 20ng/ml human epidermal growth factor, 1X B27, 1% penicillin-streptomycin 
solution; 2) K-SFM with BPituitary extract and 20 ng/ml epidermal growth factor, 1% 
penicillin-streptomycin solution. Culture media were replenished every 3 days and 
images were taken at day 7. After 7 days, mammospheres were collected and cells were 
dissociated for flow cytometry. 
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2.2.5 Migration/Invasion Assay 
Twenty four-well Falcon tissue culture plates with 8 micron cell culture insert was 
used for migration assay. Cells were first starved overnight and plated on top of the insert 
and allowed to migrate for 24 hours, using 5% FBS in DMEM as attractant. The assay 
was terminated by fixing cells with 4% paraformaldehyde on ice. Cells were stained with 
crystal violet and cells on top of the insert were removed with a cotton swab. Images 
were taken after staining. For quantification, cells migrated through the insert were lysed 
with RIPA buffer and lysate were quantified in 96 well-plate using a plate reader. 
 
2.2.6 In vitro Proliferation Assay 
MTT assays were conducted according to the manufacturer’s protocol. Cells were 
plated at 3000 cells/well in 96-well plates and cultured with the drugs for 5 days. After 
the test was completed, 26 µL of 2 mg/mL of MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide; (Sigma-Aldrich) was added to each well and 
incubated at 37 C for 4.5 hrs for crystallization. After crystallization, DMSO (100 
µL/well) was added to each well. After the crystals were dissolved completely, 90 µL 
were transferred to a clean plate and the absorbance was measured using plate reading at 
absorbance of 570 nm (Molecular Devices, Sunnyvale, CA).  
 
2.2.7 Immunofluorescence Imaging 
Immunofluorescence staining was performed on cell culture grown on cover slides. 
Cells were allowed to grow on cover-slides with or without SAHA for five days. 
Afterward, cells were washed with PBS and fixed with 4% paraformaldehyde (for E-
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cadherin and fibronectin). For vimentin staining, cells were fixed using 100% ice-cold 
methanol on ice for 7 minutes. Unspecific binding sites were blocked with 3% goat 
serum diluted in PBS for 15 minutes at room temperature. After that, the cells were 
stained with primary antibodies (mouse anti-human E-cadherin 1:500 v/v, mouse anti-
human fibronectin 1:250 v/v, mouse anti-human vimentin 1:250 v/v) diluted in blocking 
buffer overnight at 4 C, washed three times and replaced with secondary antibody (FITC 
conjugated goat anti-mouse IgG, IgM) for 45 minutes in the dark at room temperature. 
Secondary antibodies were diluted in 1:5000. After ﬁve washes of 10 minutes each, the 
cells were mounted with vectashield with DAPI (Vector Laboratories, Burlingame, CA) 
and viewed under the fluorescence microscopy. 
 
 2.2.8 Statistical Analysis 
Statistical analysis was conducted via student t-test. P ≤0.05 was used to define 
statistical significance. Cellular density was converted to percentage of the control and 
represented as mean ± standard error of mean. 
 
2.3 Results  
     Results of the studies were shown below. In this section, immunophenotype, 
mammosphere formation, 24 hr and 14 days SAHA treatment, and migration assay of the 
cells treated with SAHA were examined. 
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2.3.1 Immunophenotype of the Stem-Like Cancer Cells 
Surface markers (CD24, CD44, CD49f, CD201, and ESA) were selected according to 
current BCSC identification systems. We examined the presence of above markers using 
flow cytometry in cell lines MCF-7, MCF-7/Adr, MDA-MB-231, SkBr3, and DCIS 
(ductal carcinoma in situ cell line) (Fig. 2.1, Table 2.1). 
 
Cell lines were found to have distinct CD44/CD24 immunophenotypes (Fig. 2.1A-B, 
Table 2.1). In MCF-7/Adr, differential expressions between passages were observed-
passage 6 negatively expresses CD24 while passage 33 displays over 30% of CD24
+
 cells 
(Fig. 2.1A-B, Table 2.1). We suspect this relates to the gradual loss of drug resistance, 
thus phenotypic reversal at higher passages. MCF-7 displayed a broad range of CD24 
expression, representing the phenotypic heterogeneity within an established cell line (Fig. 
2.1B, Table 2.1). However, the presence of CD49f, ESA and CD201 seem to be 
independent of any distinctive CD44/CD24 phenotype (Fig. 2.1, Table 2.1). Compared 
with its parental cell line MCF-7, MCF-7/Adr’s acquisition of drug resistance leading to 
its malignant transformation is marked by its expression of CD44, CD49f and CD201 and 
E-cadherin to 100% and the complete negative expression of CD24.  
 
The acquisition of CD24
-
/CD44
+ 
phenotype, along with other BCSC markers, 
signifies the acquisition of stem-like properties in MCF-7/Adr cells. It has been reported 
that cells that undergo EMT also display a loss of E-cadherin and a gaining of cellular 
motility. However, the contrary is observed in MCF-7/Adr when compared to its parental 
cell line MCF-7 (Fig. 2.1). Our study is the first to report the uniform and stable display 
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of BCSC markers with an increased expression of E-cadherin in a cell line over a long 
period of time. The cell line is slow-dividing and highly chemo-resistant, while at the 
same time low in migration and invasiveness. For comparison purposes DCIS cell line, 
which negatively expresses all the above mentioned surface markers was included in the 
study (Fig. 2.1, Table 2.1).  
 
2.3.2 Mammosphere Formation Shows Distinct Cellular Properties  
Mammosphere formation capacity to a large extent mirrors the tumor-formation 
capacity in vivo. We examined both cell line’s mammosphere formation ability under 
different culture media and the immunophenotypes of the cells dissociated from 
mammospheres. Mammosphere formation starts after 2-3 days and immunophenotyping 
were done with cells dissociated from mammospheres at day 7 (Fig. 2.2A, Table 2.3). 
Cell lines respond differently to different culture media. It is worth-noting the differential 
responses of MCF-7 and MCF-7/Adr, MCF-7/Adr, MDAMB-231-D3H2LN and DCIS 
were observed to have similar responses, while MCF-7 and MCF-7/Adr responds in an 
opposite manner to culture conditions (Fig. 2.2A, Table 2.3). MCF-7/Adr stayed single 
cell suspended in DMEM which supports MCF-7 sphere formation, but grew good 
mammospheres in K-SFM which did not support MCF-7 mammospheres (Fig. 2.2A, 
Table 2.3).  
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Table 2.1 Human Breast Cancer Cell Lines Differentially Express Solid Breast Cancer 
Stem Cell Markers (% of Control). 
Cells have >90% of positive expression are counted are positive 
Cells have <10% of positive expression are counted are negative 
                   CD44           CD24           CD201           CD49f           ESA          E-Cadherin 
MCF-7               53                 85                  47                    26               89                  31 
MCF-7/Adr        +            Passage 6: −         +                      +                +                   61 
                                       Passage 33: 34% 
MDA-MB 
-231-D3H2LN     +                 75                   +                      +                10                  −                  
SkBr3                 19                 +                    88                     −                 +                   − 
DCIS                    −                  −                    −                      −                 −                   − 
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Figure 2.1 Drug resistant breast cancer cell lines characterization uncovers breast cancer 
stem cell immunophenotypes. 
Red dots are unstained and blue dots are stained cells. Marker profiling of (A) CD44, (B) 
CD24, (C) ESA, (D) CD201, (E) CD49f and (F) E-cadherin were done in cell lines MCF-
7, MCF-7/Adr, MDA-MB-231, SkBr3 and DCIS by flow cytometry (see Materials and 
Methods). Different CD44/CD24 combinations were observed across cell lines. MCF-
7/Adr showed near 100% CD44
+
/CD24
-
 phenotype, commonly recognized for BCSC. 
MCF-7, MCF-7/Adr and MDA-MB-231 showed heterogeneity of CD24 expression, 
demonstrated cellular hierarchy and the existence of sub-populations in cell cultures. 
MCF-7/Adr’s CD24+ population varied between passages, indicative of 
immunophenotypic transition.  
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Table 2.2 Alterations of BCSC Markers in Adherent vs. Mammosphere Culture 
Conditions. 
M
mammosphere-dissociated cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CD44 CD24 CD49 ESA 
MCF-7/Ar
M
 40 63 34 - 
MDA-MB-231
M
  65 95 - 
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Another interesting observation was the rapid phenotypic transition during MCF-
7/Adr mammosphere culture condition, making MCF-7/Adr cells partially lose CD44, 
CD49f and ESA expressions, and gaining CD24
+
, acquiring 
CD44
weak
/CD24
+
/CD49
weak
/ESA
-
 phenotype (Fig. 2.2B, Table 2.2). Such drastic 
alteration in immunophenotype was not observed in MDA-MB-231, which also formed 
mammospheres under K-SFM, but not DMEM culture condition (Fig. 2.2A, Table 2.3). 
This observation indicates that the complete loss of multiple surface markers in a short 
period of time in sphere culture conditions is not a common phenotype, but signifies the 
cell’s ability to reverse its acquired phenotype and the ability to divide differentially. The 
fluidity of immunophenotypic conversion observed here would open new doors to the in 
vitro studies of EMT and MET related processes in breast carcinoma, drawing parallels 
with their in vivo counterparts. The data also indicate that there is no direct correlation 
between a particular CD44/CD24 phenotype and a specific mammosphere culture 
condition (Fig 2.2A, Table 2.3).  
 
2.3.3 Short-Term SAHA Treatment Reverses Drug Resistance but not BCSC 
Immunophenotype 
SAHA treatment was incorporated because it’s shown to counter cancer cell’s 
malignancy, reverse multi-drug resistance, invasiveness and metastatic potential. Cell 
surface marker profiling of MCF-7/Adr was done after 24 hours or 14 days of SAHA 
treatment, to examine if short-term drug treatment would make alterations on the surface 
markers. I observed no alteration in surface markers (Fig 2.3A).  
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Figure 2.2 Immunophenotype changes after mammosphere culture condition. 
 (A) Mammosphere formations for different cell lines require different culture conditions. 
MCF-7 forms mammospheres in DMEM, while MCF-7/Adr and MDA-MB-231 only 
form mammospheres in K-SFM, which signifies significant differences in cellular 
properties. Surface marker profiling of MCF-7/Adr (B) and MDA-MB-231 (C) in 
mammosphere culture conditions showed MCF-7/Adr’s asymmetric division. 
Mammosphere culture condition after 7 days showed significant reversal of CSC 
phenotypes in MCF-7/Adr (the positive expression of CD44, CD49f and ESA, and the 
negative expression of CD24). MDA-MB-231, on the contrary, did not show drastic 
alteration in phenotypes under mammosphere culture condition. 
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Table 2.3 BCSC Surface Marker Expression in Cell Lines after 14 days of SAHA 
Treatment (% of control). 
 
 
 
 
 CD44 CD24 CD201 CD49f ESA 
MCF-7 S - + 34 - 31 
MCF-7/Adr S + 60 86 + 16 
 MDA-MB-231 S 
 
70 34 48 59 
- 
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Figure 2.3 SAHA treatment alterations on cell surface markers. 
(A) 24 hours SAHA treatment, which was shown to alter cell membrane fluidity, reverse 
(transiently) drug resistance, and slightly increase MCF-7/Adr’s mobility, showed no 
effect on the expression of MCF-7/Adr surface markers. (B, C, D) 14 days of SAHA 
treatment on MCF-7/Adr passage 6, MCF-7 and MDA-MB-231, respectively.  (E, F) 
human mesenchymal stem cell surface marker on hMSC before and after 7 days of 
SAHA treatment. SAHA treatment for 7 days (dosing every other day) had no effect on 
hMSC’s identification markers.  
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Mesenchymal stem cells were incorporated in the study to examine SAHA’s 
differentiation ability. The cells were treated with SAHA for 7 days (drug replenished 
every 2 days) and surface markers were examined using MSC identification marker panel, 
found to retain the same set of surface markers as before treatment (Fig. 2.3E-F). 
However, it is possible that the drug triggers the up or down-expression of other surface 
markers not tested using our purchased identification kit.   
2.3.4 Cells Affected Differently by SAHA in their Migratory Ability    
Migration assay was performed on the highly migratory cell lines hMSCs and MDA-
MB-231, and highly adherent MCF-7/Adr with or without SAHA treatment. For both 
migratory cell lines, SAHA was found to significantly lower migratory ability (Fig 2.4). 
On the other hand, MCF-7/Adr remains non-migratory, uninfluenced by SAHA treatment 
(Fig 2.4). This observation was possibly due to drug effect on MCF-7/Adr’s membrane 
properties, increasing membrane fluidity and decreasing cell-cell contact and adhesion 
ability, thus making them more mobile. MTT assay showed MCF-7/Adr to be much more 
vulnerable to SAHA than both MDA-MB-231 and hMSC (Fig 2.5). 
2.3.5 Expression of E-cadherin, fibronectin and vimentin in MCF-7/Adr cells 
MCF-7/Adr positively expresses E-cadherin and fibronectin proteins. After 5 days 
treatment, E-cadherin and fibronectin expressions were drastically reduced and vimentin 
was positively expressed (Fig 2.6).  
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2.4 Discussion  
It has been shown that cancer stem cells should be able to self-renew and differentiate 
due to their being both drug and radiation-resistant as well as being highly metastatic and 
invasive [73]. CD44/CD24 combinations categorize breast cancer cells into luminal, 
basal A and basal B subtypes [93]. High CD44
+
/CD24
- 
expression represents 
basal/mesenchymal phenotype, while CD44
-
/CD24
+
 signatures luminal/epithelial 
phenotype [93]. I observed all four combinations in our cell lines, having metastatic 
MDA-MB-231 cell line positively express CD44 and have 70% CD24
+
 expression. On 
the other hand, ductal carcinoma have uniform CD44-/CD24- phenotype (Fig 2.1), whose 
tumorigenic and metastatic properties we know very little about. For the first time, a cell 
line with uniform CD44
+
/CD24
- 
phenotype was reported, which possesses high drug 
resistance but poor migratory and proliferation potential. A number of other BCSC 
surface markers, include CD201, CD49f, and ESA, were also positively identified in 
MCF-7/Adr (Fig 2.1).  
 
The malignant transformation the parental cell line MCF-7 experiences to acquire its 
drug resistance are likely through epithelial-mesenchymal transition (EMT).  EMT genes 
in MCF-7/Adr were analysed in detail by Ozlem et al, and was confirmed to be up-
regulated comparing to its parental cell line [94]. Similar observations were made by 
Arumugam et al. have reported that cells acquire drug resistance through EMT in 
pancreatic cancer [95]. Contrary to traditional views on EMT, which have been closely 
related to tumour progression, increased cell motility and invasiveness [96], MCF-7/Adr 
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demonstrated decreased motility and a stronger cellular adhesion compared to its parental 
cell line MCF-7 (Fig. 2.5). Also, it showed no E-cadherin repression (Table 2.1).  
 
Figure 2.4 Migration Assay assesses the migratory potential of SAHA in 24 hours. 
(A, B) 24 hours SAHA treatment during migration assay dramatically reduced cellular 
motility for highly migratory cell lines hMSC and MDA-MB-231. MCF-7/Adr, a 
strongly adherent and non-migratory cell line, did not demonstrate significant change due 
to SAHA treatment. (C) Migratory rate quantification showed significant change in 
migration rate in both hMSC and MDA-MB-231. n=4. p≤0.05. 
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Figure 2.5 Comparative illustration of SAHA resistance in different cell lines. 
MTT assay showed hMSC has the greatest resistance to SAHA, while MCF-7/Adr, which 
expresses the multi-drug resistant phenotype, has the least SAHA resistance.    
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Figure 2.6 Immunoﬂuorescence staining examines the presence of E-cadherin, 
fibronectin and vimentin with or without 5 days of SAHA treatment in MCF-7/Adr. 
(A) SAHA effect on E-cadherin, fibronectin and vimentin in MCF-7/Adr. There is 
evident expression of E-cadherin, fibronectin and vimentin both with and without SAHA 
treatment. (B) Dual color imaging of both untreated and SAHA treated MCF-7/Adr. Blue: 
nucleus, green: E-cadherin or vimentin, red: fibronectin.  
 42 
 
Previous studies have identified CD44
+
/CD24
- 
sub-population in a number of cell 
lines including MDA-MB-231, MDA-MB-436, and SUM204, and was thought to have 
higher invasiveness and metastatic potential than the CD44
+
/CD24
+
 population [96]. I 
have also observed heterogeneity in our MDA-MB-231 cell line, containing roughly 25% 
of CD24
- 
phenotype (Fig. 2.1). The entire MDA-MB-231 cell line positively expresses 
CD201 and CD49f but negatively expresses ESA and E-cadherin, which relates to the 
cell’s migratory ability. Since many therapies are formulated based on cancer cell’s 
molecular profiles [97], it is important to precisely correlate immunophenotypes with 
cellular properties. Fillmore et al. also showed that CD44
+
/CD24
- 
phenotype in the 
culture have high metastatic ability and invasiveness [97]. Since CD44
+
/CD24
- 
phenotype 
is also evident in our MCF-7/Adr cell line which possesses no metastatic or invasive 
properties, I suspect either the CD44
+
/CD24
- 
 phenotype represents different properties 
which are cell-line specific, or there are other markers which are more representative of a 
greater metastatic potentials than previously reported.  Furthermore, no study has yet 
shown an entire cell-line possessing the CD44
+
/CD24
-
/ESA
+
 phenotype and able to be 
stably maintained for a long period of time without reversing back to its parental 
phenotype.  
 
Fibronectin and vimentin are both EMT proteins. Vimentin signifies basal phenotype, 
while E-cadherin represents luminal phenotype [93]. Our study shows that MCF-7/Adr 
expresses a high level of E. Cadherin while at the same time positively expressing 
vimentin and fibronectin (Fig 2.6). This observation is uniquely important in 
revolutionizing the established perceptions on BCSCs and EMT. It was reported that a 
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number of genes induced in iPS transformation were well-established oncogenes (c-myc 
and SOX2, for example) [98-100]. It is therefore reasonable to make the connection 
between the acquisition of drug resistance (the up-regulation of oncogenes) and the 
transition into BCSC-like cells.  
 
Mammosphere culture mirrors in vitro tumorigenic capacity. It has been shown that 
MCF-7 undergoes EMT through mammosphere culture condition, generating sub-
population with CD44
+
/CD24
-
 mesenchymal phenotype, E-cadherin down-regulation and 
more tumorigenic cells formation [101]. In this dissertation I report the reverse of EMT 
in MCF-7/Adr through mammosphere culture conditions which loses its acquired BCSC 
markers in 7 days (Fig. 2.2 B, Table 2.2). MDA-MB-231 mammospheres were also 
characterized and examined for comparison purposes, and no drastic phenotypic 
alterations were observed. It is possible that at in vivo implantation, similar transition 
takes place resulting in a heterogeneous tumor with partial chemo-resistance. 
 
The difficulties of sorting CSC subpopulation from tumors give rise to the need of a 
reliable system to study CSCs in vitro. Inconsistency across reported studies, especially 
in the characterizations of CSCs in primary tumors is not uncommon. Also, it is yet 
unknown whether the gaining of CD44
+
/CD24
−
 phenotype is an exclusive indication of 
EMT. Nevertheless, this study provided a new perspective on breast CSC phenotypes 
through the display of uniform CD44
+
/CD24
− 
phenotype in a cell line, which has great 
implications on the in vitro studies of transitions between epithelial and mesenchymal 
phenotypes. 
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2.5 Conclusions 
This study showed a drug resistant breast cancer cell line with BCSC 
immunophenotype and proteins which can be stably maintained overtime and undergoes 
environmentally-driven mesenchymal epithelial transition (the reversal of EMT) upon 7 
days of mammosphere formation assay or 14 days of epigenetic drug SAHA treatment. 
Phenotypically, it is high in drug resistance and low in metastasis. The unique 
characteristics presented by this cell line opens new doors for the in vitro characterization 
of BCSC-like phenotypes, and for drawing parallels with similar in vivo observations. 
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CHAPTER III 
 
RNA-SEQUENCING REVEALS DRUG RESISTANCE TRANSCRIPTOMIC 
SIGNATURES AND PATHWAYS REVERSED IN RESISTANT BREAST CANCER 
CELLS BY EPIGENETIC DRUGS 
 
Keywords: demethylation, histone deacetylation inhibitor, DAC, SAHA, drug transport 
3.1 Introduction 
Acquired drug resistance is a major issue for effective cancer chemotherapy and has 
often led to cancer relapse and a more aggressive phenotype [7].
  
Therefore, reversing the 
mechanisms and pathways involved in drug resistance is critical for developing effective 
therapeutic strategies to reverse drug resistance.
 
A major change due to drug resistance 
takes place in the epigenome (the change in the chromosome and DNA landscape) [103]. 
Epigenetic drugs, which reverse nuclear landscape and reactivate the transcriptionally 
silenced genes with anti-tumor effect [104, 105], can have significant impact on tumor 
response to drug treatments [106, 107]. Two important epigenetic indicators of drug 
resistance are DNA methylation and histone deacetylation [108]. Five-aza-2'-
deoxycytidine (DAC) is a DNA demethylation agent, which inhibits DNA 
methyltransferase and activates the otherwise suppressed genes [109, 110]. 
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Suberoylanilide hydroxamic acid (SAHA) is a histone deacetylase inhibitor, which 
binds to the active site of the histone deacetylase as a zinc ion chelator and opens up the 
histone for DNA transcription [111]. Due to the ability of DAC and SAHA to reverse 
epigenetic characteristics of drug resistant cells, they were selected for this study.  
 
The main mechanisms of acquired drug-resistance include membrane transport 
alteration, onco- and drug resistant gene up-regulation, and changes in drug metabolism 
[7, 112, 113]. In our previous study, I have demonstrated that DAC treatment enhances 
doxorubicin (Dox) cellular uptake either when treated with Dox as solution or in 
liposomal formulation, hence exerted synergistic effect in drug resistant breast cancer 
cells (MCF-7/Adr). This effect was partially caused by changes in the resistant cell 
membrane lipid composition, particularly the altered membrane fluidity from a rigid to a 
more fluid state, thus regaining drug transport and endocytic function [114]. In the same 
study, it showed that SAHA, on the other hand, only produced additive effect with Dox 
[33]. How epigenetic drugs reverse acquired drug resistance and what causes the 
differential drug effect between DAC and SAHA remain to be investigated. In this study, 
I conducted massive parallel sequencing, a genome-wide and cell-type-specific approach, 
to understand the transcriptomic alterations by DAC and SAHA and identified novel 
genes and mechanisms that reverse drug resistance.  Our result showed that despite the 
similar regulatory pattern in numerous mechanistic pathways, the differential 
effectiveness of DAC and SAHA to enhance Dox toxicity can be contributed by the 
down-regulation of drug metabolism genes by DAC and an up-regulation of drug 
resistant genes Erb-B2 Receptor Tyrosine Kinase 2 Interacting Protein (ERBB2IP), 
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Transforming Growth Factor, Beta Receptor II (TGFBR2) and E3F7 (E2F Transcription 
Factor) by SAHA. 
 
3.2 Materials and Methods 
The materials and the methods to conduct RNA sequencing on MCF-7/Adr breast cancer 
cells were listed below. 
 
3.2.1 Materials 
DAC and SAHA were purchased from Sigma-Aldrich (St. Louis, MO). Three-(4, 5-
Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium Bromide (MTT) was purchased from 
Sigma-Aldrich. Dox was purchased from Drug Source Co. LLC (Westchester, IL). 
Dulbecco's Modified Eagle's Medium (DMEM), penicillin and streptomycin, and 
Dulbecco's phosphate-buffered saline (DPBS) were obtained from our Cell Services’ 
Media Core. Fetal bovine serum (FBS) and Trypsin/EDTA were purchased from Gibco 
(Grand Island, NY). 
 
3.2.2 Cell Culture 
Breast cancer resistant cell line MCF-7/Adr was obtained from Prof. Batra’s 
laboratory at the University of Nebraska Medical Center, Omaha. Cells were cultured at 
37 °C with 5% CO2 in DMEM with 15% FBS and 1% penicillin-streptomycin. Cells were 
washed twice with DPBS before detachment using Trypsin/EDTA. The resistant status of 
cells was maintained by regularly treating the cells with 100 ng/mL of Dox. Cells were 
incubated for two passages in drug-free media before using for experiment.  
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3.2.3. Cell Viability 
Cytotoxicity of SAHA and DAC in MCF-7/Adr was evaluated by MTT assay. Cells 
(5×10
5
 cells per well) were seeded in 24 well plates (BD Biosciences, San Jose, CA) in 
500 µL of culture media and were allowed to attach for 24 hrs. The culture medium in 
plates was replaced with freshly prepared DMEM medium with FBS containing different 
concentrations of DAC or SAHA (from 5 ng/mL to 250 ng/mL). Following 24 hr 
incubation, the medium in wells was replaced with 150 µL of MTT (0.5 mg/mL in 
DMEM) reagent and allowed to incubate overnight at room temperature. The content in 
each well replaced with 500 µL of dimethyl sulfoxide, plates were incubated at 37 °C for 
3.5 hr to allow the substrate to dissolve, and the absorbance (abs) was measured at 575 
nm using a plate-reader spectrophotometer (Sunnyvale, CA). Cell viability in % was 
calculated by (abs of treated group)/ (abs of untreated cells) ×100%. 
 
3.2.4. RNA Sequencing and Analysis of the Significantly Regulated Genes  
Five million MCF-7/Adr cells were seeded in 75 cm
2 
flasks (Corning, Lowell, MA) 
until reaching 60% confluency. The cells were then treated for 24 hrs with either 250 
ng/mL SAHA or DAC as described above. The concentration of epigenetic drugs was 
selected based on their effect on inducing apoptotic pathway without significant effect on 
cell viability. The treatments were done in duplicates. Cells were washed twice with 
DPBS, trypsinized, and collected by centrifugation at 1000 g for 5 min (Thermo Electron 
Coorporation, Waltham, MA). The total RNA of the treated cells was isolated and 
purified using RNeasy MiniPlus Kit (Qiagen, Austin, TX) according to the instructions 
provided in the manual. In brief, the cells were lysed using Buffer RLT. Next, the cell 
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lysate was then homogenized by vortexing for 1 min, and genomic DNA was removed 
from the total RNA by gDNA Eliminator spin column provided with the kit. Total RNA 
bound to the column was washed and eluted into RNase-free tubes provided with the kit.  
 
RNA sequencing library was prepared and analyzed using 100 bp pair-end 
ILLUMINA HiSeq2500 (San Diego, CA) at the University of Chicago Genomics Core 
Facility (Chicago, IL). FastQC (Babraham Bioinformatics, Cambridgeshire, UK) was 
used to evaluate the quality of raw reads. Raw reads of each sample were mapped directly 
against the hg19 genome using TopHat, a public GitHub repository originally developed 
at the Center for Bioinformatics and Computational Biology at the University of 
Maryland (College Park, MD). Next, Cufflinks (Trapnell Lab, University of Washington, 
Seattle, WA) was used to assemble transcripts and estimate gene expression level, and 
Cuffdiff (Trapnell Lab) was used to perform pairwise sample comparison to detect 
significantly differentially expressed genes between two samples at a strict false 
discovery rate (FDR) of 0.05. The differentially expressed genes in epigenetic-drug 
treated cells were explored using the IPA system (Ingenuity Pathways Analysis, 
Ingenuity H Systems, www.ingenuity.com) and the analysis reports were generated on 
significantly associated pathways. The Ingenuity Report was used to generate gene 
association maps and relevant biological pathways.  
 
3.2.5. Statistical Analysis 
Student’s t test was used to conduct statistical analysis. P ≤0.05 was used to define 
statistical significance. 
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3.3 Results 
A Comprehensive view of the disrupted transcriptome profile  
The structures of DAC and SAHA are shown in Fig 3.1. The cytotoxicity data show 
that DAC and SAHA treatment at a 250 ng/mL concentration has insignificant effect on 
cell viability during a 24 hr treatment period (Fig 3.2), hence cells treated at this 
concentration were used for RNA sequencing analysis. The high throughput RNA 
sequencing analysis of resistant cells (Fig 3.3) showed that 1786 and 1687 genes were 
differentially expressed following DAC and SAHA treatment, at a strict false discovery 
rate (FDR) of 0.05. DAC treated cells showed a significantly greater down-regulation 
compare to SAHA treated cells (Fig 3.4A). The majority of the differential expressed 
genes have p≤0.01 (fall above 2 on the y-axis), independent of the fold changes (Fig 
3.4B). The Volcano Plot of the differential expressed genes further confirmed the 
independent nature between the degree of change and their statistical significance (Fig 
3.4C).  
 
Overall, DAC and SAHA resulted in the alteration of a similar number of genes, 
pathways, processes and diseases in resistant cells (Table 3.1A). Furthermore, both 
epigenetic drugs caused similar changes in gene expression patterns (both in quantity and 
direction) according to cellular location, molecular function, and genes participated in the 
DNA transcription (Fig 3.5). Nuclear genes showed the most significant up-regulation 
and plasma membrane genes had the most significant down-regulation in both treatment 
groups. The data showed significant regulation in cell functions such as apoptosis, tumor 
cell lines proliferation, and cell viability of breast cancer cell lines, where a greater 
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number of genes were down-regulated than up-regulated. Moreover, DAC treatment had 
a more significant down-regulatory effect than SAHA treatment in majority of the 
examined pathways, including apoptosis, tumor cell lines proliferation, and cell viability 
(Table 3.2, Fig 3.6). 
 
Cytotoxicity Networks Affected by Epigenetic Modulations 
According to the number of affected genes, the 5 most perturbed cytotoxicity 
networks were identical. The majority of the top altered toxicity pathways showed similar 
number of genes altered by DAC and SAHA treatment. However, G2/M checkpoint was 
specifically seen in cells treated with DAC but not in cells treated with SAHA (Table 
3.1B). Significant regulation of pathways in cell proliferation, fat synthesis/metabolism, 
cell mobility and inflammation were observed (Table 3.1C). 
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Figure 3.1 The structures of (A) DAC and (B) SAHA. 
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Figure 3.2 The cytotoxicity of epigenetic drugs in cell line MCF-7/Adr. 
The cytotoxicity of (A) DAC and (B) SAHA were examined in a 24 hr treatment. No 
significant cytotoxicity was observed at the concentrations measured. n=2. Data were 
represented as mean ± standard deviation. 
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Figure 3.3 Outline of the tools and pipeline used to conduct RNA-Seq transcriptomic 
analysis. 
(A) A list of the programs used to map and decode raw reads into transcriptomic 
expression levels. (B) Illustration of the steps taken in post-transcriptomic analysis to 
format sequencing data into gene expression levels. The transcriptomic sequencing was 
done using 100-bp pair-end lllumina HiSeq2500. The transcriptomes were mapped 
against the hg19 genome. 
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Table 3.1 The Number of Gene Alterations in Selective Pathways 
A. Epigenetic effect overview 
 
 DAC SAHA 
Total Genes Affected 1722 1615 
No. of Pathways 481 474 
No. of Processes 310 327 
No. of Diseases 123 128 
 
 
B. Number of genes in top toxicity lists  
Top Toxicity Lists 
DAC (Genes 
changed/Gene 
total) 
SAHA (Genes 
changed/Gene 
total) 
Renal Necrosis/Cell Death  164/466 (0.352) 146/466 (0.313) 
Cell Cycle: G1/S Checkpoint Regulation  34/65 (0.523) 32/65 (0.492) 
p53 Signaling  44/95 (0.463) 38/95 (0.4) 
Hepatic Fibrosis  18/96 (0.188) 38/96 (0.396) 
Cell Cycle: G2/M DNA Damage 
Checkpoint Regulation  
25/48 (0.521) -- 
 A/B (C): No. of Genes Changed/Total Genes in the Category (fraction of the total) 
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C. The major perturbed pathways and number of genes affected in each pathway 
 
Pathways DAC SAHA 
 Cell 
Proliferation 
and Cell 
Death 
  Proliferation of Cells 524          489 
Tumor Cell Lines 
Proliferation 
227 221 
Necrosis 388 347 
Transcription of RNA 227 221 
Apoptosis 390 327 
Apoptosis of Tumor Cell 
Lines  
203 177 
Cell Cycle Progression 148 140 
Cell Viability of Breast 
Cancer Cell Lines 
27 28 
DNA Damage Response 28 23 
Fat Synthesis 
and             
  Metabolism 
Synthesis of Lipid 111 95 
Fatty Acid Metabolism 99 74 
Hydrolysis of Fatty 32 8 
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Acid/Lipid 
Cell Motility 
Cell Movement 307 289 
Microtubule Dynamics 168 159 
Invasion of Cells/Tumor 
Cells 
139/99 124/89 
Inflammation Inflammatory Response 115 112 
The number of genes affected in each gene function 
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Table 3.2 Genes Significantly Regulated in Selected Pathways Affecting Drug Resistance. 
A. Pathways affecting the nuclear localization of drug molecules and nanoparticles 
 
Pathways DAC (up-regulated/total) SAHA (up-regulated/total) 
Clathrin-
mediated 
Endocytosis 
FGF1, ACTC1, SH3KBP1, DNM1
L, LDLR, ITGB4, SNAP91, 
DNM1, SH3GL2, SH3GLB2,   
CLU, RAC1, FGF18, SERPINA1,  
ACTA2 (4/15) 
FGF1, ACTC1, SH3KBP1, 
DNM1L, LDLR, ITGB4, 
SNAP91, FGF5, APOL1, 
PDGFA, VEGFA (5/11) 
Caveolar-
mediated 
Endocytosis  
ACTC1, FYN, HLA-A, ITGB4, 
ITGAX, CAV1, ITGA6,  HLA-
B, HLA-C, ACTA2 (4/10) 
ACTC1, FYN, HLA-A, ITGB4, 
ITGAX,  FLNC (3/6) 
Macropino- 
cytosis 
HRAS, PLCG2, NGF, CSF1, ITGB
4, RAC1, RRAS, PRKCG  (1/8) 
HRAS, NGF, PLCG2, CSF1, 
ITGB4, PDGFA, (1/6) 
Exocytosis TC10, TNFAIP2, CDC42, RAB11 
TC10, TNFAIP2, CDC42, 
RAB11 
Efflux 
Pumps 
ABCA7, ABCD1, SLC47A1, 
ABCA2, ABCB4, MFSD12, 
MFSD3  
ABCA7, ABCD1, SLC47A1 
RAN RCC1, KPNA2 (2/2) RCC1, TNPO1, XPO1 (3/3) 
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B. Cell lipids and drug molecules metabolism 
  DAC SAHA 
Synthesis 
of Fatty 
Acid 
FYN, BRCA1, MYO5A, IL18, FAD
S1, SREBF1, GPC1, PTGES, 
CCL5, FAAH, FADS2, PTGIS, 
IL6, C5AR1, IL8, PTGDS, LDLR, 
NFKBIA, HMOX1, CEBPB, FOXO
3, CAV1, LIMK1, MAP3K8,  
ASAH1, 
NTN1, ACADVL, DGAT1, ACSL1, 
FASN, ADA, SLC2A4, NGF, SEMA
3A, PLA2G4A, TRIB3, CLU, RAC1, 
PLA2G6,NR1H3, SIGIRR, IL1R2,  
RARB, RELB, SCD,  EDNRB, FCG
R2A, C5, ACSS2, CXCL1, 
INSIG1, IL32,  (6/53) 
BRCA1, FYN, IL18, MYO5A, 
SREBF1, LDLR, C5AR1, CCL5, 
CEBPB, CXCL1, FAAH, FADS1, 
FADS2, GPC1, HMOX1, IL1B, 
IL6,  IL8, NFKBIA, PTGDS, 
PTGES, PTGIS, KITLG, LPL, 
MAP3K14,  MAPK8, NRG1, 
OLR1, IL32, FGFR3, VEGFA, 
ACSS2, CASP1, EPHX2, IGF2, 
INSIG1, MID1IP1, NR1H3, 
SIGIRR, XBP1, C5, FASN, 
FOXA1, NGF, NTN1, SCD, 
STAT5A, TRIB3 (10/48) 
Phospholi
pases 
Pathway 
PLCB4, HMOX1, PLCG2, PLCD1, 
PLD3, PLA2G4C, PLD1, 
RARRES3, LIPG, PNPLA3 (1/10) 
PLCB4, PLCD3, PLCG2, PLA2G4
C, HMOX1, PLCD1, PLD1, LIPG, 
RARRES3, 
PLA2G4A, PLA2G16,  PLA2G6,  P
LD3 (1/13)  
Lysosoma
TFEB, CTSF, CTSB, Rab3a  TFEB, CTSF, CTSB  
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l Genes 
mTOR 
pathway 
HRAS, RHOQ, PPP2R5B, HMOX1, 
PLD3, DDIT4, PLD1, ATG13, 
RND2, RAC1, RHOC, 
RPS17/RPS17L, RRAS, PRKCG, 
RPS24, PPM1J (2/16)  
HRAS, PPP2R5B, RHOQ, 
HMOX1, PLD3, PLD1, DDIT4, 
PPP2R2A, MAPKAP1, RPS26, 
RHOV, RPS24, PRR5 VEGFA 
(4/14) 
Wnt 
Pathway 
WISP2 (-12.2 fold), DKK1(3.2 fold) WISP2 (-5.2 fold), DKK1(6.0 fold) 
PPAR 
signaling 
pathway 
IL1RAP, HSP90AA1,  IL18,  HSrc, 
IL1B,  NGFR, NFKBIA, IKBKB, 
NR1H3, IL1R21, 
IL1R1, FOS, RRAS (5/13) 
IL1RAP, IL18, HSP90AA1, NGFR, 
IL1B, HRAS, NFKBIA, MAP3K14, 
NFKB2, PPARA,  STAT5A, 
PDGFA, NR1H3 (5/13) 
Cytochro
me 450 
Family 
CYP27C1, CYP1A1, CYP1B1, 
CYP26B1, CYP2J2, CYP39A1 
                         --- 
Highlighted genes: genes that are regulated by both DAC and SAHA.  
Red: up-regulated genes; blue: down-regulated genes 
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Table 3.3 Gene Fold Changes and Functions 
A. Nuclear transport  
Gene Symbol: 
Name 
DAC SAHA Function 
Kpna2: 
Karyopherin 
Alpha 2  
--- 2.04 
Interacts with the NLSs of DNA helicase Q1 and 
SV40 T antigen, functions in nuclear protein 
import as an adapter protein for nuclear receptor 
KPNB1, and may be involved in the nuclear 
transport of proteins 
NUP153: 
Nucleoporin 
153kDa 
2.10 --- 
Component of the NPC, a complex required for the 
trafficking across the nuclear envelope. Functions 
as a scaffolding element in the nuclear phase of the 
NPC essential for normal nucleocytoplasmic 
transport of proteins and mRNAs. 
NUP35: 
Nucleoporin 
35kDa 
--- 2.25 
Localized to the nuclear rim, and is part of the 
nuclear pore complex. All molecules entering or 
leaving the nucleus either diffuse through or are 
actively transported by the nuclear pore complex.  
KPNB2 (TNPO1): 
Transportin 1 
2.23 --- 
Functions in nuclear protein import as nuclear 
transport receptor. Serves as receptor for nuclear 
localization signals (NLS) in cargo substrates.  
RCC1: Regulator 
of Chromosome 
Condensation 1 
2.83 2.77 
Plays a key role in nucleo-cytoplasmic transport, 
mitosis and nuclear-envelope assembly 
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B. Nucleoskeleton network genes 
Gene 
Symbol: 
Name 
DAC SAHA Function 
KIF4A: 
Kinesin 
Family 
Member 4A 
2.09 2.04 
Intracellular transport of membranous organelles; 
chromosome arms condensation and chromosome 
integrity during mitosis. 
KIF23: 
Kinesin 
Family 
Member 23 
 
4.21 
 
3.67 
A member of kinesin-like protein family. This 
family includes microtubule-dependent molecular 
motors that transport organelles within cells and 
move chromosomes during cell division. This 
protein has been shown to cross-bridge antiparallel 
microtubules and drive microtubule movement in 
vitro.  
LAMIN B 2.36 5.06 
Fibrous proteins providing structural function 
and transcriptional regulation in the cell nucleus 
SYNE1: 
Spectrin 
Repeat 
Containing, 
Nuclear 
Envelope 1 
2.29 2.38 
A nuclear envelope protein involved in the 
maintenance of nuclear organization and structural 
integrity, tethering the cell nucleus to 
the cytoskeleton by interacting with the nuclear 
envelope and with F-actin in the cytoplasm. 
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C. Drug resistance, EMT and drug metabolism genes 
Gene Symbol: 
Name 
DAC SAHA Function 
TGFBR3L: 
transforming 
growth factor, 
beta receptor 
III-like 
 
-3.18 
 
-3.51 
Multifunctional peptides that regulate 
proliferation, differentiation, adhesion, migration, 
and other functions regulates many other growth 
factors 
ERBB2IP: 
Erb-B2 
Receptor 
Tyrosine 
Kinase 2 
Interacting 
Protein 
--- 
4.1 
 
Regulates ERBB2 function and localization, is 
up-regulated in paclitaxel-resistant cell lines. 
ERBB2 overexpression has been shown to play an 
important role in the development and 
progression of certain aggressive types of breast 
cancer.  
SYNE2: 
Spectrin 
Repeat 
Containing, 
Nuclear 
Envelope 2 
14.7 15.9 
Binds to cytoplasmic F-actin, tethering the nucleus 
to the cytoskeleton and maintaining the structural 
integrity of the nucleus. 
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TGFBR2：
Transforming 
Growth 
Factor, Beta 
Receptor II  
--- 
2.5 
 
The encoded protein is a transmembrane protein 
that has a protein kinase domain, forms a 
heterodimeric complex with another receptor 
protein, and binds TGF-beta. TGFBR2 is 
connected with breast cancer response to tamoxifen 
 
E2F: E2F 
Transcription 
Factor  
-3.2 
(E2F2) 
2.1 
(E3F7) 
A family of transcription factors (TF) in higher 
eukaryotes involved in the cell cycle regulation 
and synthesis of DNA in mammalian cells 
SNAI3: 
snail family 
zinc finger 3 
-3.39 -3.55 
SNAG zinc-finger proteins are transcriptional 
repressors, an oncogene, implicated in 
carcinogenesis and embryogenesis 
NUPR1: 
Nuclear 
Protein, 
Transcriptiona
l Regulator, 1 
-2.93 -11.7 
Chromatin-binding protein that converts stress 
signals into a program of gene expression that 
empowers cells with resistance to the stress 
induced by a change in their 
microenvironment. Strong connections with p21 
and chemoresistance 
VIM: 
Vimentin 
-2.37 -2.61 
The major cytoskeletal component 
of mesenchymal cells, a marker of epithelial-to-
mesenchymal transition (EMT)  
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 GSTA4: 
glutathione S-
transferase 
alpha 4  
-10.5 -2.25 
Detoxification of lipid peroxidation products. 
Involved in cellular defense against toxic, 
carcinogenic, and pharmacologically active 
electrophilic compounds. 
 BRCA-1:  
breast cancer 
1, early onset  
3.17 2.12 
A human tumor suppressor gene. Its protein is 
responsible for repairing DNA. 
BCLAF1: 
BCL2-
associated 
transcription 
factor 1 
4.58 3.03 
Tumor-suppressor. Encodes a transcriptional 
repressor that interacts with several members of 
the BCL2 family of proteins. Overexpression of 
this protein induces apoptosis, which can be 
suppressed by co-expression of BCL2 proteins.  
Gene functions were obtained from Entrez Gene  
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Figure 3.4 Overview of the significantly altered transcriptomes in MCF-7/Adr after 
SAHA and DAC treatment.  
(A) Compare to control, DAC up-regulated 558 genes and down-regulated 1228 genes, 
whereas SAHA up-regulated 661 genes and down-regulated 1026 genes. From this 
statistics, DAC had a greater gene down-regulatory effect than SAHA. (B) Gene fold 
changes were plotted against their statistical significance. Most genes had from -5.66 to 
5.66 fold changes. There is no linear relationship between the fold changes and their 
statistical significance. (C) Volcano plot displayed log(fold-change) against -log(p-value). 
It compared the magnitude of fold changes (x-axis) against their statistical significance 
(y-axis), where higher y value indicates a greater statistical significance. The genes 
scattered in the far left and right on the x-axis (over 1000 fold changes) are likely to be 
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those not expressed in the control group, but are activated by the treatment, or are 
completely suppressed by the treatments. X-axis showed both positive and negative log 
(fold changes), and the values nearer to the top of y-axis are the changes with high 
statistical significance (shown in red dots). In this plot, I observed a similar pattern 
between DAC and SAHA treated groups. No relationship was observed between the fold 
changes and their statistical values, indicating that all expressions were valid and that the 
statistical significance is not affected by the fold changes. Ninety-five percent confidence 
level was used and p≤0.05 was used to define statistical significance. 
 
Figure 3.5 Overview of alternatively expressed genes in (A) DAC and (B) SAHA treated 
cells. 
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The distribution of genes based on cellular location (left most), molecular functions 
(middle) and genes participated in DNA transcription. Color range represents the level of 
fold changes. Based on the cellular location, the nucleus had more up-regulated genes 
than the extracellular space, cytoplasm, and the plasma membrane in both drug 
treatments.  
 
Down-regulation of Oncogenes and Up-regulation of Tumor Suppressors  
A number of major upstream regulators in epithelial-mesenchymal transition 
(EMT) (VIM GSTA4, SNAI3), drug resistance (e.g. NUPR1), and detoxification 
(e.g. GSTA4) were down-regulated by both DAC and SAHA. Tumor suppressor 
genes BRCA-1 and BCLAF1 were up-regulated by both DAC and SAHA. However, 
we observed drug resistance genes to be up-regulated by SAHA and either down-
regulation or not affected by DAC (ERBB2IP, TGFBR2 and E2F) (Table 3.3C).  
 
Alterations in Genes involved in Exocytosis and Intracellular Trafficking  
Analysis of lipid-related pathways (e.g. fatty acid synthesis, phospholipases signaling 
pathway, and mammalian target of rapamycin (mTOR)) showed majority of them to be  
down-regulated (Fig 3.9, Table 3.2B). Examining the pathways involved in endocytosis 
and drug transport, we demonstrated that the major endocytosis pathways had a mixed 
up- and down-regulation of genes. However, all the genes regulating drug degradation 
and export (e.g. lysosome, exocytosis, efflux pumps) were down-regulated (Fig 3.9, 
Table 3.2). All nuclear localization and nucleoskeleton genes were shown to be up-
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regulated (Table 3.3). The RAN pathway, which is involved in nuclear transport, was 
shown to be up-regulated following treatment with epigenetic drugs (Fig 3.10). 
 
Changes in Drug Metabolism Genes and Pathways  
The results showed that both DAC and SAHA effectively down-regulated the Wnt 
pathway through the suppression of WNT1 Inducible Signaling Pathway Protein 2 
(WISP2) and the up-regulation of Dickkopf WNT signaling pathway inhibitor 1 (DKK1) 
(Table 3.2B). WISP2 is significantly expressed in breast adenocarcinoma and contributes 
to malignant transformation. DKK1 is a Wnt antagonist and a tumor suppressor [115]. 
The alterations in WISP2 and DKK1 will effectively reduce the drug metabolism of 
therapeutic molecules, allowing them to exert their drug effects.  
 
Six genes in the CP450 family were significantly regulated by DAC, with 5 down-
regulated and 1 up-regulated. In contrast, SAHA did not cause significant changes in the 
expression of CP450 genes (Table 3.2B). In the peroxisome proliferator-activated 
receptors (PPAR) signaling pathway, DAC and SAHA down-regulated the majority of 
the genes, showing suppression in drug metabolism, thus allowing a greater level of 
active drug molecules to exert their effect compare to that in untreated cells (Fig 3.8). 
 
3.4 Discussion 
This study elucidated the effect of DAC and SAHA on the global transcriptomics of 
MCF-7/Adr breast cancer cell line, with focus on the pathways and genes affecting the 
level of drug resistance in a cell. Demethylation has been shown to reverse drug 
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resistance in tumor [116]. Studies also showed that histone deacetylase inhibition is able 
to overcome drug resistance in diffuse large B-cell lymphoma and other tumor cell lines 
[117, 118].  
 
 
Figure 3.6 Gene regulation overview in selected molecular functions. 
Number of the genes significantly regulated in (A) apoptosis, (B) tumor cell lines 
proliferation, and (C) cell viability of breast cancer cell lines. In all pathways, more genes 
were down-regulated than up-regulated. DAC down-regulated more genes than SAHA 
did. 
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Figure 3.7 The effect of DAC and SAHA on endocytotic regulation. 
(A) Clathrin-mediated endocytosis signaling pathway in DAC treated cells. (B) The fold 
change of genes significantly regulated in clathrin-mediated endocytosis pathway. (C) 
The fold change of genes significantly regulated in caveolar-mediated endocytosis 
pathway. In both endocytotic pathways, DAC caused more changes in gene than SAHA 
does.  
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Figure 3.8 (A) Visualization and (B) gene fold changes in PPAR signaling pathway. 
PPAR pathway affects intracellular lipid levels, fatty acid metabolism, and peroxisome 
proliferation and showed a greater level of down-regulation than up-regulation in both 
DAC and SAHA treated cells. 
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Figure 3.9 (A) Visualization and (B) list of altered genes in mTOR signaling pathway. 
mTOR is involved in cellular metabolism and lysosome regulation. There is significantly 
more down-regulation than up-regulation in both DAC and SAHA treated cells. 
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Figure 3.10 RAN signaling pathway in SAHA-treated cells. 
RCC1, TNPO1, XPO1were all significantly up-regulated.  
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Our RNA-seq data identified alteration of a number of major genes and pathways that 
are critical for reversing drug resistance following epigenetic drug treatments. The large 
number of identical genes in DAC and SAHA treated cells (Table 3.2) indicated that 
although both epigenetic drugs work by different mechanisms, they have similarities in 
their regulatory effects.  
 
In Fig 3.4B, it was shown that there are similar patterns in transcriptomic fold 
changes vs. –log(pValue) between DAC and SAHA treated cells. First, most fold changes 
in the transcriptomes are from -5.66 to -2, and from 2 to 5.66, using 2 fold changes as 
cutoffs. We observed –log(pValue) falls between 2 and 4, equals to the p-value of 0.01 to 
0.0001. This means most transcriptomic changes were highly statistically significant.  
 
In Fig 3.4C, the volcano plot showed similar patterns in transcriptomic fold changes 
vs. –log(pValue) between DAC and SAHA treated cells. All genes above 1.3 (P≤0.05) on 
the y-axis were statistically significant.  
 
The majority of the genes were in the double-filtering window, above 1.3 on the y-
axis and ≥0.3 or ≤-0.3 on the x-axis, which had greater than 2 fold changes. Large gene 
fold-changes were those farther from the center of the x-axis. The genes that were on 
similar spots in DAC and SAHA treatment groups had similar p-values and fold changes. 
The higher on the y-axis, the greater the statistical significance. The genes with over 100 
fold changes are those that are not expressed in the control, but are expressed in the 
treated groups, or vice versa.  
 76 
 
Table 3.3 showed that in both treatment groups, similar numbers of genes were 
significantly regulated in majority of the top affected signaling pathways and cellular 
functions. This is also a new trend that we observed. We saw that different epigenetic 
mechanisms could similarly affect different pathways. If we do comparative analysis 
between the 2 treatment groups, we will be able to see the exact genes that were 
differentially affected by treatments, and those will allow a more thorough examination 
on the drug effects. 
 
There are a large number of different genes with similar fold changes and statistical 
significance (ex. 2-20 fold changes). Here, I focused on how they enhance the therapeutic 
effect of chemotherapy and nanoparticles through pathway analyses. On Table 3.2 and 
3.3, both similarly and differently affected genes were observed in pathways.  
 
Several observations from the Volcano plot were: 1. among the significantly 
regulated genes, there were both up- and down-regulations, 2. A number of genes that are 
similarly regulated in the same direction—that would partially contribute to the similar 
patterns observed in both plots. Among those, part of them were the same genes, also a 
part were different genes with similar fold changes and statistical significances.  
 
The red dots on the top of the plot were genes that had the highest statistical 
significances. The genes on the far left and far right of the plot were ones with high fold 
changes but low statistical significance.  
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Compare DAC and SAHA treated cells, we observed a large number of overlaps in 
the genes significantly affected by DAC and SAHA. Second, from the examined 
pathways, we observed that in majority of the pathways, the pattern of regulation for 
DAC and SAHA treated groups were similar. For instance, in cell viability of breast 
cancer cell lines (Fig 3.6C), DAC caused 9 up-regulated genes and 18 down-regulated 
genes, whereas SAHA resulted in 11 up-regulated genes and 17 down-regulated genes. 
Thirdly, we observed that genes regulated in both pathways mostly have the same 
direction of alteration (Fig 3.7-3.9). Because of the similarities in pattern of changes in 
the transcriptome, they resulted in similar patterns shown on the Volcano Plot.  
 
Drug resistance is influenced by the level of drug intracellular localization, lipid 
quantity (as drug molecules such as Dox enter the cell by diffusion), lysosomal regulation, 
and nuclear localization, which all contribute to the level of drug sensitivity in the cell. 
Our previously published work showed that DAC effectively enhances the uptake of Dox 
and Doxil [114]. Therefore, the genes and pathways that affected uptake of drug in 
solution form and in nanoparticle form were examined. The plasma membrane is 
composed largely of lipids. Therefore, lipids represent the first major barrier to the 
intracellular localization of drugs. Once enter the cell, it is important for the drug 
molecules to escape from lysosomal degradation. The intracellular accumulation and 
retention of the drug in solution form and in nano-carriers are also affected by the 
decreased anti-cancer drug efflux and exocytosis pathway.  
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Lipid is a major component of the cell membrane and the intracellular vesicles. Their 
alterations produce major biophysical changes in the resistant cell membrane, thus 
influencing the uptake and uptake of drug molecules and nanoparticles [119]. Previous 
studies from our group showed that resistant cell membrane lipids form more condensed 
and rigid monolayers than that of sensitive cells, and epigenetic drug DAC was able to 
reverse such characteristics to restore the trafficking of cancer drugs [120]. In this study, I 
further showed that the majority of the cellular fat levels and fat synthesis genes were 
down-regulated (Table 3.2B), evidenced a reduction of fat compositions in the cell. One 
main pathway for the fatty acid synthesis and metabolism is the phospholipases signaling 
pathway. Its down-regulation confirms the previous study of the accumulation of 
phospholipids in the cell [114]. Furthermore, the down-regulation of fatty acid synthase 
(FASN) gene and mTOR pathway by both the epigenetic drugs (Table 3.2B) also had 
major impact on lipid synthesis  [121, 122]. FASN causes drug resistance through TNF-α 
inhibition, which strongly connects with poor breast cancer prognosis and higher risk of 
recurrence [123, 124]. Therefore FASN presents an effective target gene for reversing of 
cancer cell drug resistance.  
 
Lysosomes are the main vesicles for drug molecule degradation. They also play a role 
in plasma membrane repair (Table 3.2) [125]. One of the major lysosomal genes is 
transcription factor EB (TFEB), which is a major regulator of lysosomal biogenesis and 
induces both the docking and the fusion of lysosomes with the plasma membrane [126]. 
The down-regulation of TFEB, together with other lysosomal (e.g. CTSF, CTSB) and 
exocytotic (e.g. TC10, TNFAIP2) genes, exert major effect on the cellular uptake as well 
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as recycling of drug molecules [114, 127] (Table 3.2A), enabling a greater amount of 
drug to stay in the cytoplasm.  
 
Nuclear membrane penetration is the last challenge for the effective localization of 
nuclear targeting chemotherapies (e.g. Dox). The nuclear pore complex (NPC) allows the 
passive diffusion of small molecules with diameters less than 9nm [128]. It has been 
shown that drug resistant and sensitive cells have different nuclear pores and the down-
regulation of NUP protein contributes to the resistance of chemotherapy cisplatin [129, 
130]. Therefore, the increased NUP and nucleoskeleton genes may be a contributor to a 
greater amount of drugs entering the nucleus.   
 
In the nucleus, the up-regulation of RAN (RAs-related nuclear protein) plays a major 
role in transporting molecules in and out of the NUP. RAN also has effect on DNA 
synthesis and cell cycle, and its mutation has shown to disrupt DNA synthesis [131].
 
An 
essential gene in the RAN pathway, RCC1, is located inside the nucleus and is bound 
to chromatin (both to the nucleosomes and double-stranded DNA). It plays a major role 
in nucleo-cytoplasmic transport and nuclear-envelope assembly. Through up-regulating 
the above-mentioned genes (Fig 3.10, Table 3.2A), DAC and SAHA could enhance the 
therapeutic effect of drugs that require nuclear penetration (e.g., Dox) [132].  
 
One important mechanism of drug resistance is through enhancing the metabolism as 
well as detoxification of the drugs. Cytochrome P450 (CP 450) family plays an essential 
role in interacting with the drugs, breaking them down into metabolites, thus inactivating 
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their effect on the cell [133]. DNA methylation is a common mechanism among currently 
identified genes in drug-metabolism [134]. Up-regulation of drug metabolizing genes (ex. 
CYP1A1, CYP7B1) has been shown in MCF-7/Adr breast cancer cell line to enhance 
drug resistance [135, 136]. In this study, I noticed a major effect down-regulating effect 
of DAC, but not of SAHA, on cytochrome P450 enzymes (CP450), which showed a new 
mechanism of DAC in reversing drug resistance (Table 3.2B). PPARs, which were 
down-regulated by both epigenetic drugs, are also essential in drug metabolism and 
elimination of toxic metabolites [137]. 
The genetic over-expression of drug resistant genes and pathways always play a role 
in enhancing the level of drug resistance. One of such pathway is mTOR, and when this 
pathway is inhibited, increased chemo-sensitivity is observed in ovarian carcinoma cell 
lines [138]. Previous study showed SAHA able to dampen the mTOR pathway [139], 
consistent with our report (Table 3.2B, Fig 3.9). However, in this study, I uncovered 
DAC to also be an mTOR pathway suppressor, signifying yet another mechanism 
through which DAC and SAHA reverses drug resistance. A well-recognized onco-gene 
that is down-regulated in both DAC and SAHA treatment is Wnt (Table 3.2B). Wnt 
signaling pathway is important for drug resistance and associates with cancer stem cell 
phenotype [140]. The inhibition of Wnt pathway resulted in P-gp down-regulation and 
the reversal of drug resistance [141].  The up-regulation of TGFBR2, a part of the TGF-β 
pathway, has been shown to drug resistance and cell heterogeneity [142, 143].  
 
NUPR1, a chromatin-binding protein, is one important drug resistant gene that is 
down-regulated by both DAC and SAHA (Table 3.3C). When activated by the stress 
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signals, it empowers the resistant cells to change their microenvironment, leading to 
resistance of chemotherapeutic agents like doxorubicin in breast cancer cells. Therefore, 
the NUPR1 down-regulation by both SAHA and DAC treatments showed a novel 
candidate for reversing drug resistance.  
 
In the examined up-stream drug resistant genes, I found similarly as well as 
differentially regulated genes by DAC and SAHA treatment. Examples of SAHA up-
regulated drug resistant genes are ERBB2IP, TGFBR2 and E2F.  Erb-B2 Receptor 
Tyrosine Kinase 2 interacting protein (ERBB2IP) is a gene that regulates the function and 
localization of ERBB2, which mediates breast cancer chemo-resistance via receptor-
mediated anti-apoptotic signals and found to be up-regulated in paclitaxel-resistant cell 
lines [144, 145]. Also, E2F is a distinctive marker of tamoxifen resistant breast tumors, 
which is down-regulated in DAC and up-regulated in SAHA [146]. The differential 
regulation of the above 2 genes by DAC and SAHA contribute to the differential effect of 
DAC and SAHA on the drug resistance level of the cell (Table 3.3C). 
 
3.5 Conclusions 
In this study, I elucidated the effects of SAHA and DAC on drug resistant MCF-
7/Adr cells using RNA-seq. Our study showed that there are major overlaps in genes 
changed by DAC and SAHA treatments in areas of drug and nanoparticle tracking, lipid 
metabolism, carcinogenesis and nuclear transport, with consistent direction of regulation, 
either up- or down-regulated by both drugs. Nevertheless, DAC affects more genes and 
down-regulated in a larger scale in majorities of the pathways analyzed. Also, a number 
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of drug metabolism genes essential to render drugs ineffective and drug resistant 
upstream regulators are down-regulated in DAC, but not in SAHA, and a number of drug 
resistant genes were only up-regulated by SAHA but not DAC. This study is essential in 
understanding the differential effects between DAC and SAHA and can be used further to 
examine their potential as combination therapy with other drugs.  
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CHAPTER IV 
 
EFFECTIVENESS OF siRNA DELIVERY VIA ARGININE-RICH PEI-BASED 
POLYPLEXES 
  
Keywords: siRNA therapy, cationic polymers, metastatic cells, drug resistance, 
nanocomposite 
4.1 Introduction 
The therapeutic promise of small interfering RNAs (siRNAs) has gained wide 
recognition in treating different diseases, such as cancer, viral infections, HIV and non-
arteritic ischemic optic neuropathy [147-149]. A major advantage of siRNA lies in the 
fact that it functions in the cytoplasm, therefore, avoiding the need for nuclear penetration, 
a major delivery obstacle particularly for gene therapy, due to the tight regulation of the 
nuclear membrane. It has the potential to repress cancer cell proliferation and metastasis 
and to reverse drug resistance [150-152]. Despite its therapeutic potentials, translation of 
siRNA-based therapy is limited by several factors, including poor pharmacokinetic 
property, possible immune response, off-target effects and poor cellular uptake, due to 
the anionic and hydrophilic nature of the siRNA to diffuse efficiently across cell 
membrane [153-155].  
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For effective siRNA delivery, carrier needs to achieve the capacity to form stable 
complexes with minimum cytotoxicity, protect siRNA from degradation, and facilitate 
transfection [156]. To achieve the above objective, lipids (ex. liposomes), polymers (ex. 
cyclodextrin, chitosan, polyethylenimine), and inorganic (ex. carbon nanotubes, iron 
oxide) vehicles have been investigated [157, 158]. Cationic polymers have the ability to 
both complex siRNA and effectively transfect cells. The most commonly used are 
poly(ethylenimine)s (PEI) and poly(amido amine) [159, 160]. PEI can spontaneously 
self-assemble with siRNA to form polyplexes, achieving effective transfection rate [161-
164]; however, they faced significant toxicity issues including membrane damage and the 
activation of apoptotic pathway by mitochondria [165-167]. General strategy is to 
minimize the toxic effect of cationic polymers while retaining transfection ability.  
 
 Arginine has the ability to facilitate intracellular translocation. The arginine has 
strong affinity with heparan sulfate expressed on mammalian cell membranes. Also, the 
guanidine groups on arginine are able to form hydrogen bonds with polyhydroxy 
compounds in cell membrane [168-170]. Studies that conjugated arginine to dendrimers 
such as polymer amido amine (PAMAM) and polymer (propylene imine) (PPI) have also 
shown to enhance transfection efficiency [171, 172].  Here, I explored the ability of 
P(SiDAAr)5Peg3 to deliver siRNA to both breast cancer metastatic (MDA-MB-231-luc-
D3H2LN) and drug resistant (MCF-7/Adr) cell lines. I hypothesize that P(SiDAAr)5Peg3 
will be effective in facilitating siRNA transfection as PEG enhances the biocompatibility 
of the polymer and arginine facilitates cell membrane penetration. Our data show that 
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polyplexes at optimized composition are nontoxic to cells, effective in transfecting 
luciferase and therapeutic siRNA in both metastatic and drug resistant cell lines. 
 
4.2 Materials and Methods 
The materials and the methods to synthesize P(SiDAAr)5Peg3 and conduct siRNA 
transfection were listed below. 
 
4.2.1 Materials 
Three-(2-aminoethylamino) propyl-methyl-dimethoxysilane, 25-kDa branched PEI, 
aspartic acid, L-arginine, O-(2-aminoethyl)-O’-(2-carboxyethyl) polyethylene glycol-3K 
hydrochloride, 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC), 
heparin sodium, N-hydroxysuccinimide (NHS), and 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) were purchased from Sigma-Aldrich (St. Louis, 
MO). Fetal bovine serum (FBS) and Trypsin/EDTA were obtained from Gibco (Grand 
Island, NY). RNAse I (cloned) and Silencer Negative Control No.1 siRNA were 
purchased from Life Technologies (Carlsbad, CA). Sodium bicarbonate powder, 
hydroxylamine hydrochloride, uranyl acetate, and TrisAcetate-EDTA buffer were 
purchased from Sigma-Aldrich (St. Louis, MO).  Dulbecco's Modified Eagle's Medium 
(DMEM), DPBS, penicillin and streptomycin were purchased from the Cell Services’ 
Media Core at the Cleveland Clinic.  
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4.2.2 Synthesis of P(SiDAAr)5Peg3 
Three molars equivalents of polyethylene glycol and 5 molars equivalents of L-
arginine oligo (alkylaminosiloxane) grafted poly(ethylenimine) (P(SiDAAr)5Peg3) were 
synthesized as shown in appendix D [173]. PEI conjugation of SiDAAr was done by 
using aspartic acid as a linker. The acid groups of the aspartic acid were activated using 
0.1208 g (3.5/5 mmol) of EDC and 0.0725 g (3.5/5 mmol) of NHS at 4 
o
C for 6 hr. 
Thereafter, 0.05712 g (0.06 mmol equivalents) of SiDAAr and 0.3 g (0.012 mmol 
equivalents) of PEI were added into the reaction mixture and kept for 18 hr at room 
temperature, followed by dialysis using 12kDa MWCO dialyzer. To conjugate PEG to 
P(SiDAAr)5, briefly, the free acid group of 0.1 g (3 mmol) equivalents of 
NH2−PEG−COOH was activated using 0.1208 g (3.5/5 mmol) of EDC and 0.0725 g 
(3.5/5 mmol) NHS (catalyst) in MES buffer at pH 6 for 3.5 hrs at 4 °C. Thereafter, the 
activated PEG were added to 0.3 g (1 mmol equivalents) of P(SiDAAr)5 in 2 mL of PBS 
at pH 7.5 overnight (16 hr). Afterward, the polymer was dialyzed for 2 days in 2 liters of 
dH2O using 12kDa MWCO dialysis membrane (Spectrum Laboratories, Rancho 
Dominguez, CA) to remove unreacted elements. The polymer was then lyophilized and 
re-dissolved in dH2O and filtered through a sterile filter. Please refer to Appendix D for 
detailed synthetic procedures of parent polymer P(SiDAAr)5. 
 
4.2.3 TRITC Conjugation of P(SiDAAr)5Peg3 
To visualize the polyplexes uptake using flow cytometry, I first conjugated 
P(SiDAAr)5Peg3 with TRITC fluorescence dye. Six-tetramethylrhodamine-6-
isothiocyanate (TRITC) dye was obtained from Invitrogen (Carlsbad, CA). To conjugate 
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TRITC to polymer P(SiDAAr)5Peg3, first, 2 mg of polymer was dissolved in 1 mL of 0.1 
M sodium bicarbonate (8.4 mg in 1 mL) buffer, and 1 mg of TRITC was dissolved in 500 
µL of DMSO. While stirring, 100 µL of reactive TRITC dye was slowly added to the 
polymer solution dropwise. The reaction was kept for 1 hr at room temperature with 
continuous stirring. Afterward, the reaction was stopped by adding 0.1 mL of freshly 
prepared 1.5 M hydroxylamine (pH 8.5), which was prepared by dissolving 
hydroxylamine hydrochloride at 210 mg/mL in distilled water and adjusting the pH to 8.5 
with 5 M (1 g in 5 mL) NaOH. The polymer was dialyzed overnight using 12K MWCO 
dialysis membrane to remove excess TRITC dye. 
 
4.2.4 Polymer Complexation and Polyplexes Characterization 
P(SiDAAr)5 (parent polymer before PEG conjugation) and P(SiDAAr)5Peg3 were 
dissolved in dH2O at 1 mg/mL and filtered through a 0.22 µm sterile polyethersulfone 
filter (Millipore, Darmstadt, Germany). siRNA was diluted to 1 mg/mL in RNAse free 
dH2O (Qiagen, Valencia, CA). Polyplexes were prepared by pipet-mixing siRNA and 
polymer for 30 times and allowing self-assembly by incubating for 1 hr. Three µg of 
siRNA were used per sample. Size and zeta potential measurements were conducted with 
the sample in dH2O using quasi-elastic light scattering (NICOMP 380 ZLS Particle 
Sizing System, Santa Barbara, CA). The morphology of the polyplexes was characterized 
by transmission electron microscopy (TEM) using a Tecnai G2 TEM microscope (FEI, 
Hillsboro, Oregon). Polyplexes with a 1/4 siRNA/polymer w/w ratio were prepared in 
dH2O using the same method described above. After that, 10 µL of the polyplex 
dispersion was dropped on TEM grids coated with silicon monoxide stabilized formvar 
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films (Electron Microscopy Sciences (Hatfield, PA)).  The samples were then air dried, 
stained with 2% uranyl acetate for 7 min and imaged.  
 
4.2.5 Determination of the Complete siRNA to P(SiDAAr)5Peg3 Complexation Ratio  
Agarose gel electrophoresis was used to analyze the siRNA/P(SiDAAr)5Peg3 
complexation ratio. The polyplexes were prepared at nucleotide/polymer (N/P) w/w  
ratios of 1/0.5, 1/1, 1/2, 1/4 and 1/6, keeping the siRNA amount constant at 1 µg while 
varying the quantity of the polymer to achieve the desired N/P ratio. Using naked DNA 
as a reference, naked siRNA and siRNA polyplexes were loaded onto a 1% Gold Agarose 
gel (Lonza, Allendale, NJ) in TrisAcetate-EDTA buffer. The samples were run for 60 
min at 60 V on an electrophoresis system (Bio-Rad, Hercules, CA). The gel was stained 
using SYBR Green (Thermo Scientific, Rockford, lL) and visualized using a UV imager 
(FUJIFILM FLA-5100, FUJIFILM Life Science, Stamford, CT). 
 
4.2.6 Protection from siRNA RNase Degradation 
The effectiveness of P(SiDAAr)5Peg3 to protect siRNA from RNAse degradation was 
measured using a Nanodrop 1000 (Thermo Scientific, Waltham, MA). Briefly, naked 
siRNA and siRNA polyplexes were incubated in 100IU of RNAse buffer for 30 min. 
Thereafter, measurements were carried out using a nanodrop to assess the degradation of 
the siRNA.  
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4.2.7 Polyplexes Stability Evaluation  
The stability of siRNA polyplexes at 1/4 w/w siRNA/P(SiDAAr)5Peg3 ratio was 
measured in the presence of heparin polyanions using a polyanion competition assay. The 
polyplexes, consisting of 5 µg of siRNA and 20 µg of P(SiDAAr)5Peg3 were incubated in 
15 µL of various concentrations of heparin sodium solution (Sigma-Aldrich) for 15 min. 
The samples were run on a 1% gold agarose gel (Lonza, Allendale, NJ) in TrisAcetate-
EDTA buffer, and the gel was stained and visualized by the same method described in 
section 2.5. 
 
4.2.8 Cell Culture 
The resistant cell line MCF-7/Adr cells was obtained from UNMC, and maintained 
through long-term Dox treatment [114]. Cells were changed to drug free media for 2 
passages prior to use in an experiment. Cell line MDA-MB-231-luc-D3H2LN was 
purchased from Caliper Life Sciences (Hopkinton, MA). Both cell lines were cultured in 
15% FBS enriched DMEM with 1% penicillin-streptomycin under 5% CO2 and 95% 
humidity at 37 ºC.  
 
4.2.9 Cytotoxicity Evaluation 
MDA-MB-231-luc-D3H2LN cells were seeded at 5×10
4 
cells/well in a 24 well-plate 
(BD Biosciences, San Jose, CA) in DMEM with 15% FBS. Polyplexes made of 1 µg 
luciferase siRNA and varying ratios of P(SiDAAr)5Peg3 in 15 µL of DMEM were gently 
dropped into each well followed by mixing with the culture medium. DMEM containing 
polyplexes were replaced with fresh media after 16 hr and MTT assay was carried out 
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after 3 days. After that, cell culture medium was removed and replaced with 150 µL of 
MTT (0.5 mg/mL in colorless DMEM) and incubated for 3.5 hr in cell culture conditions. 
Thereafter, MTT solution was replaced with 250 µL of DMSO and incubated for another 
30 min at 37 ºC. One hundred and fifty µL of the dissolved solution was taken out to a 
clear 96-well plate and absorbance was measured at 595 nm using a plate reader 
(SpectraMax M2, Molecular Devices Inc., Sunnyvale, CA). Cell viability was calculated 
as (abs of treated cells)/(abs of untreated cells)×100%. 
 
4.2.10 Polyplexes Intracellular Accumulation by Flow Cytometry  
The cellular uptake of 1/4 N/P siRNA polyplexes with FITC-conjugated 
P(SiDAAr)5Peg3 described in section 2.3 was examined in both MDA-MB-231-luc-
D3H2LN and MCF-7/Adr cell lines. Cells were seeded in 6 well plates in 15% DMEM. 
After 24 hrs, polyplexes made of 3 µg of siRNA and 12 µg of TRITC-conjugated 
P(SiDAAr)5Peg3 were added to each well, incubated for 4 hrs, and then flow cytometry 
was carried out to quantify intracellular polyplex accumulation. 
 
4.2.11 siRNA-mediated Gene Silencing in vitro  
For ubiquitous gene knockdown, I assayed firefly luciferase gene because it has no 
apparent effect on the regulatory machinery of the cell. For luciferase gene silencing, 
cells were seeded at a density of 2×10
5
 cells/well in 24 well plates. DMEM with 15% 
FBS and 1% penicillin-streptomycin was used for all transfections. Polyplex solution 
containing 2 µg of siRNA was added to each well and incubated for 24 hrs. Thereafter, 
cells were washed with PBS and lysed with 100 µL of Reporter Lysis Buffer (Promega, 
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Madison, WI). Twenty µL of cell lysate and 50 µL of Luciferase Assay Reagent 
(Promega) were added into a Nunc F96-MicroWell White Polystyrene plate (Nunc, 
Thermo Scientific). Luciferase activity was then measured using a Luminescence Plate 
Reader (Wallac 1420 VICTOR
2™, PerkinElmer, Waltham, MA).  
 
Cell protein levels were analyzed via BCA protein assay. The BCA assay kit was 
purchased from Thermo Scientific (Rockford, lL). To perform the assay, 10 µL of cell 
lysate and 150 µL of freshly prepared BCA reagent (1 part of reagent A and 50 parts of 
reagent B) were added to a 96 well-plate and incubated at 37 ºC for 30 min. Absorbance 
was measured at a wavelength of 562 nm using a Microplate Reader (Molecular Devices, 
Sunnyvale, CA).  
The in vivo delivery of luciferase siRNA was described in Appendix B. 
 
4.2.12. Testing Target Protein Knockdown Effectiveness in Enhancing Dox Uptake 
and as Chemotherapy 
To examine the effectiveness of functional siRNA in down-regulating its target 
protein in drug resistant MCF-7/Adr, cells were incubated with anti-ABCB1 siRNA 
(Dharmacon, Lafayette, CO) for 24, 48 and 72 hrs in 6-well plate. Two µg of anti-
ABCB1 siRNA were used for each condition with no solution change during incubation 
time. After incubation time as above, cells were washed, trypsinized and incubated with 3 
µL of phycoerythrin-conjugated anti-ABCB1 antibody (eBioscience, San Diego, CA) at 
0.1 µg/µL for 30 min on ice bath. The cells were then washed twice and kept in flow 
buffer (PBS with 10% FBS and 0.1% NaN3 sodium azide) for flow cytometry. All flow 
 92 
 
cytometry was done with freshly collected cells using a LSR II System (BD Biosciences, 
Franklin Lakes, NJ).  
 
To analyze the effect of anti-ABCB1 siRNA on the cellular uptake of Dox, Dox 
solution at 2500 ng/mL and the unlabeled anti-ABCB1 siRNA P(SiDAAr)5Peg3 
polyplexes were added to cells in a 6-well plate with MCF-7/Adr cells. After 4.5 hrs, the 
cells were washed, trypsinized and collected for flow cytometry to examine the 
accumulation of Dox in the cell.  
 
To examine the effect of anti-ABCB1 siRNA in enhancing the Dox cytotoxicity, the 
cells were seeded in a 96 well plate at 5,000 cells/well. After 24 hrs of cell attachment, 
anti-ABCB1 siRNA polyplexes and Dox solution were co-dosed to the cells with 0.5µg 
of siRNA/well and a range of Dox concentrations from 100 to 10,000 ng/mL. Treatments 
were extended for 3 days and MTT was conducted thereafter to examine the effect of 
anti-ABCB1 transfection on doxorubicin toxicity.  
 
4.3 Results 
Physical characterization of siRNA Polyplexes 
 Particle size and ζ-potential measured via dynamic light scattering showed that at 
lower N/P ratios (1/2 and 1/3), P(SiDAAr)5Peg3 polyplexes had in average smaller 
hydrodynamic size than P(SiDAAr)5 polyplexes. For each polymer, as the polymeric 
ratio increases, the size of the polyplexes was reduced. As the polymeric ratio increased, 
both P(SiDAAr)5 and P(SiDAAr)5Peg3 had increased ζ-potentials (Table 4.1). However, 
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PEG conjugation significant reduced the ζ-potentials at low polymeric ratios but not at 
higher ones (1/5 and 1.6). The ζ-potential reduced from 34.3 to 8.7 mV at N/P of 1/2, and 
again from 35.5 to 26.2 mV at N/P of 1/3. In addition, all siRNA polyplexes had positive 
zeta potentials. Please refer to appendix C for the distribution of size and zeta potential 
measurements. 
 
TEM images showed round polyplexes well dispersed on the TEM grid (Fig 4.1). Gel 
electrophoresis data showed complete siRNA complexation at 1/4 N/P ratio as indicated 
by no observed free siRNA migration on the gel (Fig 4.2 A).  
 
siRNA Stability in the Presence of RNAse 
In the presence of RNAse, free siRNA showed significant fragmentation within 30 
min; however, there was no degradation of siRNA when complexed as 1/4 N/P ratio 
P(SiDAAr)5Peg3 polyplexes (Fig 4.2 B). 
 
Polyplex Stability in the Presence of Competing Polyanions 
Polyanion competition assay showed high polyplex integrity and stability in the 
presence of competing heparin. The polyplexes remained intact up to a heparin 
concertation of 2500 µg/mL. At 2500 µg/mL, free siRNA migrated down the gel, 
signifying a partial release of siRNA. When reached an even higher heparin 
concentration (5000 µg/mL), the near complete release of siRNA took place and a 
migrating siRNA band with roughly equal band size as that of free siRNA was observed 
(Fig 4.3). 
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Figure 4.1 Morphological analysis of siRNA polyplexes. 
TEM images of 1/4 siRNA/P(SiDAAr)5Peg3 polyplexes at (A) low (×23000, bar=1μm) 
and (B) high (×68000, bar=0.5μm) magnifications. Two images were taken of the 
polyplexes-1 at low resolution and 1 at high resolution.  
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Figure 4.2 P(SiDAAr)5Peg3 completely complexed siRNA and protected it from RNAse 
degradation at N/P ratio of 1/4. 
(A) Agarose gel electrophoresis of a range of polyplexes from N/P ratio of 1/0.5 to 1/6. 
The un-complexed siRNA was shown as white bands on the gel. Complete complexation 
took place at N/P of 1/4 and 1/6. At 1/6 siRNA/polymer w/w ratio, there is complete 
masking of siRNA taking place, shielding it from the interaction with CybrGreen dye, 
thus showing no band in the well on the gel. (B) siRNA fragmentation is an indicator of 
its degradation. The siRNA fragmentation will result in an increase of absorbance. siRNA 
degradation assay showed no increase in siRNA absorbance in 1/4 P(SiDAAr)5Peg3 
polyplexes, indicated polymer protection of siRNA from RNAse degradation. Free 
siRNA without polymer complexation showed significant siRNA fragmentation, thus 
increased absorbance. *: p<0.0001. n=3. 
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Figure 4.3 Polyanion competition assay revealed the polyplex stability. 
Polyanion competition assay revealed siRNA polyplex stability in the presence of 
varying concentrations of heparin solutions, as visualized via gel electrophoresis. A 
partial siRNA release was observed at 2500 µg/mL. At 5000µg/mL of heparin, the total 
release of siRNA was observed. 
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Cellular Uptake of siRNA Polyplexes 
The intracellular uptake of the polyplexes using TRITC-conjugated P(SiDAAr)5Peg3 
polymer showed uniform polyplexes distribution among MDA-MB-231-luc-D3H2LN 
and MCF-7/Adr cells, evident by a narrow peak in the fluorescence intensity. Uneven 
distribution of polyplexes among cells would result in a wide fluorescence peak under 
flow cytometry. Also, at a short polyplex incubation time (4.5 hrs), rapid polyplex 
internalization was observed (Fig 4.4).  
 
Polyplex Cytotoxicity  
Toxicity was observed only with the highest polymeric ratio (N/P of 1/6) among the 
examined samples (Fig 4.5A). The in vitro transfection depended on the polyplex 
composition. As shown in Fig 4.5B, the transfection levels significantly increased with 
increasing polymeric ratio, until reaching a plateau at N/P of 1/4. Because 1/4 polyplexes 
produces similar target knockdown with the least amount of polymer and the least 
toxicity (Fig 4.5A), I selected this ratio for the following experiments. 
 
Anti-ABCB1 siRNA Down-regulates ABCB1 Protein and Enhances the Toxicity of 
Dox 
Next, I determined if high levels of polyplex uptake in hard-to-transfect MCF-7/Adr 
can be translated into high levels of functional siRNA transfection. At 72 hrs, ~70% of 
the target anti-ABCB1 protein was down-regulated, based on the shift in the fluorescence 
intensity curve. Anti-ABCB1 siRNA polyplexes also enabled a significantly greater level 
of Dox intracellular accumulation, shown by the shift in Dox fluorescence intensity. To 
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correlate ABCB1 target transcript knockdown with its effect on Dox cytotoxicity, I 
observed Dox toxicity to increase by around 90% based on the absorbance level 
following drug incubation for 3 days. 
 
4.4 Discussion 
Critical issues for siRNA delivery include effective incorporation of siRNA into the 
polymeric vector, forming polyplexes that have tolerable toxicities, able to protect siRNA 
from degradation, have strong polyplex stability and achieving effective transfection. In 
this study, I show that P(SiDAAr)5Peg3 effectively facilitated siRNA transfection in 
metastatic and drug resistant breast cancer cell lines, and ABCB1 siRNA transfection 
effectively enhanced the cytotoxicity of Dox upon  co-treatment. 
 
To enhance the effectiveness as well as the biocompatibility of PEI, we utilized PEG 
decorated L-arginine modified oligo (alkylaminosiloxane) grafted poly (ethylenimine) 
polymer, P(SiDAAr)5Peg3. The PEG chains on the polymer could undergo detachment 
through hydrolytic degradation, which enables a better endocytosis of the polyplexes 
[174]. Our previous work showed that this polymer had lower toxicity compare to PEI 
[173]. It has also been shown that long linear PEG was able to exert balanced steric 
hindrance and minimize the lysis of RBC [175]. The arginine on our polymer could also 
play a role in the swift uptake of polyplexes due to its ability to conduct transmembrane 
localization.  
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Figure 4.4 The cellular uptake of 1/4 TRITC-conjugated P(SiDAAr)5Peg3 polyplexes 
examined by flow cytometry. 
The level of intracellular uptake of P(SiDAAr)5Peg3  polyplexes in (A) MDA-MB-231-
luc-D3H2LN and (B) MCF-7/Adr cell lines. Level of fluorescence quantified by flow 
cytometry showed that siRNA uptake was rapid and uniform in both MDA-MB-231-luc-
D3H2LN and MCF-7/Adr cell lines at a short incubation time (4 hrs). The level of 
polyplexes uptake was equivalent in both MDA-MB-231-luc-D3H2LN and MCF-7/Adr 
cell lines. 
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Table 4.1 Average Hydrodynamic Diameter (Dh) (nm), Polydispersity Index (PDI) and 
Zeta Potential (mV) of P(SiDAAr)5 and P(SiDAAr)5Peg3 Polyplexes at Different siRNA 
to Polymer Weight Ratios. Three samples were measured per polyplex ratio.  
 
 
 
 
 
siRNA/P(SiDAAr)5 Size, Mean (SD) PDI  (SD) Zeta, Mean (SD) 
1/2 546 (242) 0.13 (0.1) 34.3 (24.7) 
1/3 558 (290) 0.17 (0.1) 35.5 (25.7) 
1/4 565 (177) 0.20 (0.02) 28.3 (3.3) 
1/5 598 (134) 0.51 (0.4) 21.9 (11.2) 
1/6 364 (40) 0.18 (0.01) 34.1 (16.9) 
siRNA/P(SiDAAr)5Peg3 Size, Mean (SD) PDI  (SD) Zeta, Mean (SD) 
1/2 327 (170) 0.21 (0.06) 8.7 (18.3) 
1/3 295 (230) 0.64 (0.43) 26.2 (13.7) 
1/4 350 (147) 0.34 (0.09) 30.0 (11.4) 
1/5 231 (67) 0.52 (0.29) 42.5 (11.1) 
1/6 240 (22) 0.46 (0.19) 36.3 (16.0) 
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Figure 4.5 Cytotoxicity and transfection efficiency of siRNA/P(SiDAAr)5Peg3 polyplexes 
in MDA-MB-231-luc-D3H2LN cell line. 
(A) Cell toxicity after 72 hr of polyplexes treatment. *: p<0.05 compared to the control 
group, n=2. The polyplexes up to N/P of 1/5 showed no toxicity to the cells. However, at 
1/6 N/P ratio, cytotoxicity was observed. (B) Luc-siRNA transfection with polyplexes at 
varying N/P ratios. Transfection level increased at increasing polymeric ratio. Highest 
transfection levels were achieved at 1/4, 1/5 and 1/6 N/P ratios. The increased 
transfection level at N/P of 1/4 compared to 1/2 and 1/3 showed the effect of complete 
siRNA complexation.  *: p<0.01 compare to control group, n=2.  
 
The polyplexes underwent self-assembly and were able to protect siRNA from 
degradation. They achieved over 70 fold siRNA knockdown in vitro in MDA-MB-231-
luc-D3H2LN. 
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The efficacy of siRNA polyplexes depended on their hydrodynamic size and surface 
potential. siRNA polyplexes had a relatively wide range of size and zeta potential  (Table 
4.1). The smaller hydrodynamic size of P(SiDAAr)5Peg3 polyplexes compared to 
P(SiDAAr)5 showed the effectiveness of high molecular weight linear PEG in forming 
more compact polyplexes. The observation that PEG reduced the zeta potential of the 
polyplexes at lower N/P ratios (1/2 and 1/3) but not high N/P ratios was likely due to the 
effect of PEG in masking the cationic charge at low N/P ratios. However, as polymer to 
siRNA ratio increases, the polyplexes may undergo structure rearrangement causing a 
greater exposure of PEI to be on the surface, which reduces the PEG exposure to the 
surface and results in higher polyplex charge. The mild cationic surface charge of the 
polyplexes at the optimal ratio effectively facilitates transfection without exerting 
cytotoxicity PEG may also assist in forming well dispersed polyplexes by forming a 
hydrated shell around the polyplexes. 
 
One method to examine the polyplex integrity and complexation strength in the 
presence of serum (anionic proteins), is through visualizing its stability in the presence of 
competing polyanions.  
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Figure 4.6 The effect of anti-ABCB1 siRNA on ABCB1 surface protein expression, Dox 
accumulation and cell cytotoxicity. 
(A) ABCB1 surface protein expression was significantly down-regulated after 3 days of 
anti-ABCB1 siRNA polyplexes incubation as examined by flow cytometry. (B) Co-
treatment of anti-ABCB1 siRNA polyplexes and Dox solution enhanced Dox uptake, 
examined by flow cytometry. (C) Anti-ABCB1 siRNA polyplexes and Dox solution co-
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treatment for 3 days at varying Dox concentrations showed significantly enhanced 
cellular cytotoxicity examined by MTT assay.  
 
My results show that the complexation strength between 1/4 w/w siRNA polyplexes 
and 1/1/4 w/w DNA-siRNA polyplexes (from the previous study) [173] were comparable, 
signifying that siRNA polyplexes had a loosened structure at the absence of DNA (Fig 
4.3) because it takes a higher polymer ratio to complete complex siRNA than DNA-
siRNA mixture.  
 
Drug resistance and metastasis are the two most challenging issues in cancer 
treatment. Therefore, both metastatic MDA-MB-231-luc-D3H2LN cell line and the 
chemo- and transfection-resistant MCF-7/Adr cell line were selected for this study. The 
uniform internalization of the polyplexes observed in this study could be caused by the 
enhanced cell membrane penetration of arginine (Fig 4.4) [176].  
 
Degree of siRNA complexation is an important factor in the transfection level of 
siRNA polyplexes. The plateau of siRNA transfection from 1/4 onward showed that the 
significantly enhanced transfection from 1/2 to 1/4 polyplexes was a result of the degree 
of nucleotide complexation (Fig 4.5).  
 
ABCB1 is a major contributor of multi-drug resistance in MCF-7/Adr. ABCB1 
actively pumps out chemo-drugs such as Dox, thus lowers the drug concentration inside 
the cells. Studies have shown that effective anti-ABCB1 siRNA transfection was able to 
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reverse the multi-drug resistance characteristics and sensitize cells for chemotherapy 
[177]. MCF-7/Adr was known to have an ABCB1 efflux pump over-expression. The 
swift ability of the polyplexes to enhance Dox uptake within 4.5 hrs was in contrast with 
the effective surface protein knockdown that took place after 3 days. This could due to 
the fact that when endocytosis of polyplex takes place, free Dox in solution was also 
taken up through the same mechanism, thus causing an enhanced Dox accumulation in 
the cell. The half-life and degradation time of ABCB1 protein is a deciding factor for the 
time it takes for the level of protein to decrease. Anti-ABCB1 siRNA showed its 
effectiveness as a combinational therapy with Dox. However, at a higher Dox 
concentration, the cytotoxicity level leveled off, suggested the need to overcome other 
mechanisms of resistance in order to completely eradicate drug resistant cells (Fig 4.6).  
 
4.5 Conclusions 
In conclusion, I have shown an arginine and PEG decorated polymer P(SiDAAr)5Peg3 
to effectively deliver siRNA. The overall results suggested that at an optimal composition, 
the polyplexes were able to achieve a complete siRNA complexation with good 
cytocompatibility, protect siRNA from degradation, and effectively transfect cells in both 
metastatic and drug resistant breast cancer cell lines. By effectively targeting ABCB1 in 
drug resistant cells to enhance Dox cellular uptake as well as cytotoxicity, we further 
demonstrated the potential of functional siRNA polyplexes as a combination therapy with 
drugs to treat resistant cancer cells. Future studies are needed to enhance the drug effect 
in resistant cells using multiple functional siRNAs. 
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CHAPTER V 
 
CO-DELIVERY OF DNA AND SIRNA VIA ARGININE-RICH PEI-BASED 
POLYPLEXES 
 
Keywords: combination therapy, nonviral gene delivery, cancer therapy, cationic 
polymers, cellular uptake 
5.1 Introduction  
The discovery of siRNA has drawn much attention to gene therapy in the last few 
years, particularly for its usefulness in targeting a number of genetic diseases [178-181]. 
However, challenges remain in gene therapies, such as low transfection efficiencies, 
particularly with non-viral vectors, and achieving therapeutic effects at tolerable doses. 
Many diseases are the result of a single gene mutation. Yet single gene disorders are not 
common in the population. Therefore, simultaneously targeting multiple genetic 
components and regulatory pathways pose the possibility of reaching a greater 
therapeutic potential for a number of diseases, including cancer [182]. In addition, the 
different physical characteristics of DNA and siRNA (size, morphology, rigidity and 
charge) could cause them to have different electrostatic interaction strengths with cationic 
polymers like PEI, thus changing the binding affinity of the polyplexes [183].  
 
  
 
Polyethylenimine (PEI) is a commonly used nucleic acid delivery vehicle [184]. It 
condenses nucleotides through electrostatic interactions, protects them from nuclease 
degradation and facilitates endosomal escape [185, 186]. The cationic charges on the 
polyplex surface also promote cellular uptake through adsorptive endocytosis [187, 188]. 
Despite its promising features, a number of drawbacks hinder it from achieving its 
therapeutic potential. For example, interaction of the high cationic charge of PEI with the 
anionic cell surface can destabilize the plasma-membrane and induce toxicity [189, 190]. 
PEI could also interact with negatively charged serum proteins (such as albumin) and red 
blood cells, causing protein precipitation or red blood cell aggregation and lysis.[191] 
Therefore, chemical modifications are usually necessary to mitigate the effect of high 
cationic charge of PEI [192].  
 
In this study, to attenuate toxicity, enhance biocompatibility and improve cellular 
uptake, we modified PEI with 5 molar equivalents of L-arginine modified oligo 
(alkylaminosiloxane) graft and 3 molar equivalents of PEG, forming P(SiDAAr)5Peg3. 
The previous study had shown better transfection with P(SiDAAr)5 than with PEI in vitro 
due to L-arginine residues that assist in adsorptive endocytosis, enhancing membrane 
permeability, and facilitating nuclear localization [193]. P(SiDAAr)5’s siloxane 
derivative is biodegradable and is excreted in the urine [194]. Furthermore, P(SiDAAr)5 
following PEG and folic acid conjugation showed greater tumor accumulation than the 
unconjugated polymer [175].  
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DNA and siRNA delivery systems have many similar characteristics, such as 
facilitating efficient cellular uptake and rapid endosomal escape. However, their 
distinctive structural and chemical characteristics determine their different complex 
formation properties. DNA is usually several kilobase pairs in length while siRNA is only 
21-23 base pairs. Topologically, siRNA forms A-form helixes, while DNA forms B-form 
helixes. The A-form siRNA has a larger diameter and a smaller rise per base pair, and 
thus is stiffer than the B-form DNA [195]. Therefore, the structural differences between 
DNA and siRNA may result in DNA-siRNA polyplexes having different structural 
properties than DNA- or siRNA-only polyplexes [196]. This study shows that DNA-
siRNA co-delivery significantly enhances both nucleotides’ gene transfection levels 
compared to that of single-nucleotides. Also, comparing polyplexes, P(SiDAAr)5Peg3 
polyplexes have significantly better cytocompatibility than PEI polyplexes with the same 
nucleotide composition. 
 
5.2 Materials and Methods  
The materials and the methods to synthesize P(SiDAAr)5Peg3 and conduct siRNA 
transfection were listed below. 
 
5.2.1 Materials 
3-(2-aminoethylamino) propyl-methyl-dimethoxysilane, 25-kDa branched PEI, L-
arginine, O-(2-Carboxyethyl)polyethylene glycol PEG-3kDa hydrochloride, L-aspartic 
acid, 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC), N-
hydroxysuccinimide (NHS) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
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bromide (MTT) were purchased from Sigma-Aldrich (St. Louis, MO). Fetal bovine 
serum (FBS) and Trypsin/EDTA were obtained from Gibco (Grand Island, NY). The 
luciferase assay system and reporter lysis buffer were purchased from Promega 
(Madison, WI). Scrambled siRNA (s-siRNA) and YOYO-1 DNA intercalating dye were 
purchased from Life Technologies (Carlsbad, CA). The 1% Gold Agarose Reliant Gel 
System was purchased from Lonza (Allendale, NJ). Anti-luciferase siRNA (luc-siRNA) 
was purchased from Dharmacon, Inc. (Lafayette, CO). The BCA Protein Assay Kit was 
purchased from Thermo Scientific (Rockford, lL). Cell culture media Dulbecco's 
Modified Eagle's Medium (DMEM), DPBS, penicillin and streptomycin were purchased 
from our Cell Services’ Media Preparation Core.  
 
5.2.2 pDNA Amplification and Purification 
The Pgl3 (luciferase reporter vector) and control (noncoding) plasmid DNA from 
Promega (Madison, WI) were cloned via E. coli (JM109, Promega) according to the 
manufacture’s technical manual. Pdna was purified using Qiagen EndoFree Plasmid 
Mega Kit (Qiagen, Valencia, CA) according to the manufacturer’s instructions and re-
suspended in Dnase-free Dh2O. The Pdna concentration were measured with a Nanodrop 
1000  (Thermo Scientific, Waltham, MA). 
 
5.2.3 Polymer Synthesis   
Oligo-(alkylaminosiloxane) (SiDA), arginine conjugated oligo amino 
alkyldialkoxymethylsilane (SiDAAr) and arginine modified oligo-(alkylaminosiloxane)-
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graft-PEI ((P(SiDAAr)5) (5:1 graft: PEI molar ratio) were synthesized as previously 
described [193, 197] (Appendix D). 
 
Conjugation of PEG to P(SiDAAr)5: Briefly, the free acid group of CH3-PEG-COOH 
(0.1 g, 3 mmol equivalents) was dissolved in 2 mL of MES buffer at pH=6. The acid 
group of PEG was activated using 0.1208 g (3.5/5 mmol) of EDC as a coupling agent and 
0.0725 g (3.5/5 mmol) NHS as a catalyst in MES buffer at pH=6 for 3.5 hr at 4 °C. Three 
molar equivalents of the activated PEG were then reacted with 1 molar equivalent of 
P(SiDAAr)5 (0.3 g, 3 mmol equivalents) in 2 mL of PBS (pH=7.5) overnight (16 hours). 
The synthesized polymer was dialyzed for 2 days using 12KDa MWCO dialysis 
membrane (Spectrum Labs, Rancho Dominguez, CA) to remove the un-reacted elements.
 
The polymer was then filtered through a 0.22 µm sterile filter and lyophilized. The 
polymer was dissolved in D2O for 
1H NMR analysis (δ, ppm) on a Varian Mercury 300 
(300 MHz) spectrometer. The resonances were measured referencing to TSP (4.66 ppm) 
using TSP. The yield for P(SiDAAr)5Peg3 is 140 mg (35%). Please refer to Appendix D 
for detailed synthetic procedures of polymer P(SiDAAr)5. 
 
5.2.4 Polymer/Nucleotide Complexation 
The polymers were dissolved in MilliQ water (dH2O) and filtered through a 0.22 µm 
sterile polyethersulfone filter (Millipore, Darmstadt, Germany). SiRNA was dissolved at 
1 mg/mL in RNase-free dH2O. For characterization studies, DNA and polymers were 
dissolved separately at 1 mg/mL in DNase- and RNase-free dH2O. For cell culture 
experiments, DNA and polymer were dissolved separately at 1 mg/mL in serum-free 
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Dulbecco's Modified Eagle Medium (DMEM). Polyplexes were formed by combining 
DNA, siRNA and polymer solutions, pipetting to mix thoroughly, and self-assembling for 
30 min. PEI was used in parallel with P(SiDAAr)5Peg3 for comparison purposes. 
 
5.2.5 Size/Zeta Potential Measurements 
Polymers PEI and P(SiDAAr)5Peg3, and the corresponding polyplexes with different 
D/S/P ratios, were measured for mean hydrodynamic diameters and zeta potentials in 
dH2O via dynamic light scattering (DLS) using the NICOMP 380 ZLS Particle Sizing 
System (Santa Barbara, CA). All polymer and polyplex measurements were done in 3 
replicates. Average and standard deviation were calculated for each polyplex composition.  
 
5.2.6 Examine the Complete Nucleotide Complexation via Gel Retardation Assay 
Agarose gel electrophoresis was used to determine if there was complete nucleotide 
complexation in each polyplex formulation. The polyplex solutions were prepared at 
varying polymer/nucleotide (P/N) weight/weight ratios. Naked non-coding plasmid DNA 
(Ø-pDNA), luc-siRNA and polyplex solutions were loaded in a 1% Gold Agarose gel 
(Lonza, Allendale, NJ) in TrisAcetate-EDTA buffer at pH 8.0. For control wells, 2 µL of 
DNA or siRNA was used per well. For other wells, 2 µL of DNA was used per well, and 
the quantities of the siRNA and the polymer were adjusted accordingly. The free 
nucleotides and polyplexes were run on an electrophoresis system (Bio-Rad, Hercules, 
CA). The gels were stained using SYBR Green (Thermo Scientific) and visualized under 
a Carestream Molecular Imaging Gel Logic 112 Imaging System (Carestream Health, 
Inc., Rochester, NY). 
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5.2.7 Examine the Polyplexes Morphology via Transmission Electron Microscopy 
(TEM) 
1/1/4 D/S/P polyplexes were prepared in dH2O by vigorous pipetting and incubating 
for 30 min for polyplex self-assembly. Thereafter, 10 µL of the polyplex solution was 
dropped on TEM grids coated with silicon monoxide stabilized formvar films (Ted Pella 
Inc., Redding, CA). After drying, the samples were stained with 2% uranyl acetate for 7 
minutes and imaged using a Tecnai G2 TEM microscope (FEI, Hillsboro, Oregon). 
5.2.8 Polyanion Competition Assay 
The relative stability of 1/1/4 D/S/P(SiDAAr)5Peg3 polyplexes was investigated using 
a heparin polyanion competition assay, where the nucleotides released from polyplexes 
were measured using gel electrophoresis. Polyplex solutions were first prepared by 
mixing 5 µg of DNA, 5 µg of siRNA and 20 µg of polymer and incubating in dH2O for 
30 minutes. The polyplexes were then exposed to heparin sodium (Sigma-Aldrich, St. 
Louis, MO) solution (10 µL) of varying concentrations for 15 min. Then the samples 
were run on a 1% Gold Agarose gel (Lonza, Allendale, NJ) in TrisAcetate-EDTA buffer, 
and the gel stained and visualized by the same method described in section 2.6. 
5.2.9 Cell Culture 
Cell line MCF-7 was purchased from American Type Culture Collection (Manassas, 
VA). Luciferase-expressing breast cancer metastatic cell line MDA-MB-231-luc-
D3H2LN was purchased from Caliper Life Sciences (Hopkinton, MA). MCF-7/Adr was 
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obtained from Prof. Batra’s laboratory at the University of Nebraska Medical Center, 
Omaha, and maintained by culturing in media with 100 ng/mL doxorubicin. MCF-7/Adr 
was incubated in drug-free medium for two passages before being used in experiments. 
All cell lines were cultured at 37 °C in humidified air containing 5% CO2. DMEM with 
15% FBS and 1% penicillin-streptomycin was used in all cell-culture related studies, 
including MTT, in vitro transfections, flow cytometry and confocal microscopic studies. 
Cell detachment was done using trypsin/EDTA at 37 °C.  
 
5.2.10 In Vitro Cytotoxicity Assay 
The MTT assay was used to evaluate polymer and polyplex toxicities in vitro in 
MCF-7 and MCF-7/Adr cell lines. For the 72-hr polymer toxicity assay, 5×10
4
 cells were 
seeded per well in a 24-well plate. For the 24-hr polyplex toxicity assay, 5×10
5
 cells were 
seeded per well in a 24-well plate (BD Biosciences, San Jose, CA) and 1 µg of DNA was 
used per well. The 72-hr polymer MTT was designed to assess the polymer’s differential 
growth inhibition effects, while the 24-hr polyplex MTT was designed to assess the 
polyplex’s toxicity under transfection conditions. After 24 hr of cell attachment, all media 
was removed, and each well received fresh media containing polymers or polyplexes. 
After a designated incubation time, media was removed again and replaced with 150 µL 
of MTT (2 mg/mL in DMEM).  Plates were incubated at room temperature overnight 
according to the standard MTT protocol. On the next day, the MTT was removed, the 
wells received 500 µL DMSO, and the plates were incubated for 3.5 hr at 37 °C to allow 
the substrate to dissolve. One hundred and fifty µL of the dissolved solution was then 
taken out and absorbance (abs) measured at 575 nm using a clear 96-well plate. Cell 
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viability (as a %) was calculated as (abs of sample-background)/(abs of control-
background) ×100%. 
 
5.2.11 In Vitro Luciferase Transfection Assay 
Luciferase-DNA (luc-DNA)’s transfection levels in luc-DNA or luc-DNA/s-siRNA 
polyplexes were measured in MCF-7 and MCF-7/Adr cells. Luc-siRNA’s transfection 
levels in luc-siRNA or luc-siRNA/Ø-pDNA polyplexes were measured in MDA-MB-
231-luc-D3H2LN cells. One µg of luc-DNA/well was used for MCF-7, 2 µg of luc-
DNA/well for MCF-7/Adr, and 2 µg of luc-siRNA/well for MDA-MB-231-luc-D3H2LN. 
MCF-7 and MCF-7/Adr cells were seeded at 5×10
5
 cells/well and MDA-MB-231-luc-
D3H2LN cells at 2×10
5
 cells/well in 24 well plates. After 24 hours, the media was 
replaced and the polyplex suspensions prepared in DMEM were added drop-wise to each 
well. After 1 day of transfection, the cells were washed twice with PBS and lysed with 
100 µL of Reporter Lysis Buffer (Promega). Luciferase activity in relative luminescence 
units (RLU) was measured by combining 25 µL of lysate and 50 µL of Luciferase Assay 
Reagent and measured in an opaque 96-well plate (Sigma-Aldrich) using a micro plate 
reader (FLUOstar OPTIMA (BMG Labtech, Durham, NC).   
 
Protein levels were determined using BCA protein assay (Thermo Scientific). Ten µL 
of each lysate and 150 µL of BCA reagent were combined in clear 96-well plates and 
incubated at 37
 
°C for 30 minutes. Absorbance was measured at a wavelength of 562 nm 
using an Absorbance Microplate Reader (Molecular Devices, Sunnyvale, CA).  
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5.2.12 DNA Cellular Uptake/Flow Cytometry 
YOYO-pDNA intercalation was carried out by adding 30 µL of 10 µM YOYO-1 to 1 
µg of 1 mg/mL DNA and incubating for 30 minutes at room temperature in the dark. 
MCF-7 and MCF-7/Adr cells were seeded in 6-well plates and allowed to grow to 70% 
confluence. Polyplex solutions were added to each well and flow cytometry was carried 
out after 24 hr. One µg of DNA per well was used for MCF-7 cells and 2.5 µg of DNA 
per well were used for MCF-7/Adr cells. Cells were washed twice with PBS, trypsinized 
and collected for flow cytometry (LSR II System, BD Biosciences). Fluorescence 
detector 530 ± 15 nm was used for YOYO-1 detection. A population of 10,000 freshly 
collected cells was used per condition. 
 
5.2.13 DNA Intracellular Visualization 
MCF-7 and MCF-7/Adr cells were seeded on coverslips placed in 6 well plates and 
allowed to reach 60% confluence. At 60% confluence, polyplexes formed with YOYO-1 
stained DNA were added to each well in FBS enriched media. One µg of DNA per well 
was used for MCF-7 cells and 2.5 µg of DNA for MCF-7/Adr cells. After 24 hr 
incubation, the cells were rinsed with DPBS and fixed with 4% paraformaldehyde 
(Sigma-Aldrich). Coverslips were then mounted on clean glass slides using DAPI 
ProLong Gold Anti-fade Mounting Media (Invitrogen, Eugene, OR). The cells were then 
evaluated with a laser scanning confocal microscope (Leica TCS-SP II Spectral Laser 
Scanning Confocal Microscope, Leica Microsystems GmbH, Wetzlar, Germany). 
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5.2.14 Statistical Analysis 
Data are presented as mean ± standard deviation. Statistical analysis of the 
differences between any mean values was performed using 1-sided Student’s t-test. 
Statistical significance was defined at p≤0.05; and highly significant at p≤0.01 and 
p≤0.001. 
 
5.3 Results and Discussion 
Polymer Synthesis and Characterization.  
Polyethylene glycol modified L-arginine oligo(alkylaminosiloxane) grafted 
poly(ethylenimine) (P(SiDAAr)5Peg3) was synthesized using a route shown in Scheme 
5.1 and Appendix D.2. Synthesis was carried out with reference to prior works published 
on oligo(alkylaminosiloxane) and L-arginine oligo(alkylaminosiloxane) grafted 
poly(ethylenimine) [193, 197]. SiDA is a mixture of ring and linear oligomers, with more 
linear architecture than ring architecture. The characterization of linear vs. ring 
architecture of the oligomer has not been performed. We assumed our synthesis will yield 
the same architectures as published in prior publications. Following our previously 
established procedure, the polymer P(SiDAAr)5 was first synthesized by carbodiimide 
chemistry using EDC/NHS with molar ratio of arginine (Ar) to SiDA (5:1) and SiDAAr 
to PEI (5:1).  
 
The synthesis was carried out in 4 steps, conjugated SiDA, arginine, PEI and PEG 
components. The work I conducted is PEG conjugation to the P(SiDAAr)5 polymer. PEI, 
SiDA and arginine effectively contributed to the transfection efficiency of the polymer 
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and PEG reduced the cytotoxicity of the polymer. SiDA is biodegradable, and has shown 
to be able to complex DNA and transfect DNA in HeLa cells [197]. In addition, arginine 
has been reported to enhance endocytosis and assist in nuclear translocation [193].  
 
The conjugations of arginine, aspartic acid, PEI and PEG were carried out using 
carbodiimide chemistry. P(SiDAAr)5 polymer may have different numbers of SiDAArs 
per PEI unit, since the number of SiDAAr conjugated to each PEI cannot be controlled in 
the coupling process. The same also applies to PEG conjugation. Some P(SiDAAr)5 may 
be conjugated to more than 3 PEG chains and other less than 3. This gives rise to the 
higher polydispersity of P(SiDAAr)5Peg3 compared to PEI from which it was synthesized, 
measured by particle sizer.  The Rapid stirring of the solution in the SiDAAr and PEG 
coupling process can minimize the dispersities in the polymer conjugation. In PEG 
conjugation to P(SiDAAr)5, since both PEI and arginine possess amide groups, PEG 
could be conjugated directly to PEI as well as to the to the arginine arms. However, the 
different conjugation site of PEG does not change the properties of the polymer. See 
Appendix D for detailed synthesis procedures of P(SiDAAr)5. 
 
Figure 5.2 represents 
1
H NMR spectra of L-arginine oligo (alkylaminosiloxane) 
grafted poly(ethylenimine) (P(SiDAAr)5) (300 MHz) and polyethylene glycol modified 
L-arginine oligo (alkylaminosiloxane) grafted poly(ethylenimine) (P(SiDAAr)5Peg3) (300 
MHz). PEI with 25kDa has 5 times as much H proton (2906 H protons) as that of 
(SiDAAr)5 (500 H protons). The integrals of SiDAAr (133.38) and PEI (618.16) on the
 1
H 
NMR spectrum also showed approximately 5 times more H protons from PEI than from  
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(SiDAAr)5 (Fig 5.1A). The resonance at 0.11 ppm is-(bs, Si-CH3). Chemical shifts at δ = 
0.89 and δ = 1.15 are from the two ethylene groups of SiDA. Chemical shifts at δ =1.76 
and δ = 2.26 are from SiDA (-Si-CH2CH2CH2NH-); Chemical shifts at δ =3.69-3.09 are 
SiDAAr (-HCCH2CH2CH2NH-). Chemical shifts at δ =3.0-2.4 are (-NHCH2CH2-, PEI 
ethylene). The 
1
H NMR spectrums of P(SiDAAr)5 is dominated by the PEI resonances: (-
HNCH2CH2-) at 3.0-2.5 ppm.  Nevertheless, the ethylene resonances of the SiDAAr units 
were clearly visible. The resonances of PEG (-OCH2CH2-) were also visualized at δ 
=3.7-3.6 (Fig 5.1).  
 
P(SiDAAr)5 has roughly 3 times as much ethylene groups as 3 equivalents of 3kDa 
PEG, as shown by the integrals in Figure 5.2B. Branched PEI has much more abundant 
amino groups than the hydroxyl groups on PEG. Therefore, from the moles inputted in 
the reaction mixture, all of the activated PEGs should react with P(SiDAAr)5. However, 
the large molecular weight of PEG may result in incomplete reaction with P(SiDAAr)5; 
thus a higher reaction time may be needed to generate a higher polymer yield. The 
resolution of Figure 5.2B is not ideal; higher polymeric concentration or a longer time of 
NMR acquisition could be adapted to enhance the resolution of the spectrum.  
 
The final polymer P(SiDAAr)5Peg3 has a white sponge-like morphology as dried 
polymer. The polymer was water soluble, and was stable at room temperature. It was 
stored in vacuum as dry polymer to eliminate the influence of moisture in the air. For 
experiments, it was reconstituted in dH2O and kept in -20 
o
C for storage. 
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In the previously  published works on SiDA, it has been shown that the basic 
hydrolysis condition generates a mixture of linear and cyclic oligomers with linear/cyclic 
ratio of 3.42/1 [197]. The study also showed that the oligomer interacted effectively with 
DNA and was able to bind DNA through electrostatic interactions, as revealed via the 
electron microscopy and DNA retardation assays. In HeLa cells, the basic hydrolysis of 
SiDA showed efficient transfection through proton capture process of endocytosis. Its 
effect toward DNA transfection should not be affected by the linear vs. ring forms of the 
oligomer. Since my work focuses primarily on the impact of SiDA, arginine and PEG 
modification on PEI for siRNA and DNA-siRNA co-delivery, the presence of ring and 
linear forms of SiDA would not affect the cytotoxicity as well as transfection levels in the 
cells. 
 
In the published work of Morris et al on the synthesis of P(SiDAAr)n [193], the 
1
H 
NMR (D2O) spectrum showed δ (ppm) of 0.1-(bs, Si-CH3), 1.66-arginine(-
HCCH2CH2CH2NH-), 1.86-arginine (-HCCH2CH2CH2NH-), 3.24-arginine(-
HCCH2CH2CH2NH-), 3.86-arginine (-HCCH2CH2CH2NH-), and 3.3-2.5 (-NHCH2CH2-, 
PEI ethylene). The chemical shifts were close to the ones I have identified on the 
1
H 
NMR spectrum in Figure 5.2A. The NMR spectrum showed other peaks than that of the 
polymer, which could be from the side products of the polymer. Morris et al also 
demonstrated that among all of the P(SiDAAr)n derivatives, 5 units of (SiDAAr) were the 
most effective in reducing the PEI cytotoxicity and achieving the highest transfections in 
KB cell line.  
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The average hydrodynamic diameter (Dh) of polymers PEI, P(SiDAAr)5 and 
P(SiDAAr)5Peg3  measured by DLS increased after each step of modification, from PEI 
to P(SiDAAr)5 to P(SiDAAr)5Peg3 (Table 5.1). PEI and P(SiDAAr)5 have similar 
polydispersity indices (PDI) (0.3-0.4), whereas P(SiDAAr)5Peg3 has a greater PDI (0.62). 
Zeta potential increased slightly from PEI to P(SiDAAr)5 as a result of the amine groups 
present on arginine. Compared to P(SiDAAr)5, PEG-conjugation reduced 
P(SiDAAr)5Peg3’s zeta potential.  
Polyplexes Characterization. 
The PDIs of the polyplexes measured via particle sizer using dynamic light scattering 
were similar among the commercial branched PEI (Sigma Aldrich), the intermediate 
polymer P(SiDAAr)5, and P(SiDAAr)5Peg3 (Table 5.2). The relatively high 
polydispersity of the polymers was a result of the lack of uniformity of the commercial 
PEI and the lack of control in the conjugation process of SiDAAr and PEG to PEI, 
resulting in some PEIs having more than 5 (SiDAAr)s and 3 PEGs and others less. The 
variations in zeta potential among the 3 polymers were not significant. The hydrophilic 
properties of PEG resulted in P(SiDAAr)5Peg3 to have significantly higher hydrodynamic 
diameters than PEI and P(SiDAAr)5. First, the linear and hydrophilic nature of PEG gave 
it a larger hydrodynamic diameter in dH2O compare branched PEI, which is a lot more 
condensed and hydrophobic. Please refer to appendix C for the distribution of size and 
zeta potential measurements. 
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P(SiDAAr)5 polyplexes had larger particle sizes and broader standard deviations 
compared to P(SiDAAr)5Peg3 polyplexes (Table 5.2). This demonstrated that 
P(SiDAAr)5Peg3 was able to form polyplexes with more consistent hydrodynamic sizes 
than P(SiDAAr)5 did. The increase of P(SiDAAr)5Peg3 polymer size compared to PEI and 
P(SiDAAr)5 could potentially assist P(SiDAAr)5Peg3 to form more homogeneous 
polyplexes. PEG could reduce the formation of aggregates. 
P(SiDAAr)5Peg3 polyplexes had drastically reduced zeta potentials compare to 
P(SiDAAr)5 polyplexes at lower polymeric ratios (1/2 and 1/3) (Table 5.2). This was a 
result of PEG masking the cationic charges from the polyplexes. As the polymeric ratio 
increases (1/4 and above), PEG can no longer shield the high cationic charges due to the 
possible re-structuring and rearrangement of the polyplexes, thus resulting in an increased 
zeta potentials. 
From Table 5.2, several trends were observed: 1) PEI polyplexes had a larger size 
standard deviation and a larger zeta potential compared to P(SiDAAr)5Peg3 polyplexes, 
proving P(SiDAAr)5Peg3 was able to form more uniform and neutral polyplexes than PEI. 
This can be attributed to the presence of SiDAAr in assisting nucleotide complexation 
and PEG in reducing the cationic charges in P(SiDAAr)5Peg3. 
In DNA, siRNA and DNA-co-siRNA polyplexes (Table 4.1, 5.1 and 5.2), broad 
polydispersity in H2O was observed. This was contributed by the large PDI among PEI, 
P(SiDAAr)5 and P(SiDAAr)5Peg3, the incorporation of both DNA and siRNA, and the 
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possibilities of polyplex aggregates. Also, the self-assembly process makes us unable to 
modulate the variation in size and zeta potentials. Comparing the morphologies of siRNA, 
DNA and DNA-siRNA polyplexes, I found siRNA polyplexes much more dispersed 
(forming loose polyplexes), whereas DNA polyplexes were much more coherent. DNA-
siRNA polyplexes, on the other hand, are a lot more dispersed. Darker color represents a 
coherent structure, whereas lighter is an indicator of a looser structure. 
A gel retardation assay showed P(SiDAAr)5Peg3’s nucleotide-binding capacity with 
different DNA and siRNA weight ratios based on the nucleotides’ electrophoretic 
mobility (Fig 5.3). Compared to the controls (free luc-DNA and s-siRNA), the 
nucleotides showed no band on the gel, dim band in the wells with low P/N polyplexes 
and no band in the wells with high P/N polyplexes. The absence of DNA migration 
signifies complete DNA-polymer complexation. Absent of visible DNA in the wells 
signifies complete DNA masking by the polymer, therefore giving no exposure to the 
staining dye (Fig 5.3). 
DSL and TEM were both incorporated in the characterization of DNA, siRNA and 
DNA-co-siRNA polyplexes (Table 5.1, Table 5.2, Fig 5.4). DLS gave the hydrodynamic 
diameters of the particles whereas TEM gave the morphologies as well as the estimated 
diameters of the polyplexes as dry samples. Hydrodynamic diameters revealed the 
hydrophilic layer around the particle under brownian motion, whereas TEM estimated the 
size absent of the hydration layer. Often, the hydrodynamic diameter measured by DLS is 
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larger than the size estimated by TEM. TEM, however, reveals the morphologies and 
possible aggregates of the polyplexes. 
Polyplex morphologies were visualized under TEM in both high and low 
magnifications (Fig 5.4). The polyplexes have an almost spherical shape. Furthermore, 
polyplex hydrodynamic sizes and zeta potentials were measured via dynamic light 
scattering. Both nucleotide to polymer ratio and the polymeric material play a role in the 
size and surface charge of the polyplexes. On average, P(SiDAAr)5Peg3 polyplexes are 
smaller and have a smaller size range compared to PEI polyplexes (Table 5.2). 
Regarding polydispersity, most polyplexes have a PDI ranging from 0.2-0.5. Comparing 
average zeta potentials, P(SiDAAr)5Peg3 polyplexes have on average lower zeta 
potentials than PEI polyplexes. For both PEI and P(SiDAAr)5Peg3 polyplexes, surface 
charges increase as the polymer ratio increases in the polyplexes. P(SiDAAr)5Peg3 
polyplexes have both positive and negative surface charges, whereas all PEI polyplexes 
have positive charges (Table 5.2). Finally, both siRNA polyplexes and siRNA-co-DNA 
polyplexes made from P(SiDAAr)5Peg3 have similar hydrodynamic sizes. 
1/1/4 P(SiDAAr)5Peg3 polyplexes were incubated with heparin solution of varying 
concentrations, then separated using gel electrophoresis. Polyplexes incubated in 5 
mg/mL of heparin released their nucleotides. 
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A heparin displacement assay was used to examine the integrity and stability of 
DNA/siRNA/ P(SiDAAr)5Peg3 polyplexes in the presence of heparin sodium (Fig 5.5). 
Different concentrations of heparin sodium solutions were used to gradually induce DNA 
and siRNA decomplexation within the polyplex. When no heparin was added, neither 
DNA or siRNA was released from the polyplexes. This is an indication of the polyplexes’ 
stability in the absence of competing polyanions. With increasing heparin concentration, 
polyplexes were sufficiently stable, until reaching 5 mg/mL heparin concentration. At 5 
mg/mL, polyplex decomplexation took place, where both DNA and siRNA were replaced 
by competing polyanions and released from the polyplexes. 
Figure 5.1 Chemical structures of starting materials for polymer P(SiDAAr)5Peg3. (A) 3-
(2-aminoethylamino) propyl-methyl-dimethoxysilane, (B) L-arginine, (C) 25-kDa 
Polyplexes Stability in the Presence of Competing Polyanions. 
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branched PEI, (D) O-(2-Carboxyethyl)polyethylene glycol PEG-3kDa hydrochloride, (E) 
L-aspartic acid, (F) 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride 
(EDC), (G) N-hydroxysuccinimide (NHS). 
 
 
Scheme 5.1 Synthesis of Polyethylene glycol modified L-arginine oligo 
(alkylaminosiloxane) grafted poly(ethylenimine) P(SiDAAr)5Peg3. 
The final polymer has a white sponge-like morphology after lyophilization. The polymer 
is water soluble, and is stable in room temperature. However, we stored it in vacuum as 
dry polymer to eliminate the influence of moisture in the air. It is reconstituted in dH2O 
and frozen at -20
o
C for experiments. 
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Figure 5.2 Spectral characterization of P(SiDAAr)5Peg3. 
1
H NMR spectra of (A) L-
arginine oligo (alkylaminosiloxane) grafted poly(ethylenimine) (P(SiDAAr)5) (300 MHz), 
and (B) Polyethylene glycol modified L-arginine oligo (alkylaminosiloxane) grafted 
poly(ethylenimine) (P(SiDAAr)5Peg3) (300 MHz) containing 5 mmol equivalents of 
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SiDAAr per 1 mmol equivalent of PEI and 3 mmol equivalents of PEG for 1 mmol of 
P(SiDAAr)5, using EDC as a coupling agent and NHS  as a catalyst.  
Table 5.1 Mean Hydrodynamic Diameter (Dh) (nm) and Zeta Potential (mV) of Polymer 
Solutions in dH2O. Three measurements were done per polymer. 
PDI: polydispersity index. 
 
Cytotoxicity Evaluation.  
In the 72-hour dose-dependent polymer toxicity assay of MDA-MB-231-luc-
D3H2LN cells, both P(SiDAAr)5 and P(SiDAAr)5Peg3 had significantly reduced toxicity 
compared to PEI [(p≤0.05) at 25 and 50 µg/mL] (Fig 5.6A). Compared to P(SiDAAr)5,  
P(SiDAAr)5Peg3 showed further cytotoxicity reduction. Cytotoxicity evaluation 
following 24 hr of PEI and P(SiDAAr)5Peg3 polyplex exposure showed that both MCF-7 
and MCF-7/Adr at high polymer concentrations (1/1/4 and 1/2/6 polyplexes), inhibited 
cell growth  (Fig 5.6B, C). However, P(SiDAAr)5Peg3 achieved significantly higher cell 
viability compared to PEI in MCF-7/Adr in a 1/2/6 D/S/P ratio.  
 
Luciferase DNA Transfection.  
Luciferase DNA transfection using luc-DNA-co-s-siRNA polyplexes in MCF-7 and 
MCF-7/Adr cell lines showed that MCF-7 was more prone to DNA transfection than 
Polymer Average (Stdev) PDI (Stdev) zeta (Stdev) 
PEI 9 (1) 0.40 (0.10) 8.1 (6.3) 
P(SiDAAr)5 11 (1) 0.38 (0.11) 12.1 (3.7) 
P(SiDAAr)5Peg3  41 (11) 0.62 (0.38) 10.4 (5.7) 
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MCF-7/Adr (Fig 5.7A, B). With a 2 fold lower dose of DNA, MCF-7 still had higher 
transfection levels (from 10 to 100-fold) than MCF-7/Adr. In MCF-7, where both P/N 
ratios of 1 and 2 were used, polyplexes with P/N of 2 showed a greater transfection level 
than P/N of 1. In polyplexes with both polymers in both cell lines, s-siRNA incorporation 
resulted in enhanced transfection expressions. In MCF-7, 1/2/3 (D/S/P ratio) PEI 
polyplexes achieved 26-fold higher transfections than 1/O/1 PEI polyplexes. In 
P(SiDAAr)5Peg3 polyplexes, both 1/1/2 and 1/2/3 polyplexes expressed an over 10 fold 
higher transfection level compared to 1/O/1 polyplexes. In addition, the 2 polymers 
affected different cell lines differently. In MCF-7, P(SiDAAr)5Peg3 polyplexes showed 
significantly higher transfections, whereas in MCF-7/Adr, higher transfections were 
observed with PEI polyplexes. 
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Figure 5.3 Polyplex agarose gel electrophoresis identifies the un-complexed nucleotides.  
Complete nucleotide (Ø-pDNA and anti-luc siRNA) and polymer (P(SiDAAr)5Peg3) 
complexation was shown in all D/S/P w/w ratios.  
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Figure 5.4 Polyplexes characterization via TEM. 
TEM images of 1/2 DNA/P(SiDAAr)5Peg3 and 1/1/4 DNA/siRNA/P(SiDAAr)5Peg3 
polyplexes at low and high magnifications.  To specifically examine the morphological 
differences between DNA and DNA-siRNA polyplexes, DNA polyplexes showed to be 
more separated and well-dispersed, while DNA-siRNA polyplexes formed more 
aggregates. Both polyplexes compositions were roughly spherical in morphology. Darker 
as well as lighter colored polyplexes were observed. The darker polyplexes probably had 
a greater amount of DNA supercoils while the lighter polyplexes had a greater amount of 
siRNA in it. The images for each polyplex composition are representatives of 6 TEM 
images. 
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Table 5.1 Average Hydrodynamic Diameter (Dh) (nm) and Zeta Potential (mV) of PEI 
and P(SiDAAr)5Peg3 Polyplexes at Different Weight Ratios. Three samples were 
measured per polyplex ratio. 
DNA/siRNA/     
P(SiDAAr)5Peg3 
Size (stdev) PDI (stdev) Zeta (stdev) 
1/O/1 289 (23) 0.24 (0.04) 3.9 (2.5) 
1/1/2 386 (47) 0.37 (0.15) -2.4 (18.1) 
1/0.5/1.5 307 (66) 0.24 (0.14) 14.3 (15.8) 
1/2/3 302 (56) 0.29 (0.35) 20.2 (7.3) 
1/O/2 280 (17) 0.28 (0.04) 21.2 (14.5) 
1/1/4 284 (29) 0.26 (0.10) 22.7 (19.4) 
1/0.5/3 307 (14) 0.29 (0.06) 22.6 (6.0) 
1/2/6 319 (44) 0.31 (0.07) 17.9 (8.8) 
siRNA/DNA/ Size (stdev) PDI (stdev) Zeta (stdev) 
DNA/siRNA/PEI Size (stdev) PDI (stdev) Zeta (stdev) 
1/O/1 276 (156) 0.44 (0.21) 40.6 (6.0) 
1/1/2 301 (148) 0.34 (0.25) 39.1 (8.7) 
1/0.5/1.5 454 (160) 0.29 (0.10) 38.3 (9.0) 
1/2/3 386 (142) 0.34 (0.21) 38.8 (3.2) 
1/O/2 313 (81) 0.37 (0.17) 48.2 (9.4) 
1/1/4 439 (127) 0.23 (0.18) 36.9 (10.1) 
1/0.5/3 387 (200) 0.33 (0.09) 53.6 (23.1) 
1/2/6 356 (85) 0.29 (0.15) 67.2 (18.0) 
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P(SiDAAr)5Peg3 
1/O/2 233 (18) 0.25 (0.07) 20.4 (15.0) 
1/0.5/3 228 (11) 0.19 (0.06) 11.0 (1.0) 
1/1/4 272 (87) 0.31 (0.23) 29.1 (16.0) 
1/2/6 297 (85) 0.30 (0.14) 18.3 (7.5) 
PDI: Polydispersity Index, D/S/P: DNA/siRNA/polymer, S/D/P: siRNA/DNA/polymer.  
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Figure 5.5 Stability of polyplexes measured through the polyanion competition assay. 
1/1/4 P(SiDAAr)5Peg3 polyplexes were incubated for 15 minutes with heparin solutions 
of varying concentrations from 100 µg/mL to 5000 µg/mL. Gel electrophoresis was used 
to visualize the migration of free DNA and siRNA as polyanion replacement took place. 
Polyanion replacement is defined as the replacement of DNA and siRNA molecules by 
heparin molecules, causing nucleotide polyplexes to release their encapsulated 
nucleotides. As shown on the gel, at a concentration of 5000 µg/mL, the polyplexes 
incubated in heparin released their nucleotides. 
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Figure 5.6 Polymer and polyplex cytotoxicity assays in drug-sensitive and resistant cell 
lines. 
In all 3 experiments (A, B, and C), PEI was used as a reference to compare to 
P(SiDAAr)5 and P(SiDAAr)5Peg3. (A) Polymer solution MTT assay was conducted after 
72 hr of polymer incubation in MDA-MB-231-luc-D3H2LN cell line. n=8. *: statistically 
significant compared to PEI polymer at the same concentration. †: statistically significant 
compared to P(SiDAAr)5 polymer at the same concentration. Compared to PEI, both 
P(SiDAAr)5 and P(SiDAAr)5Peg3 had a much more reduced cytotoxicity. Also, compared 
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P(SiDAAr)5 and P(SiDAAr)5Peg3, P(SiDAAr)5Peg3 showed reduced toxicity at higher 
polymer concentrations (25ng/mL and 50 ng/mL). (B) Polyplex cytotoxicity in MCF-7 
after 24 hr polyplexes incubation. In drug sensitive cell line MCF-7, P(SiDAAr)5Peg3 
generated reduced polyplexes toxicity at N/P ratios of 1/1/4 and 1/2/3. (C) Polyplex 
cytotoxicity in MCF-7/Adr after 24 hr of polyplex incubation. In drug resistant cell line 
MCF-7/Adr, P(SiDAAr)5Peg3 polyplexes resulted in reduced cytotoxicity compared to 
PEI polyplexes. (B)&(C): n=2 *: statistically significant compared to the control group; †: 
statistically significant compared to PEI polyplexes of the same composition. *, † p≤0.05; 
**, †† p≤0.01; ***, ††† p≤0.001. All data were represented as mean±standard deviation. 
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Figure 5.7 DNA transfection levels of both PEI and P(SiDAAr)5Peg3 luc-DNA-co-s-
siRNA polyplexes in MCF-7 and MCF-7/Adr cells. 
Data represented as mean ± standard deviation. n=2. (A) In MCF-7 cell line, 
P(SiDAAr)5Peg3 polyplexes achieved a significantly higher transfection level than PEI 
polyplexes with the same composition. (B) In MCF-7/Adr cell line, PEI polyplexes 
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achieved significantly higher transfection levels than P(SiDAAr)5Peg3 polyplexes with 
the same composition. siRNA incorporation significantly enhanced DNA transfection 
levels in both cell lines. †: statistically significant compared to PEI polyplexes of the 
same composition. *, † p≤0.05; **, †† p≤0.01; ***, ††† p≤0.001.  
Luciferase expression reduction in MDA-MB-231-luc-D3H2LN cells using luc-
siRNA and Ø-pDNA polyplexes showed that ØDNA significantly enhanced siRNA’s 
transfection levels (Fig 5.8). Consistent with MCF-7, P(SiDAAr)5Peg3 showed greater 
transfections than PEI. The maximum transfection level (97% luciferase expression 
knock-down) was achieved with 1/2/6 D/S/P polyplexes. 
 
DNA Intracellular Uptake in MCF-7 and MCF-7/Adr Cell Lines. 
The intracellular uptake of DNA examined in MCF-7 by flow cytometry showed that 
1/1/4 polyplexes had a greater DNA uptake level than 1/O/2 polyplexes (Fig 5.9A). 
Confocal microscopy showed higher DNA cellular internalization in 1/2/3 polyplexes 
than in 1/1/2 polyplexes, and both expressed higher DNA cellular internalization than 
1/O/1 polyplexes (Fig 5.9B).    
 
In MCF-7/Adr, both flow cytometry and confocal microscopy showed a higher DNA 
uptake in 1/1/4 polyplexes compared to 1/O/2 polyplexes. However, 1/2/6 polyplexes 
showed a reduced DNA uptake, confirmed by both flow cytometry and confocal imaging 
(Fig 5.10). In all studies, DNA uptake is affected by polyplex compositions and the 
presence of siRNA in the polyplex.  
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The PDIs of the polyplexes measured via particle sizer using dynamic light scattering 
were similar among the commercial branched PEI (Sigma Aldrich), the intermediate 
polymer P(SiDAAr)5, and P(SiDAAr)5Peg3. The relatively high polydispersity of the 
polymers was a result of the lack of uniformity of the commercial PEI and the lack of 
control in the conjugation process of SiDAAr and PEG to PEI, resulting in some PEIs 
having more than 5 (SiDAAr)s and 3 PEGs and others less. The variations in zeta 
potential among the 3 polymers were not significant. The hydrophilic properties of PEG 
resulted in P(SiDAAr)5Peg3 to have significantly higher hydrodynamic diameters than 
PEI and P(SiDAAr)5. First, the linear and hydrophilic nature of PEG gave it a larger 
hydrodynamic diameter in dH2O compare branched PEI, which is a lot more condensed 
and hydrophobic.  
 
In DNA, siRNA and DNA-co-siRNA polyplexes (Table 4.1, 5.1 and 5.2), broad 
polydispersity was observed. This was contributed by the large PDI among PEI, 
P(SiDAAr)5 and P(SiDAAr)5Peg3, the incorporation of both DNA and siRNA, and the 
possibilities of polyplex aggregates. Also, the self-assembly process makes us unable to 
modulate the variation in size and zeta potentials. Compare the morphologies of siRNA, 
DNA and DNA-siRNA polyplexes, I found siRNA polyplexes much more dispersed 
(forming loose polyplexes), whereas DNA polyplexes were much more coherent. DNA-
siRNA polyplexes, on the other hand, are a lot more dispersed. Darker color represents a 
coherent structure, whereas lighter is an indicator of a looser structure.  
 
 140 
 
DSL and TEM were both incorporated in the characterization of DNA, siRNA and 
DNA-co-siRNA polyplexes. DLS gave the hydrodynamic diameters of the particles 
whereas TEM gave the morphologies as well as the estimated diameters of the polyplexes 
as dry samples. Hydrodynamic diameters revealed the hydrophilic layer around the 
particle under brownian motion, whereas TEM estimated the size absent of the hydration 
layer. Often, the hydrodynamic diameter measured by DLS is larger than the size 
estimated by TEM. TEM however, reveals the morphologies and possible aggregates of 
the polyplexes. 
 
Polyplex sizes and zeta potentials have major effects on the particle interactions with 
the biological system, including the endocytotic pathways the particles undertake and the 
ability of the particles to perform endosomal escape and to assist in nucleotide 
transfections. Zeta potential is the electrokinetic potential of the particles dispersed in 
colloidal forms. Investigating the size and zeta properties of DNA polyplexes and 
DNA/siRNA polyplexes, I found that in the same N/P ratio, there are no major 
differences in the size of the polyplexes. Moreover, I did not observe significant 
differences between the polydispersities and zeta potentials of 1/O/2 and 1/1/4 polyplexes. 
Comparing PEI and P(SiDAAr)5Peg3 polymers, however, P(SiDAAr)5Peg3 polyplexes 
had a smaller zeta potential than PEI polyplexes. This is a result of PEG modifications, 
which reduced the surface charge of the polyplexes. From the above observation, we can 
conclude that the differences in transfections between DNA and DNA-siRNA polyplexes  
was not caused by the sizes and zeta potentials of the polyplexes.  
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The polyplexes were formed via self-assembly process through electrostatic 
interactions. The polymer sizes as well as charges are major factors for the formation of 
polyplexes, the release of the nucleotides in the cell through endosomal escape, as well as 
effectiveness in transfections. The level of polydispersity in P(SiDAAr)5Peg3 will also 
cause formed polyplexes to have different sizes 
 
In our PEI-based delivery systems, we showed that DNA and siRNA enhances each 
other’s transfection levels. Luc-DNA was combined with s-siRNA, and luc-siRNA 
combined with Ø-pDNA. S-siRNA and Ø-pDNA had no genetic interferences with 
functional nucleotides. Polymer characterization demonstrated that polymer size 
increased significantly from P(SiDAAr)5 to P(SiDAAr)5Peg3, partly due to the 
hydrodynamic size of the long linear PEG chains (Table 5.1). P(SiDAAr)5 polyplexes 
had larger particle sizes and broader standard deviations compare to P(SiDAAr)5Peg3 
polyplexes (Table 5.2). This demonstrated that P(SiDAAr)5Peg3 was able to form 
polyplexes with more consistent hydrodynamic sizes than P(SiDAAr)5 did. The increase 
of P(SiDAAr)5Peg3 polymer size compared to PEI and P(SiDAAr)5 could potentially 
assist P(SiDAAr)5Peg3 to form more homogeneous polyplexes. PEG could reduce the 
formation of aggregates. 
 
P(SiDAAr)5Peg3 polyplexes had drastically reduced zeta potentials compare to 
P(SiDAAr)5 polyplexes at lower polymeric ratios (1/2 and 1/3) (Table 5.2). This was a 
result of PEG masking the cationic charges from the polyplexes. As the polymeric ratio 
increases (1/4 and above), PEG can no longer shield the high cationic charges due to the 
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possible re-structuring and rearrangement of the polyplexes, thus resulting in an increased 
zeta potentials. 
 
From Table 5.2, several trends were observed: 1) PEI polyplexes had a larger size 
standard deviation and a larger zeta potential compared to P(SiDAAr)5Peg3 polyplexes, 
proving P(SiDAAr)5Peg3 was able to form more uniform and neutral polyplexes than PEI. 
This can be contributed by the presence of SiDAAr in assisting nucleotide complexation 
and PEG in reducing the cationic charges in P(SiDAAr)5Peg3.  
 
The reduction in zeta potential from P(SiDAAr)5 to P(SiDAAr)5Peg3 indicated the 
PEG’s ability to neutralize polymeric charges. PEI and P(SiDAAr)5Peg3 polyplex 
demonstrated different characteristics as carrier materials (Table 5.2). Polyplex size and 
zeta potential have a major effect on the particle interactions within the biological system. 
Zeta potential is the electrokinetic potential of the particles dispersed in colloidal forms. 
The particle size and zeta potential play a major role in the endocytotic pathways that the 
particles undertake and the ability of the particles to perform endosomal escape and to 
assist in nucleotide transfections. Investigating the size and zeta properties of DNA 
polyplexes with DNA/siRNA polyplexes, I found that in the same N/P ratio, there is no 
major difference in sizes between the compositions, indicating that the siRNA and DNA 
components do not result in significant differences in the sizes of the polyplexes. 
Moreover, comparing the polydispersity of 1/O/2 and 1/1/4 polyplexes in PEI and 
P(SiDAAr)5Peg3 polymers, Ifound no significant difference, indicating that DNA and 
siRNA components do not increase the dispersity nature of the polyplexes. Comparing 
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the zeta potentials, I saw that 1/O/2 and 1/1/4 polyplexes showed no major difference in 
zeta potentials.  However, P(SiDAAr)5Peg3 polyplexes have a smaller zeta potential than 
PEI polyplexes. This is a result of PEG conjugation, which reduces the surface charges of 
the polyplexes. 
 
Figure 5.8 Polyplexes’ siRNA transfections in MDA-MB-231-luc-D3H2LN cell line. 
In siRNA/DNA/polymer (PEI or P(SiDAAr)5Peg3) polyplexes, Ø-pDNA significantly 
enhanced luc-siRNA’s transfection levels in MDA-MB-231-luc-D3H2LN cell line. In 
this condition, P(SiDAAr)5Peg3 is a more effective transfection agent compared to PEI. 
Data as mean ± standard deviation. n=2. †: statistically significant compared to PEI 
polyplexes of the same weight ratio. *, † p≤0.05; **, †† p≤0.01; ***, ††† p≤0.001. 
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Figure 5.9 P(SiDAAr)5Peg3 polyplexes’ intracellular DNA quantification in MCF-7 cell 
line. 
 (A) Flow cytometry revealed that DNA-siRNA polyplexes have a greater DNA cellular 
uptake than DNA polyplexes. (B) Intracellular DNA was visualized by confocal 
microscopy showed that polyplexes with siRNA (1/2/3 and 1/1/4) have a stronger DNA 
internalization than those without siRNA (1/O/1 and 1/O/2). Images were captured using 
a 40× objective lens. Bar = 100 μm. 
 145 
 
 
Figure 5.10 P(SiDAAr)5Peg3 polyplexes’ intracellular DNA quantification in MCF-
7/Adr cell line. 
(A) Flow cytometry quantified P(SiDAAr)5Peg3 polyplexes’ DNA uptake levels in MCF-
7/Adr cell line. 1/1/4 polyplexes showed over 2-fold higher DNA uptake than 1/O/2 
polyplexes. The level dropped in 1/2/6 polyplexes due to polymer masking. (B) Confocal 
microscopy visualized YOYO-1-DNA’s cellular internalization. 1/1/4 polyplexes showed 
a stronger DNA internalization than 1/O/2 polyplexes. Fluorescence intensity dropped in 
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1/2/6 polyplexes, confirming the flow cytometry results. Images were captured using 80× 
objective lens. Bar=50 μm. 
 
Compared to PEI polyplexes, P(SiDAAr)5Peg3’s PEG groups have charge shielding 
effects. Furthermore, PEI has more positive charges per weight unit compare to 
P(SiDAAr)5Peg3. Both factors result in PEI polyplexes having a higher average zeta 
potential than P(SiDAAr)5Peg3 polyplexes. Since polyplex formation is a self-assembly 
process, the nucleotide exposure to the exterior cationic charge results in negative 
polyplex surface charge due to nucleic acids’ anionic nature. On average, 
P(SiDAAr)5Peg3 formed smaller and more uniform sized polyplexes than those formed 
with PEI polyplexes because P(SiDAAr)5Peg3’s PEG chains could help in preventing 
polyplexes aggregation. 
 
In all complexation ratios, complete nucleotide conjugation was observed, indicated 
by the lack of nucleotide migration on the electrophoresis gel (Fig 5.3). Upon complete 
nucleotide masking by the polymer, SYBR Green dye had no binding with the nucleotide, 
thus showing no fluorescent band in the well. 1/1/4 polyplexes visualized by TEM 
showed well dispersion at low magnification. At high magnification, nearly spherical 
individual polyplexes polyplexes were observed (Fig 5.4). 
 
Heparin is a large polyanion. It is a glycosaminoglycan, linear and negatively charged 
with sulfonate groups. It can be found inside cells and on the surface of the cell 
membrane [198]. Heparin is also a major component of the extracellular matrix of some 
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tissues, including connective tissues.[198] Therefore, we chose heparin as a competition 
anion to evaluate the polyplex stabilities. 1/1/4 D/S/P polyplexes showed no 
disintegration at concentrations of up to 5 mg/mL heparin solution, demonstrating the 
polyplex stability in an anionic environment. The data thus suggest the polyplex would 
remain stable in the presence of serum or plasma proteins which is critical for its in vivo 
application. Premature release of the cargo in the circulation could make the polyplex 
ineffective as a transfecting agent.  
 
Polymer toxicities were determined after 3 days of polymer incubation because 3 
days incubation allows a more precise examination of the polymer effect on cell 
proliferations (Fig 5.6A). Polyplex toxicities, however, were examined in transfection 
conditions (1 day incubation) to more clearly reflect the polyplexes’ growth inhibitory 
effects during the transfection period (Fig 5.6B, C). Although they contain equal amounts 
of DNA, 1/1/4 polyplexes weigh twice as much as 1/O/2 polyplexes, and showed higher 
toxicity. Although it appears that polyplexes have similar toxic effect in MCF-7 and 
MCF-7/Adr, the doses of polyplexes used in MCF-7/Adr was twice as much of each 
polyplex as MCF-7. Therefore MCF-7/Adr is in reality more resistant to polyplex toxicity 
than MCF-7. Most polyplexes had a mild growth-inhibitory effect. However, 
P(SiDAAr)5Peg3 polyplexes showed less toxicity than PEI at higher polyplex 
concentrations (ex. 1/2/6).  
 
Concerning DNA transfections, PEI and P(SiDAAr)5Peg3 show different transfection 
levels which is also cell line dependent.  For example, P(SiDAAr)5Peg3 shows higher 
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transfection in MCF-7 and PEI in MCF-7/Adr (Fig 5.7-8).  In the process of acquiring 
drug resistance, MCF-7/Adr’s membrane lipid composition undergoes changes, forming 
more compact cell membranes and increased lysosomes compared to MCF-7. This 
change affects its cellular endocytosis, membrane trafficking and intracellular 
processing/transport, which contribute to decreased DNA transfection [119, 199]. Thus 
MCF-7/Adr could require a highly cationic delivery vehicle for interaction with cell 
membrane to trigger cellular uptake process. Drug sensitive cell lines (MCF-7 and MDA-
MB-231-luc-D3H2LN), however, have relatively higher membrane permeabilities due to 
the fluid nature of their membranes, allowing endocytosis. In drug sensitive cells, 
P(SiDAAr)5Peg3 may better facilitate intracellular nucleotide release and nuclear 
localization due to arginine and siloxane’s aforementioned properties, therefore 
enhancing endocytosis. 
 
Significantly enhanced luciferase protein knock-down was observed in siRNA-pDNA 
polyplexes (Fig 5.8), yet their average size and zeta potential do not differ significantly 
from siRNA polyplexes. Therefore, there may be other mechanisms that assist in 
transfection, such as the polyplexes’ endosomal escape and intracellular trafficking. DNA 
uptake studies confirmed that high nucleic acid internalization and nuclear localization 
rates are not the only influences on transfection rates. For example, free YOYO-DNA’s 
cellular uptake was significantly higher than that of 1/O/2 polyplexes in MCF-7 (Fig 5.9), 
yet naked DNA showed insignificant transfections compared to polyplexes (Fig 5.7A). 
Also, 1/1/4 P(SiDAAr)5Peg3 polyplexes had approximately 2-fold higher DNA uptake 
than 1/O/2 polyplexes, yet showed over 6-fold DNA transfection (Fig 5.7A). All these 
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indicate that the polymers not only play a role in DNA’s intracellular uptake, they also 
affect other parameters that influence gene transfections. In all gene therapies, 
transfection level is heavily dependent upon the carrier’s ability to overcome extracellular 
and intracellular barriers, including (1) cellular uptake, (2) endosomal escape and 
protection from lysosomal degradation, and (3) intracellular polyplex de-complexation 
for effective gene functioning [200].  Therefore, further studies are needed to understand 
their intracellular trafficking that could impact transfection.  
 
The decrease in fluorescence from 1/1/4 to 1/2/6 polyplexes (Figure 5.9 and 5.10) 
can be a result of two factors. One, since we only visualized the fluorescence intensity of 
YOYO-DNA, a large quantity of 1/2/6 polyplexes was needed to be ingested in order to 
internalize the same amount of DNA as that of 1/O/2 or 1/1/4 polyplexes. Therefore, in 
reality, the quantity of 1/2/6 polyplexes internalized was a lot greater than that of 1/O/2 
polyplexes. Another reason is that some of YOYO-1 fluorescence is quenched upon 
complexation and unquenched upon decomplexation. Therefore I could not conclude if 
the strong intracellular fluorescence intensity was related exclusively to polyplexes 
internalization, or if it is due in part by the decomplexation of DNA. One experiment to 
perform is to use the dye-conjugated polymer instead of YOYO-DNA for the 
quantification of polyplex internalization. 
 
One observation to note is that 1/2/6 polyplexes showed a lower intracellular DNA 
uptake, as detected by both flow cytometry and confocal microscopy (Fig 5.10). This 
may due to YOYO-1-DNA’s fluorescence quenching as a result of polymer and siRNA 
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masking. When the overall ratio of (siRNA and polymer) to DNA increases, DNA 
masking is likely to result, thus lowering the detected DNA signal. 
 
One possibility for co-delivery to enhance DNA and siRNA’s transfection levels is by 
alterations in polyplex structures. DNA, which has long and winding strands, and siRNA, 
which has short and rigid strands, has different PEI binding behaviors. Study has shown 
differences in hierarchical mechanism of formation between DNA-PEI and siRNA-PEI 
polyplexes [201]. Further, siRNA undergoes biphasic binding with the polycations and 
molecular reorganization at low N/P ratios, which is not present with DNA [201]. When 
combined, they will form different polyplex structures from those formed by single 
nucleotides, thus potentially affecting the nucleotides’ intracellular release, localization, 
and interaction with intracellular molecules. 
 
Co-delivery is a promising yet challenging field. siRNA and paclitaxel co-delivery 
has been achieved by cationic core-shell nanoparticles with enhanced transfection 
efficiencies [202]. Poly(2-ethyl-2-oxazoline)-PLA-g-PEI, multifunctional chitosan 
nanoparticles  and PEI-functionalized lipid nano-capsules have all been used to explore 
nucleotide and drug co-delivery to enhance transfection outcomes [203-205]. In this 
study, DNA and siRNA have been co-delivered in PEI-based polyplexes as helper 
polyanions to enhance each other’s transfection levels. Mechanistically, both DNA and 
siRNA are complementary to one other. For example, when siRNA targets one gene and 
pDNA targets its suppressor gene, the combination may elongate the silencing effects.  
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5.4 Conclusions 
This study demonstrated that long, supercoiled pDNA and short, rigid siRNA 
enhance each other’s gene transfection levels in a cell. Co-delivery of siRNA and pDNA 
using a PEI-based carrier is a promising approach to maximize gene transfection 
efficiency. Specifically, 1/1/4 D/S/P polyplexes resulted in higher DNA and siRNA 
transfection with reduced toxicity than other polyplex compositions tested; thus 1/1/4 
D/S/P polyplexes is the best composition for co-delivery of DNA and siRNA among the 
ones we tested. Such an approach has the potential to achieve synergistic therapeutic 
effects by simultaneously targeting multiple genetic levels. This study showed that in all 
of the complexation ratios tested, synergistic effects observed in co-delivery were due to 
the presence of a helper polyanion (DNA or siRNA). The study also gives incentive for 
future explorations in designing and implementing multi-nucleic acid delivery strategies, 
such as functional DNA P53 and siRNA anti-bcl2. A better understanding of co-
delivery’s physicochemical, biological and therapeutic characteristics will be essential to 
future implementation of co-delivery strategies in clinical settings. 
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CHAPTER VI 
 
SUMMARY, CONCLUSIONS AND FUTURE DIRECTION 
6.1 Summary 
The cure for cancer lags despite the best efforts from the medical community. The 
failure to treat advanced breast cancer can be attributed by the development of drug 
resistance and metastasis, where the cells undergo epigenetic and genetic mutations to 
acquire EMT and the CSC phenotype. 
 
The aims of this thesis are 1) to examine the CSC characteristics in breast cancer cell 
lines and the effects of epigenetic drug SAHA; 2) to analyze the transcriptomic 
alterations in drug resistant breast cancer cells as a result of epigenetic drug treatments; 
and 3) To generate a cationic construct to facilitate siRNA and DNA-co-siRNA delivery. 
 
The development of drug resistance and malignant transformation has been correlated 
with the presence of CSC, which drives metastasis and drug resistance. In chapter 2, I 
first examined the presence of breast tumor CSC immunophenotype (CD44
+
/CD24
-
, 
ESA
+
, CD201
+
, CD49f
+
) in drug resistant breast cancer cell line MCF-7/Adr in 
comparison with metastatic cell line MDA-MB-231 and other breast cancer cell lines, 
and found MCF-7/Adr to possess the surface markers currently identified for breast CSC. 
I further identified the presence of CSC proteins (fibronectin
+
, vimentin
+
) as well as 
  
 
epithelial protein marker E-cadherin using fluorescence microscopy. Next, I evaluated the 
ability of the cells to form tumors in vitro under different cell culture conditions 
(mammosphere formation assay). The migratory rate of MCF-7/Adr in comparison to 
MDA-MB-231-D3H2LN in vitro was also examined using migration assay. Despite the 
fact that MCF-7/Adr possesses all the surface markers of CSC, it showed low migratory 
ability, where is contributed by the presence of E-cadherin. 
 
Reversing epigenetic patterns can be effective in eradicating drug resistant cells. 
Therefore, next, I investigated the effectiveness of histone deacetylation inhibitor SAHA 
in eliminating MCF-7/Adr. I found that compared to cell lines MDA-MB-231 and hMSC, 
SAHA is more effective in killing MCF-7/Adr. Comparing the effect of SAHA on the 
migratory rate of the cell, the metastatic ability of both hMSC and MDA-MB-231 was 
hampered significantly by SAHA. Also, I found that 7 days treatment of SAHA did not 
completely reverse the breast cancer stem-cell immunophenotype possessed by MCF-
7/Adr.  
 
In chapter 3, I further investigated the transcriptomic changes by the epigenetic drugs 
DAC and SAHA in reversing drug resistant characteristics. Massively parallel 
sequencing/RNA-seq was conducted to elucidate the underlying mechanisms by which 
DAC and SAHA reverse pathways affecting cellular drug resistance. By quantitative 
analysis, I identified over 1000 transcripts that exhibited greater than two-fold differential 
expression (p<0.005) from each drug treatment compare to untreated cells. We found 
DAC and SAHA to regulate a large number of the same genes in the above pathways; 
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however, only DAC significantly down-regulate drug metabolism genes whereas SAHA 
showed an up-regulation of drug resistant genes ERBB2IP, TGFBR2 and E3F7. This 
work elucidated the genetic effect of DAC and SAHA that enhances the therapeutic 
efficacy of chemotherapy in both solution and nano- delivery vehicles.  
 
siRNA has potential as a gene therapy due to its high potency and ability to exert 
gene knockdown with high specificity. However, poor cellular uptake and rapid 
degradation by RNAse are major barriers for achieving its therapeutic efficacy. Therefore, 
it is essential to protect siRNA from RNAse degradation, maintain polyplex stability, and 
increase transfection efficiency during siRNA delivery. In chapter 4, we investigated the 
ability of P(SiDAAr)5Peg3, an arginine oligopeptide-grafted and polyethylene glycol 
modified bPEI, to successfully deliver siRNA to MDA-MB-231-luc-D3H2LN and 
MCF7/Adr. First, we examined the physical characteristics (hydrodynamic diameter and 
zeta potential) of the siRNA polyplexes using dynamic light scattering. Then I examined 
the polyplexes integrity using a polyanion competition assay. Thirdly, I examined the 
morphology of the polyplexes using TEM, its ability of the polyplexes to protect siRNA 
from RNAse degradation, and the polyplexes cytotoxicity using MTT assay. Lastly, I 
examined the siRNA transfection level in vitro. I showed over 70 fold luciferase 
expression knockdown by luc-siRNA in metastatic MDA-MB-231-luc-D3H2LN and 
effective suppression of ABCB1 protein by anti-ABCB1 siRNA in drug resistant MCF-
7/Adr cell line. 
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A wide range of gene therapies are under clinical trials. However, a major challenge 
is the low transfection level. In chapter 5, I aimed to enhance the transfection levels of 
DNA and siRNA through co-delivery approach. I formulated polyplexes with different 
nucleotide to polymer ratios and examined the effectiveness of each ratio in conducting 
transfection. Cationic polymer 25 kDa bPEI was used as a standard in comparison with 
polyethylene glycol modified L-arginine oligo (alkylaminosiloxane)-graft poly 
(ethylenimine) P(SiDAAr)5Peg3, the polymer I used for siRNA delivery. Polyplexes at 
different nucleic acid to polymer weight ratios were characterized and used for 
transfecting sensitive (MCF-7) and resistant (MCF-7/Adr) breast cancer cell lines. The 
gene silencing effect of the polyplexes through siRNA transfection was examined in 
MDA-MB-231-luc-D3H2LN cell line. The results showed that the polyplexes formed 
with derivative P(SiDAAr)5Peg3 exhibited lower toxicity compared to polyplexes formed 
using bPEI. Furthermore, co-delivery using P(SiDAAr)5Peg3 resulted in a maximum of 
~20-fold higher DNA transfection and 2-fold higher siRNA transfection as compared to 
the single nucleotide delivery with the same N/P w/w ratio. Confocal microscopy 
imaging and flow cytometry analysis demonstrated that the enhanced transfection does 
not solely depend on the cellular uptake of DNA, suggesting that we need a combination 
of different therapeutic agents to overcome drug resistance. DNA and siRNA co-delivery 
could be a promising therapeutic approach to achieve synergistic effects, as it has 
demonstrated the ability to enhance each nucleotide’s transfection rate in both drug 
sensitive and resistant breast cancer cell lines. DNA-siRNA co-delivery also has the 
advantage of simultaneously targeting multiple regulatory pathways in a single 
formulation to halt and reverse disease progression. 
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In this work, there are a number of interesting findings. First, CSC characteristics 
were observed in the drug resistant MCF-7/Adr cell line but not in the metastatic MDA-
MB-231 cell line, even though both cell lines possess triple negative and basal 
phenotypes. This suggests that the existing breast CSC immunophenotype has a strong 
connection with the level of drug resistance, but not with metastatic ability. This point 
has never been addressed in the literature. Also, for the first time, this study identified 
uniform breast CSC surface marker expression (CD44
+
/CD24
-
) in a cell line.  
 
In RNA sequencing study, a large number of genes and pathways, including PPAR, 
mTOR and lysosomal signaling pathways, were similarly affected by DAC and SAHA. 
By analyzing the gene alteration patterns based on cellular locations, it was shown that 
nuclear genes were mostly up-regulated while plasma membrane genes were mostly 
down-regulated by both DAC and SAHA. The differential expression pattern could 
possibly be due to the cascade effect of the nuclear genes on the down-stream genes and 
pathways.  
 
In DNA siRNA co-delivery using PEI-based cationic polymer, it was surprising to 
find DNA and siRNA enhanced each other’s transfection levels. In the past, co-delivery 
of functional DNA and siRNA was studied. However, their ability to enhance each 
other’s transfections as helper anions has not been investigated. This study provides 
incentives for the future works using functional DNA and siRNA.  
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6.2 Limitations  
A number of experimental limitations were present in this work.  First, all of the 
MCF/7/Adr cell-related works were conducted using the cell line obtained from Dr. 
Batra’s group at the University of Nebraska Medical Center, Omaha, and maintained by 
culturing with 100 ng/mL of doxorubicin in culture media. For CSC characterization, 
uniform CSC immunophenotype in early MCF-7/Adr passages was observed. However, 
there was a reversal of the CSC characteristics at a later passage (P36), with increasing 
CD24
+ 
sub-population in the culture. Due to the potential differences in the cell line 
sources and the variations in culture conditions, it is possible that MCF-7/Adr from 
another source with different culture conditions may not possess 100% of the 
CD44
+
/CD24
-
 immunophenotype. Also, in the study, the possible variations between in 
vitro and in vivo conditions have not been ddressed, although the cells showed alterations 
in immunophenotype when cultured in floating mammosphere conditions. As there are 
different cytokines and growth factors in in vivo growth environments, there was a 
possibility of obtaining a different immunophenotype when MCF-7/Adr was grown in an 
in vivo condition. A future study could be to form tumors in mice with stem-like cancer 
cells, treating with drugs or epigenetic drugs, followed by tumor dissociation and surface 
immunophenotype characterization to examine in parallel the different states the cells are 
as cell culture in vitro and as tumors in vivo. 
 
For RNA sequencing, due to the large number of gene outputs, only pathways based 
on the current knowledge of endocytosis, drug transport and metabolism were analyzed. 
DAC and SAHA affected a large number of genes (ex. KIF23, LAMIN B, SYNE1, 
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SYNE2) in a similar way. However, there are still genes and pathways that were not 
comprehensively examined. The gene distribution patterns on the Volcano Plot had many 
similarities. However, with the software limitations, it was difficult to identify the exact 
gene represented by each dot on the Volcano Plot. Therefore, it was not feasible to 
comparatively analyze the gene fold changes with their statistical significance on the 
Volcano plot. One way to better correlate the genes differentially regulated by DAC and 
SAHA was to directly compare these two groups without first comparing with the control. 
Another way was to manually select the genes with high fold changes from the 2 groups, 
and conduct analyses on similarly as well as differently affected genes.  
 
The third limitation of this study was the presence of polymer side products, for 
instance, the mixture of linear and ring forms of SiDA in our polymer P(SiDAAr)5Peg3. 
However, I have not further pursued the side-product separations for two reasons. First, 
the synthetic procedure allows the presence of side products such as P(SiDAAr) with 
different PEG chains, and the incomplete reaction due to the large molecular weight of 
PEI and PEG. However, the different side-products could be separated through column 
chromatography due to their different architectures, where the ring formed oligomers will 
be eluted first. However, since I focused on the overall effect of the polymer in assisting 
nucleotide transfections, structural variations of the polymer should not greatly affect the 
transfection efficiency.  
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6.3 Final Conclusion and Future Directions 
In this study, CSC surface markers in drug resistant breast cancer cells MCF-7/Adr 
were identified, which could undergo surface marker reversal under different culture 
conditions (mammosphere or epigenetic drug SAHA treatment). The effectiveness of 
epigenetic drugs DAC and SAHA in altering the transcriptomes of MCF-7/Adr was also 
examined, and was found to effectively reverse the genes and pathways affecting drug 
resistance. Finally, siRNA delivery and DNA-siRNA co-delivery polyplexes were 
formulated to target breast cancer cells, especially in metastatic and drug resistant cell 
lines. 
  
There are a number of future studies that could be carried out as a continuation of this 
work. One is to use functional DNA-siRNA combination for future studies. In this work, 
DNA and siRNA have demonstrated to effectively enhance each other’s transfections, 
therefore upon effective combination, DNA-siRNA co-treatment using P(SiDAAr)5Peg3 
could result in superior effect than both DNA and siRNA delivered individually. On the 
other hand, if functional DNA and siRNA achieve a greater synergistic effect than what 
was observed with the incorporation of non-coding helper DNA and siRNA, the 
combination would be highly synergistic in their therapeutic effects. Another area of 
exploration is to analyze other genes and pathways identified by RNA-seq. This work 
focused on the different aspects of gene regulations associated with drug resistance. 
However, other areas such as resistance to immunotherapy and free radical generation 
could also be examined in future works.  
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It has been shown that epigenetic drugs were less effective in solid tumor treatment 
than in blood cancer [206]. However, they have strong synergistic effects with 
chemotherapy, such as doxorubicin [33]. Much study is needed to find out the optimal 
drug combinations to use and to formulate treatment strategies. For future studies, 
epigenetic drugs could be combined with other drug and gene therapies to test their 
combination effects. 
 
Future in vivo works could be carried out in addition to the studies detailed in the 
appendix, including using animal model to study the in vivo efficacy of luc-siRNA after 
multiple injections as well as using functional DNA and siRNA co-delivery strategies. 
Specifically, on anti-luciferase siRNA delivery, single dosage of luc-siRNA injection 
resulted in insignificant luciferase expression knockdowns. However, further analysis on 
different types of treatment conditions, such as multiple systemic injections of siRNA 
polyplexes throughout a few days could be conducted to examine the differential effects 
under different treatment conditions. This will allow a more comprehensive 
understanding of the clinical value of P(SiDAAr)5Peg3 for gene therapy. Up to this point, 
no study has shown the clinical effectiveness of the polymer P(SiDAAr)5Peg3.  
  
Finally, this project investigated the presence of breast CSC immunophenotypes in 
breast cancer cell lines, analyzed the effect of epigenetic drugs on the transcriptomic level 
of drug resistant cells MCF-7/Adr, and formulated siRNA and DNA-siRNA co-delivery 
systems to transfect drug resistant and metastatic breast cancer cell lines. 
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APPENDIX A 
LIST OF ABBREVIATIONS 
ABCB1 – multidrug resistance protein 1 
Ab – Antibody 
Abs – absorbance 
BCSC – breast cancer stem cell 
bPEI – branched polyethylenimine 
BRCA1 – breast cancer gene 1 
BRCA2 – breast cancer gene 2 
BSA – bovine serum albumin 
CSC – cancer stem cell 
DAC – decitabine 
DCC – dicyclohexylcarbodiimide 
Dh – hydrodynamic diameters 
DLS – dynamic light scattering 
DMEM – Dulbecco’s modified eagle’s medium 
DOTAP – dioleyltrimethylammoniumpropane 
DOX (Dox) – doxorubicin 
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Doxil – trade name of a liposome form of doxorubicin  
DPBS – Dulbecco’s phosphate-buffered saline  
D/S/P ratio – DNA/siRNA/polymer weight/weight ratio 
EDC – 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
EMT – epithelial-mesenchymal transition 
ER- estrogen receptor 
ESA – epithelial-specific antigen 
FASN – fatty acid synthase  
HDAC – histone deacetylase  
hMSC – human mesenchymal stem cell 
HPLC – high-performance liquid chromatography 
HNRNPU – heterogeneous nuclear ribonucleoprotin U (scaffold attachment factor A) 
IV – intravenous 
luc-DNA – luciferase-DNA  
luc-siRNA – anti-luciferase siRNA  
mTOR – mammalian target of rapamycin  
MTT – 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide  
MWCO – molecular weight cutoff 
N/P ratio – siRNA/polymer weight/weight ratio;  
NPC – nuclear pore complex  
NUP35 – nucleoporin 35kDa  
NUP153 – nucleoporin 153kDa  
NUPR1 – nuclear protein, transcriptional regulator, 1  
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PAMAM – poly(amidoamine)  
PDI – Polydispersity Index 
PEG – poly(ethylene glycol) 
Pgp – P-glycoprotein 
PLGA – poly(lactide co-glycolic acid)  
P/N – polymer/nucleotide weight/weight ratio  
PPARs – peroxisome proliferator-activated receptors  
P(SiDAAr)5–5 siloxane-arginine modified bPEI polymer 
P(SiDAAr)5Peg3 – 3 PEG-conjugated 5 siloxane-arginine modified bPEI polymer 
Ø-pDNA – noncoding plasmid DNA index 
RAN – RAs-related Nuclear protein  
RCC1 – regulator of chromosome condensation 1 
RISCs – RNA-induced silencing complexes 
RNAi – RNA interference  
SAHA – suberanilohydroxamic acid 
siRNA – small interfering RNA 
s-siRNA – scramble siRNA 
SNAI1 – zinc finger protein snail 1 
TEM – transmission electron microscopy 
TGFbeta – transforming growth factor beta 
TFEB: Transcription Factor EB 
TNPO1: transportin 1 
V/v – volume/volume  
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VIM – vimentin  
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APPENDIX B 
THE REDUCTION OF LUCIFERASE PROTEIN EXPRESSION IN VIVO 
Introduction: 
Although siRNA has shown significant therapeutic promises and to effectively 
transfect cell lines in vitro, its clinical applications are still in their infancy due to the 
challenges presented in the in vivo delivery of siRNA. Since naked siRNA is too large 
and hydrophilic to diffuse across the cell membrane, the poor cellular uptake of siRNA in 
vivo remains a significant barrier for the advancement of the technology [154, 155] Some 
other limitations include poor pharmacokinetic property, siRNA nucleases degradation 
after systemic administration, the triggering of the innate immune system in vivo, and a 
lack of effective systemic delivery methods that are safe and nontoxic [56-58, 207]. 
P(SiDAAr)5Peg3 has shown to effectively deliver siRNA for in vitro transfections, with 
reduced toxicity compare to PEI, therefore its effectiveness in vivo was also examined to 
explore its potential therapeutic value in clinical applications. 
Methods: 
Nude/nude athymic mice (5-6 weeks-old, female) obtained from Charles River 
Laboratories (Willmington, MA) were housed in isolated cages at room temperatures 
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with access to food and water. MDA-MB-231-luc-D3H2LN cells were cultured in 15% 
DMEM in 150 cm
2 
flasks till reaching confluency. Cells were then washed, detached and 
mixed with matrigel matrix (1:1 v/v ratio), and 3 million cells were inoculated 
subcutaneously into the mammary complex of each mouse. After tumors of >100 mm
3
 
were formed, luc-siRNA polyplexes (150 µL) with 1:4 siRNA to polymer w/w ratio were 
injected into the animal via tail vein injection. One hundred and fifty µL of free luc-
siRNA solution in PBS and scramble siRNA polyplexes were used as negative controls. 
Animals were imaged for luciferase expressions on the following day after treatments. 
Prior to imaging, 100 µL of VivoGlo Luciferin (Promega) at 10 mg/mL were injected 
intraperitoneal (IP) and images were taken at 10 min using IVIS® Lumina II 
(PerkinElmer, Hopkinton, MA) post luciferin injection.  
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Figure B.1 Examining the in vivo effectiveness of luc-siRNA P(SiDAAr)5Peg3 polyplex. 
One dose of the polyplexes formulated with the anti-luc siRNA was injected through the 
tail vein in mice, and images were taken after 1 day post treatment. Control is mice 
without any treatments. Animals with multiple tumors were used for this study. Data are 
shown as mean (of the number of tumors) ± SEM. Five mice were injected with scramble 
siRNA NP, 4 mice were used with free luc-siRNA in saline treatment, and 4 with luc-
siRNA polyplexes. 
 
Results and Discussion:  
Compare the effect of free luc-siRNA and luc-siRNA polyplexes via tail vein 
injection, a single-dose of the polyplexes showed no significant reduction in the 
luminescence expression (Fig A1). This could due to a number of reasons. First, multiple 
doses may be needed to achieve a more significant knock-down effect in vivo. Second, a 
longer time period may be required for the polyplexes to achieve effectiveness in vivo. In 
the past, studies have shown PEI-siRNA polyplexes able to transfect different animal 
models [208]. In mice model, effective HER-2 gene knock-down has been reported by 
single-dose of siRNA polyplexes via IP injection [64]. However, majority of the studies 
use either intra-tumoral injection [209] or have relatively poor effect [210]. Future works 
are needed to elucidate the effectiveness of this P(SiDAAr)5Peg3 in siRNA delivery. 
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APPENDIX C 
HYDRODYNAMIC DIAMETERS AND THE ZETA POTENTIALS OF POLYMERS 
AND POLYPLEXES 
PEI polymer: mean diameter: 7.8nm, Stdev (nm): 4.487, variance: 0.331 
 187 
 
P(SiAAr)5 polymer: mean diameter: 10.5 nm, stdev (nm): 6.557, variance: 0.389 
 
 
P(SiAAr)5Peg3 polymer: mean diameter: 45.8 nm, stdev (nm): 29.58, variance: 0.41 
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1/O/2 DNA/siRNA/PEI Polyplexes: mean diameter: 249.9 nm, stdev (nm): 129.2, 
variance: 0.267 
 
1/2 siRNA/ P(SiDAAr)5 Polyplexes: mean diameter: 571.7 nm, stdev (nm): 290.42, 
variance: 0.258 
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1/1/4 DNA/siRNA/P(SiDAAr)5Peg3 Polyplexes: mean diameter: 273.2 nm, stdev (nm): 
115.8, variance: 0.180 
 
1/4 siRNA/ P(SiDAAr)5 Polyplexes: mean diameter: 429.2 nm, stdev (nm): 230.075, 
variance: 0.287 
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Zeta Potential: 
Polymer: PEI 
 
Polymer: P(SiDAAr)5 
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Polymer: P(SiDAAr)5Peg3 
 
 
1/1/2 DNA/siRNA/P(SiDAAr)5Peg3 Polyplexes 
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1/1/4 DNA/siRNA/P(SiDAAr)5Peg3 Polyplexes 
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APPENDIX D 
SYNTHESIS OF P(SIDAAR)5
Materials 
Three-(2-aminoethylamino) propyl-methyl-dimethoxysilane, 25-kDa branched PEI, 
aspartic acid, L-arginine, O-(2-aminoethyl)-O’-(2-carboxyethyl) polyethylene glycol-3K 
hydrochloride, 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC), 
heparin sodium, N-hydroxysuccinimide (NHS), and 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) were purchased from Sigma-Aldrich (St. Louis, 
MO). Fetal bovine serum (FBS) and Trypsin/EDTA were obtained from Gibco (Grand 
Island, NY). RNAse I (cloned) and Silencer Negative Control No.1 siRNA were 
purchased from Life Technologies (Carlsbad, CA). Sodium bicarbonate powder, 
hydroxylamine hydrochloride, uranyl acetate, and TrisAcetate-EDTA buffer were 
purchased from Sigma Aldrich (St. Louis, MO).  Dulbecco's Modified Eagle's Medium 
(DMEM), DPBS, penicillin and streptomycin were purchased from the Cell Services’ 
Media Core at the Cleveland Clinic. 
Methods 
Oligo(alkylaminosiloxane) (SiDA), arginine conjugated oligo amino 
alkyldialkoxymethylsilane (SiDAAr) and arginine modified 
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oligo(alkylaminosiloxane)graft-PEI ((P(SiDAAr)5) (5:1 SiDAAr: PEI mol:mol ratio) was 
synthesized as previously described [193, 197].  
 
For oligo(alkylaminosiloxane) (SiDA) synthesis, 32 μL of 1 N NaOH solution was 
added to 1.8 mmol (0.371 g) of 3-(2-aminoethylamino)propyl-methyldimethoxysilane. 
The reaction was carried on for 20 hours via stirring at room temperature. After that, 
reduced pressure was applied to the oligomers to remove the volatiles. Following that, 5 
ml of dH2O was added to the reaction mixture and 1 N HCl was used to neutralize the 
mixture to pH of 7. The product of the reaction was analyzed by 
1
H NMR and mass 
spectrometry. Ratio linear/cyclic: 3.42/1. Mass: m/z = 641, 143, 302, 321, 481, 802  
(Kichler et al) [197].  
 
Arginine conjugated oligo amino alkyldialkoxymethylsilane (SiDAAr) at 5:1 molar 
ratio was prepared by EDC/NHS chemistry. Briefly, 0.785 g of L-arginine (5 mmol 
equivalents) and NHS (7 mmol equivalents, 0.725 g) was dissolved in 2.5 mL of PBS of 
pH 8. The solution was cooled to 4 
o
C and EDC (7 mmol equivalents, 1.2 g) was slowly 
added into the solution to activate the carboxylic acid of L-arginine. The reaction was 
continued for 4 hours at 4 
o
C and the reaction mixture was then added into 
alkylaminosiloxane oligomer (1 mmol equivalent, 0.8 g) dissolved in 1.5 mL of PBS. The 
reaction was carried out for 24 hours at room temperature. The product was then dialyzed 
(MWCO=1000 Da) using deionized water for 48 hours to remove un-reacted substrates 
and lyophilized.  
 
 195 
 
Conjugation of N-(tert-Butoxycarbonyl)-L-Aspartic acid (Boc-Asp) to SiDAAr:  
SiDAAr coupling to PEI using 5 molar equivalents of SiDAAr (P(SiDAAr)5) was 
performed by EDC/NHS chemistry using Boc-Asp as a linker. Briefly, one of the acid 
groups of the carboxylic acid of BOC-Aspartic acid (1/5 mmol equivalents, 0.042g) was 
activated with 3.5/5 mmol equivalents of NHS (0.0725 g) and EDC (0.1208 g) in 0.5 mL 
MES of pH 8 for 4 hours at 4 
o
C. The reaction mixture was then added into the 1.53 g 
(1mmol equivalent) of SiDAAr solution and the reaction was continued for 18 hours. 
Afterward, the reaction mixture was kept for dialysis (MWCO=1000 Da) for 48 hours to 
remove the un-reacted substrates. 
 
Synthesis of P(SiDAAr)5: The other carboxylic acid of BOC-Aspartic acid (1/5 mmol 
equivalents, 0.042 g) was activated using 3.5/5 mmol equivalents of NHS (0.0725 g) and 
EDC (0.1208 g) and the reaction was carried out for 6 hours at 4 
o
C. After the activation 
of aspartic acid, 0.05712 g (0.06 mmol equivalents) of SiDAAr with the activated BOC-
aspartic acid was added to PEI (0.012 mmol equivalents; 0.3 g) dissolved in 6 mL (5% 
w/v) of PBS at pH of 8. Reaction was carried on for 18 hours at room temperature. The 
resultant mixture was dialyzed (MWCO=12k Da) for 48 hours and then lyophilized. The 
yield of P(SiDAAr)5 was approximately 30%. Above polymer conjugations were carried 
out by Viola Morris, a former postdoc in Dr. Labhasetwar group. 
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Scheme D.1 Synthesis of (A) oligo(-alkylaminosiloxanes) (SiDA), (B) L-arginine 
modified oligo (-alkylaminosiloxanes) (SiDAAr5), (C) L-arginine oligo 
(alkylaminosiloxane) grafted poly(ethylenimine) (P(SiDAAr)5).  
 
 
 
 
 
 
